-- MySQL dump 10.13  Distrib 5.7.17, for macos10.12 (x86_64)
--
-- Host: 127.0.0.1    Database: PYTHON_DB
-- ------------------------------------------------------
-- Server version	5.7.16

/*!40101 SET @OLD_CHARACTER_SET_CLIENT=@@CHARACTER_SET_CLIENT */;
/*!40101 SET @OLD_CHARACTER_SET_RESULTS=@@CHARACTER_SET_RESULTS */;
/*!40101 SET @OLD_COLLATION_CONNECTION=@@COLLATION_CONNECTION */;
/*!40101 SET NAMES utf8 */;
/*!40103 SET @OLD_TIME_ZONE=@@TIME_ZONE */;
/*!40103 SET TIME_ZONE='+00:00' */;
/*!40014 SET @OLD_UNIQUE_CHECKS=@@UNIQUE_CHECKS, UNIQUE_CHECKS=0 */;
/*!40014 SET @OLD_FOREIGN_KEY_CHECKS=@@FOREIGN_KEY_CHECKS, FOREIGN_KEY_CHECKS=0 */;
/*!40101 SET @OLD_SQL_MODE=@@SQL_MODE, SQL_MODE='NO_AUTO_VALUE_ON_ZERO' */;
/*!40111 SET @OLD_SQL_NOTES=@@SQL_NOTES, SQL_NOTES=0 */;

--
-- Table structure for table `scraped`
--

DROP TABLE IF EXISTS `scraped`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `scraped` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `last_scrape` datetime DEFAULT CURRENT_TIMESTAMP,
  `url` varchar(256) NOT NULL,
  `rr_start` date DEFAULT NULL,
  `rr_end` date DEFAULT NULL,
  `rr_outcome` varchar(1024) DEFAULT NULL,
  `rr_dates` varchar(256) DEFAULT NULL,
  `rr_multiple` tinyint(1) DEFAULT NULL,
  `drug_name` varchar(128) DEFAULT NULL,
  `trade_name` varchar(64) DEFAULT NULL,
  `indication` varchar(2048) DEFAULT NULL,
  `ncpe_year` year(4) DEFAULT NULL,
  `eu_market` date DEFAULT NULL,
  `company` varchar(64) DEFAULT NULL,
  `orphan` tinyint(1) DEFAULT NULL,
  `earliest` date DEFAULT NULL,
  `latest` date DEFAULT NULL,
  `ema_url` varchar(256) NOT NULL,
  `ta_list` varchar(256) DEFAULT NULL,
  `rr_status` varchar(64) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=2562 DEFAULT CHARSET=utf8mb4;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `scraped`
--

LOCK TABLES `scraped` WRITE;
/*!40000 ALTER TABLE `scraped` DISABLE KEYS */;
INSERT INTO `scraped` VALUES (2164,'2018-12-13 16:24:32','http://www.ncpe.ie/drugs/abatacept-orencia/','2012-11-28','2012-12-21','Full Pharmacoeconomic Assessment Recommended','2012-11-28, 2012-12-21',0,'Abatacept (Orencia®)','Orencia','Subcutaneous Abatacept (Orencia®) in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor.',2015,'2007-05-21','',0,'2012-11-28','2015-11-01','https://www.ema.europa.eu/en/medicines/human/EPAR/orencia','Unknown','HTA recommended at submitted price'),(2165,'2018-12-13 16:24:36','http://www.ncpe.ie/drugs/abiraterone-acetate-zytiga-for-mhspc/','2018-10-03','2018-11-15','A full pharmacoeconomic assessment is recommended','2018-10-03, 2018-11-15',0,'Abiraterone acetate (Zytiga®) for mHSPC','Zytiga','Abiraterone acetate (Zytiga®) for the treatment of newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).',2018,'2011-09-05','Janssen-Cilag',0,'2018-10-03','2018-11-15','https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga','Prostatic Neoplasms','HTA recommended at submitted price'),(2166,'2018-12-13 16:24:41','http://www.ncpe.ie/drugs/abiratone-acetate-zytiga-for-mcrpc-post-adt/','2013-01-03','2013-02-01','Full Pharmacoeconomic Evaluation Recommended.','2013-01-03, 2013-02-01',0,'Abiraterone acetate (Zytiga®) for mCRPC post ADT','Zytiga','Pharmacoeconomic evaluation of Abiratone acetate (Zytiga®) for the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated',2015,'2011-09-05','Janssen-Cilag',0,'2013-01-03','2015-12-01','https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga','Prostatic Neoplasms','HTA recommended at submitted price'),(2167,'2018-12-13 16:24:46','http://www.ncpe.ie/drugs/abiratone-acetate-zytiga/','2011-10-21','2011-11-02','Full Pharmacoeconomic Evaluation Recommended.','2011-10-21, 2011-11-02',0,'Abiraterone Acetate (Zytiga®) for mCRPC','Zytiga','Pharmacoeconomic evaluation and resource implications of Zytiga ® (abiraterone acetate) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior docetaxel-based chemotherapy.',2014,'2011-09-05','Janssen-Cilag',0,'2011-10-21','2014-04-01','https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga','Prostatic Neoplasms','HTA recommended at submitted price'),(2168,'2018-12-13 16:24:49','http://www.ncpe.ie/drugs/aceclofenac-vitafen/','2016-12-21','2017-01-24','Following a resubmission of the rapid review a full pharmacoeconomic evaluation is recommended at the submitted price.','2016-12-21, 2017-01-24',0,'Aceclofenac (Vitafen®)','Vitafen','Aceclofenac (Vitafen®) is indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.',2017,NULL,'Unknown',0,'2016-07-22','2017-11-01','','Unknown','HTA recommended at submitted price'),(2169,'2018-12-13 16:24:56','http://www.ncpe.ie/drugs/aclidinium-bromide-eklira-genuair/','2012-10-23','2012-10-26','Full Pharmacoeconomic Evaluation Not Recommended','2012-10-23, 2012-10-26',0,'Aclidinium bromide (Eklira Genuair®)','Eklira Genuair','Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)',2012,'2012-07-20','AstraZeneca',0,'2012-10-23','2012-10-26','https://www.ema.europa.eu/en/medicines/human/EPAR/eklira-genuair','Pulmonary Disease, Chronic Obstructive','No HTA'),(2170,'2018-12-13 16:25:00','http://www.ncpe.ie/drugs/aclidinium-bromide-formoterol-fumarate-dihydrate-brimica-genuair/','2015-01-05','2015-02-09','Full Pharmacoeconomic Evaluation Recommended at submitted price.','2015-01-05, 2015-02-09',0,'Aclidinium bromide / formoterol fumarate dihydrate (Brimica®  Genuair®)','Brimica Genuair','Brimica® Genuair® is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.',2015,'2014-11-19','AstraZeneca',0,'2015-01-05','2015-02-09','https://www.ema.europa.eu/en/medicines/human/EPAR/brimica-genuair','Pulmonary Disease, Chronic Obstructive','HTA recommended at submitted price'),(2171,'2018-12-13 16:25:37','http://www.ncpe.ie/drugs/adalimumab-humira/','2011-05-20','2011-06-02','Full Pharmacoeconomic Evaluation not Recommended','2011-05-20, 2011-06-02',0,'Adalimumab (Humira®)','Humira','Economic evaluation of Adalimumab (Humira®) in combination with methotrexate for polyarticular juvenile idiopathic arthritis in children and adolescents (4-17yrs) in patients who have had an inadequate response to DMARDs.  Also licensed as monotherapy in cases of intolerance to MTX or when continued therapy with MTX is inappropriate.',2011,'2003-09-07','AbbVie',0,'2011-05-20','2011-06-02','https://www.ema.europa.eu/en/medicines/human/EPAR/humira','Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Arthritis, Rheumatoid','No HTA'),(2172,'2018-12-13 16:25:40','http://www.ncpe.ie/drugs/adenuric-febuxostat/','2009-12-08','2009-12-08','Full Pharmacoeconomic Evaluation not Recommended','2009-12-08',0,'Adenuric (Febuxostat®)','Febuxostat','NCPE review of Adenuric (Febuxostat®) a xanthine oxidase inhibitor for the treatment of gout.',2009,'2008-04-21','Menarini',0,'2009-12-08','2009-12-08','https://www.ema.europa.eu/en/medicines/human/EPAR/adenuric','Gout','No HTA'),(2173,'2018-12-13 16:25:45','http://www.ncpe.ie/drugs/afatinib-giotrif/','2013-10-01','2013-10-13','Full HTA not recommended','2013-10-01, 2013-10-13',0,'Afatinib (Giotrif®)','Giotrif','GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).',2013,'2013-09-25','Boehringer',0,'2013-10-01','2013-10-13','https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif','Carcinoma, Non-Small-Cell Lung','No HTA'),(2174,'2018-12-13 16:25:49','http://www.ncpe.ie/drugs/aflibercept-eylea/','2012-12-10','2012-12-21','Full Pharmacoeconomic Assessment Recommended','2012-12-10, 2012-12-21',0,'Aflibercept (Eylea®)','Eylea','Aflibercept (Eylea®) is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).',2012,'2012-11-21','Bayer',0,'2012-12-10','2012-12-21','https://www.ema.europa.eu/en/medicines/human/EPAR/eylea','Wet Macular Degeneration; Macular Edema; Diabetes Complications','HTA recommended at submitted price'),(2175,'2018-12-13 16:25:52','http://www.ncpe.ie/drugs/aflibercept-zaltrap/','2013-03-21','2013-04-10','Full Pharmacoeconomic Evaluation Recommended','2013-03-21, 2013-04-10',0,'Aflibercept (Zaltrap®)','Zaltrap','Aflibercept for the treatment of metastatic colorectal cancer in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.',2014,'2013-02-01','Sanofi-Aventis',0,'2013-03-21','2014-02-12','https://www.ema.europa.eu/en/medicines/human/EPAR/zaltrap','Colorectal Neoplasms','HTA recommended at submitted price'),(2176,'2018-12-13 16:25:58','http://www.ncpe.ie/drugs/agomelatine-valdoxan-4/',NULL,'2013-04-10','','',0,'Agomelatine (Valdoxan®)','Valdoxan','Economic evaluation of Agomelatine (Valdoxan®) for the treatment of major depressive disorder.',2009,'2009-02-19','Les',0,'2009-09-03','2009-12-11','https://www.ema.europa.eu/en/medicines/human/EPAR/valdoxan','Depressive Disorder, Major','RR not conducted'),(2177,'2018-12-13 16:26:06','http://www.ncpe.ie/drugs/alectinib-alecensa/','2017-01-03','2017-12-04','Full pharmacoeconomic evaluation recommended','2017-01-03, 2017-02-27, 2017-11-08, 2017-12-04',1,'Alectinib (Alecensa®)','Alecensa','Alectinib (Alecensa ®) for the treatment of patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose disease has progressed following treatment with crizotinib.',2018,'2017-02-16','Roche',0,'2017-01-03','2018-12-05','https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa','Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2178,'2018-12-13 16:26:12','http://www.ncpe.ie/drugs/alemtuzumab-lemtrada/','2013-11-08','2013-12-02','Full HTA Recommended','2013-11-08, 2013-12-02',0,'Alemtuzumab (Lemtrada®)','Lemtrada','Alemtuzumab (Lemtrada®) is indicated for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features',2014,'2013-09-12','Sanofi',0,'2013-11-08','2014-06-25','https://www.ema.europa.eu/en/medicines/human/EPAR/lemtrada','Multiple Sclerosis','HTA recommended at submitted price'),(2179,'2018-12-13 16:26:14','http://www.ncpe.ie/drugs/alirocumab-praluent/','2015-10-13','2015-11-02','Full Pharmacoeconomic Evaluation Recommended','2015-10-13, 2015-11-02',0,'Alirocumab (Praluent®)','Praluent','Praluent® is indicated for both primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia.',2018,'2015-09-23','sanofi-aventis',0,'2015-10-13','2018-03-20','https://www.ema.europa.eu/en/medicines/human/EPAR/praluent','Dyslipidemias','HTA recommended at submitted price'),(2180,'2018-12-13 16:26:16','http://www.ncpe.ie/drugs/alogliptin-vipidia/','2013-09-27','2013-10-30','Full HTA not recommended','2013-09-27, 2013-10-30',0,'Alogliptin (Vipidia®)','Vipidia','Alogliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.',2013,'2013-09-18','Takeda',0,'2013-09-27','2013-10-30','https://www.ema.europa.eu/en/medicines/human/EPAR/vipidia','Diabetes Mellitus, Type 2','No HTA'),(2181,'2018-12-13 16:26:21','http://www.ncpe.ie/drugs/ambrisentan-volibris/','2014-05-27','2014-07-04','Full Pharmacoeconomic Evaluation not Recommended.','2014-05-27, 2014-07-04',0,'Ambrisentan (Volibris®)','Volibris','Cost Effectiveness of ambrisentan (Volibris®) in the treatment of patients with Functional Class II or III pulmonary arterial hypertension.',2014,'2008-04-20','GlaxoSmithKline',1,'2008-10-01','2014-07-04','https://www.ema.europa.eu/en/medicines/human/EPAR/volibris','Hypertension, Pulmonary','No HTA'),(2182,'2018-12-13 16:26:23','http://www.ncpe.ie/drugs/amifampridine-firdapse/','2011-11-07','2011-12-09','Full Pharmacoeconomic Evaluation Recommended.','2011-11-07, 2011-12-09',0,'Amifampridine (Firdapse®)','Firdapse','For Lambert Eaton Myasthenic Syndrome (LEMS).  This high cost drug is likely to require a full HTA due to significant budget impact.',2011,'1996-10-04','CIS',0,'2011-11-07','2011-12-09','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','HTA recommended at submitted price'),(2183,'2018-12-13 16:26:29','http://www.ncpe.ie/drugs/amsacrine-amsidine/','2017-01-10','2017-02-15','Full Pharmacoeconomic Evaluation not Recommended','2017-01-10, 2017-02-15',0,'Amsacrine (Amsidine®)','Amsidine','Amsidine® is indicated for the induction and maintenance of remission in acute leukaemia of adults.',2017,NULL,'Unknown',0,'2017-01-10','2017-02-15','','Unknown','No HTA'),(2184,'2018-12-13 16:26:35','http://www.ncpe.ie/drugs/apixaban-eliquis-for-treatment-of-deep-vein-thrombosis-dvt-and-pulmonary-embolism-pe-and-prevention-of-recurrent-dvt-and-pe-in-adults/','2014-07-29','2014-08-10','Full pharmacoeconomic evaluation not recommended','2014-07-29, 2014-08-10',0,'Apixaban (Eliquis®) for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and','Eliquis','Apixaban (Eliquis®) for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.',2014,'2011-05-18','Bristol-Myers',0,'2014-07-29','2014-08-10','https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis','Arthroplasty; Venous Thromboembolism','No HTA'),(2185,'2018-12-13 16:26:39','http://www.ncpe.ie/drugs/apixaban-eliquis/','2011-10-19','2011-11-02','Full Pharmacoeconomic Evaluation Recommended.','2011-10-19, 2011-11-02',0,'Apixaban (Eliquis®) for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee','Eliquis','Apixaban (Eliquis®) for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery.',2012,'2011-05-18','Bristol-Myers',0,'2011-10-19','2012-06-19','https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis','Arthroplasty; Venous Thromboembolism','HTA recommended at submitted price'),(2186,'2018-12-13 16:26:45','http://www.ncpe.ie/drugs/apremilast-otezla-for-moderate-to-severe-chronic-plaque-psoriasis/','2015-02-24','2015-04-03','Full Pharmacoeconomic Evaluation Recommended.','2015-02-24, 2015-04-03',0,'Apremilast (Otezla®) for moderate to severe chronic plaque psoriasis.','Otezla','Indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who have failed to respond to or who have a contraindication to, or are intolerant to systemic non-biologic therapies including cyclosporine, methotrexate or psoralen and ultraviolet A light (PUVA).',2017,'2015-01-15','Celgene',0,'2015-02-24','2017-10-01','https://www.ema.europa.eu/en/medicines/human/EPAR/otezla','Arthritis, Psoriatic; Psoriasis','HTA recommended at submitted price'),(2187,'2018-12-13 16:26:47','http://www.ncpe.ie/drugs/apremilast-otezla-for-psoriatic-arthritis/','2015-02-24','2015-04-03','Full Pharmacoeconomic Evaluation Recommended.','2015-02-24, 2015-04-03',0,'Apremilast (Otezla®) for psoriatic arthritis.','Otezla','Apremilist (Otezla®), alone or in combination with DMARDs, for the treatment of active PsA in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.',2017,'2015-01-15','Celgene',0,'2015-02-24','2017-10-01','https://www.ema.europa.eu/en/medicines/human/EPAR/otezla','Arthritis, Psoriatic; Psoriasis','HTA recommended at submitted price'),(2188,'2018-12-13 16:26:49','http://www.ncpe.ie/drugs/aripiprazole-abilify-maintena/','2014-07-02','2014-08-06','Full Pharmacoeconomic Evaluation not Recommended','2014-07-02, 2014-08-06',0,'Aripiprazole (Abilify Maintena®)','Abilify Maintena','Aripiprazole (Abilify Maintena®) for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole',2014,'2013-11-14','Otsuka',0,'2014-07-02','2014-08-06','https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena','Schizophrenia','No HTA'),(2189,'2018-12-13 16:26:55','http://www.ncpe.ie/drugs/asenapine-sycrest/','2011-08-17','2011-09-06','Full Pharmacoeconomic Evaluation not Recommended.','2011-08-17, 2011-09-06',0,'Asenapine (Sycrest®)','Sycrest','Asenapine (Sycrest®) for the treatment of moderate to severe manic episodes associated with biopolar 1 disorder in adults.',2011,'2010-09-01','Organon',0,'2011-08-17','2011-09-06','https://www.ema.europa.eu/en/medicines/human/EPAR/sycrest','Bipolar Disorder','No HTA'),(2190,'2018-12-13 16:27:00','http://www.ncpe.ie/drugs/atezolizumab-tecentriq/','2017-08-08','2017-10-09','Full pharmacoeconomic assessment recommended','2017-08-08, 2017-10-09',0,'Atezolizumab (Tecentriq®)','Tecentriq','Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK‑positive tumour mutations should also have received targeted therapy before receiving atezolizumab.',2018,'2017-09-21','Roche',0,'2017-08-08','2018-09-20','https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq','Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2191,'2018-12-13 16:27:05','http://www.ncpe.ie/drugs/avanafil-spedra/','2014-02-19','2014-03-12','Full Pharmacoeconomic Evaluation Not Recommended','2014-02-19, 2014-03-12',0,'Avanafil (Spedra®)','Spedra','Avanafil (Spedra®) is indicated for the treatment of erectile dysfunction in adult men.',2014,'2013-06-21','Menarini',0,'2014-02-19','2014-03-12','https://www.ema.europa.eu/en/medicines/human/EPAR/spedra','Erectile Dysfunction','No HTA'),(2192,'2018-12-13 16:27:06','http://www.ncpe.ie/drugs/avelumab-bavencio/','2017-10-17','2017-11-21','Full pharmacoeconomic assessment recommended','2017-10-17, 2017-11-21',0,'Avelumab (Bavencio®)','Bavencio','Avelumab (Bavencio®) is indicated for the treatment of adults with metastatic Merkel Cell Carcinoma.',2018,'2017-09-18','Merck',1,'2017-10-17','2018-10-08','https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio','Neuroendocrine Tumors','HTA recommended at submitted price'),(2193,'2018-12-13 16:27:08','http://www.ncpe.ie/drugs/axanum-aspirin-81mgesomeprazole-20mg/','2012-04-12','2012-04-20','Full Pharmacoeconomic Evaluation not Recommended.','2012-04-12, 2012-04-20',0,'Aspirin 81mg/Esomeprazole 20mg (Axanum®)','Axanum','Prevention of thrombotic cardiovascular and cerebrovascular events in patients requiring continuous low-dose acetylsalicylic acid treatment, and who are in need of prophylaxis against acetylsalicylic acid associated gastric and /or duodenal ulcers.',2012,'2009-10-10','GlaxoSmithKline',0,'2012-04-12','2012-04-20','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','No HTA'),(2194,'2018-12-13 16:27:14','http://www.ncpe.ie/drugs/axicabtagene-ciloleucel-yescarta/','2018-09-10','2018-10-18','A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of  axi-cel compared with the current standard of care.\n ','2018-09-10, 2018-10-18',0,'Axicabtagene Ciloleucel (Yescarta®)','Yescarta','Axi-cel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.',2018,'2018-08-23','Kite',1,'2018-09-10','2018-10-18','https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta','Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse','HTA recommended at submitted price'),(2195,'2018-12-13 16:27:23','http://www.ncpe.ie/drugs/axitinib-inlyta/','2012-11-07','2012-11-19','Full pharmacoeconomic assessment recommended','2012-11-07, 2012-11-19',0,'Axitinib (Inlyta®)','Inlyta','For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine',2012,'2012-09-03','Pfizer',0,'2012-11-07','2012-11-19','https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta','Carcinoma, Renal Cell','HTA recommended at submitted price'),(2196,'2018-12-13 16:27:24','http://www.ncpe.ie/drugs/azelastine-hydrochloride-and-fluticasone-propionate-nasal-spray-dymista/','2013-02-12','2013-02-28','Full Pharmacoeconomic Assessment not Recommended.','2013-02-12, 2013-02-28',0,'Azelastine hydrochloride and fluticasone propionate (nasal spray) (Dymista®)','Dymista','Indicated for symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.',2013,NULL,'Unknown',0,'2013-02-12','2013-02-28','','Unknown','No HTA'),(2197,'2018-12-13 16:27:25','http://www.ncpe.ie/drugs/azilsartan-edarbi/','2012-01-10','2012-01-11','Full Pharmacoeconomic Evaluation not Recommended','2012-01-10, 2012-01-11',0,'Azilsartan (Edarbi®)','Edarbi','Edarbi is indicated for the treatment of essential hypertension in adults.',2012,'2011-12-07','Takeda',0,'2012-01-10','2012-01-11','https://www.ema.europa.eu/en/medicines/human/EPAR/edarbi','Hypertension','No HTA'),(2198,'2018-12-13 16:27:27','http://www.ncpe.ie/drugs/baricitinib-olumiant/','2017-06-14','2017-07-13','Full Pharmacoeconomic Evaluation Recommended at the Submitted Price','2017-06-14, 2017-07-13',0,'Baricitinib (Olumiant®)','Olumiant','Baricitinib (Olumiant®) is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Baricitinib may be used as monotherapy or in combination with methotrexate.',2017,'2017-02-12','Eli',0,'2017-06-14','2017-11-01','https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant','Arthritis, Rheumatoid','HTA recommended at submitted price'),(2199,'2018-12-13 16:27:33','http://www.ncpe.ie/drugs/bazedoxifene-conbriza/','2011-09-20','2011-11-02','Full Pharmacoeconomic Evaluation not Recommended.','2011-09-20, 2011-11-02',0,'Bazedoxifene (Conbriza®)','Conbriza','Bazedoxifene (Conbriza®) for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.  A significant reduction in the incidence of verterbral fractures has been demonstrated; efficacy on hip fractures has not been established.',2011,'2009-04-17','Pfizer',0,'2011-09-20','2011-11-02','https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza','Osteoporosis, Postmenopausal','No HTA'),(2200,'2018-12-13 16:27:36','http://www.ncpe.ie/drugs/bedaquiline-sirturo/','2015-01-23','2015-02-20','Full Pharmacoeconomic Evaluation Not Recommended','2015-01-23, 2015-02-20',0,'Bedaquiline (Sirturo®)','Sirturo','Bedaquiline (Sirturo®) is indicated for use as part of an appropriate combination regimen for pulmonary MDR‑TB in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.',2015,'2014-03-05','Janssen-Cilag',1,'2015-01-23','2015-02-20','https://www.ema.europa.eu/en/medicines/human/EPAR/sirturo','Tuberculosis, Multidrug-Resistant','No HTA'),(2201,'2018-12-13 16:27:37','http://www.ncpe.ie/drugs/belatacept-nulojix/','2011-11-15','2012-01-23','Full Pharmacoeconomic Evaluation Recommended','2011-11-15, 2012-01-23',0,'Belatacept (Nulojix®)','Nulojix','Belatacept, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen.\n',2012,'2011-06-17','Bristol-Myers',0,'2011-11-15','2012-01-23','https://www.ema.europa.eu/en/medicines/human/EPAR/nulojix','Graft Rejection; Kidney Transplantation','HTA recommended at submitted price'),(2202,'2018-12-13 16:27:40','http://www.ncpe.ie/drugs/belimumab-benlysta/','2011-08-11','2011-08-11','Full Pharmacoeconomic Evaluation Recommended','2011-08-11, 2011-08-11',0,'Belimumab (Benlysta®)','Benlysta','Cost-effectiveness of Belimumab (Benlysta®)',2011,'2011-07-13','Glaxo',0,'2011-08-01','2011-08-11','https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta','Lupus Erythematosus, Systemic','HTA recommended at submitted price'),(2203,'2018-12-13 16:27:46','http://www.ncpe.ie/drugs/bendamustine-levact/','2011-03-21','2011-03-01','Full Pharmacoeconomic Evaluation Recommended','2011-03-21, 2011-03-01',0,'Bendamustine (Levact®)','Levact','Bendamustine (Levact®) for the treatment of Chronic Lymphocytic Leukaemia (CLL)',2012,'2009-10-10','GlaxoSmithKline',0,'2011-03-01','2012-11-20','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','HTA recommended at submitted price'),(2204,'2018-12-13 16:27:50','http://www.ncpe.ie/drugs/benralizumab-fasenra/','2018-01-15','2018-02-14','Full pharamcoeconomic assessment recommended at the submitted price','2018-01-15, 2018-02-14',0,'Benralizumab (Fasenra®)','Fasenra','Benralizumab (Fasenra®) is indicated as add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.',2018,'2018-01-08','AstraZeneca',0,'2018-01-15','2018-02-14','https://www.ema.europa.eu/en/medicines/human/EPAR/fasenra','Asthma','HTA recommended at submitted price'),(2205,'2018-12-13 16:27:56','http://www.ncpe.ie/drugs/bezlotoxumab-zinplava/','2017-05-11','2017-06-14','Full pharmacoeconomic evaluation recommended','2017-05-11, 2017-06-14',0,'Bezlotoxumab (Zinplava®)','Zinplava','Bezlotoxumab (Zinplava®) is indicated for the prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.',2017,'2017-01-18','Merck',0,'2017-05-11','2017-06-14','https://www.ema.europa.eu/en/medicines/human/EPAR/zinplava','Enterocolitis, Pseudomembranous','HTA recommended at submitted price'),(2206,'2018-12-13 16:27:58','http://www.ncpe.ie/drugs/bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy/','2018-04-30','2018-06-07','Full pharmacoeconomic assessment not recommended. The NCPE recommends that Biktarvy® not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.','2018-04-30, 2018-06-07',0,'Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®)','Biktarvy','Biktarvy® for the treatment of adults infected with HIV-1 without any known mutations associated with resistance to the individual components.',2018,'2018-06-21','Gilead',0,'2018-04-30','2018-12-01','https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy','HIV Infections','No HTA at submitted price'),(2207,'2018-12-13 16:28:01','http://www.ncpe.ie/drugs/bilastine-drynol/','2011-03-10','2011-03-23','Full Pharmacoeconomic Evaluation not Recommended.','2011-03-10, 2011-03-23',0,'Bilastine (Drynol®)','Drynol',' Bilastine (Drynol®) for the Symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria.',2011,'1996-10-04','CIS',0,'2011-03-10','2011-03-23','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','No HTA'),(2208,'2018-12-13 16:28:05','http://www.ncpe.ie/drugs/blinatumomab-blincyto/','2015-12-08','2015-12-22','Full Pharmacoeconomic Evaluation Not Recommended.  The NCPE cannot recommend reimbursement of Blinctyo® at this point in time.','2015-12-08, 2015-12-22',0,'Blinatumomab (Blincyto®)','Blincyto','Blincyto® is indicated for the treatment of adults with Philadelphia chromosome negative (Ph-) relapsed or refractory\nB-precursor acute lymphoblastic leukaemia.',2018,'2015-11-23','Amgen',1,'2015-12-08','2018-04-16','https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto','Precursor Cell Lymphoblastic Leukemia-Lymphoma','No HTA'),(2209,'2018-12-13 16:28:11','http://www.ncpe.ie/drugs/boceprevir-victrelis/',NULL,'2015-12-22','','',0,'Boceprevir (Victrelis®)','Victrelis','Economic evaluation of Boceprevir (Victrelis®) as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.',2012,'2011-07-18','Merck',0,'2011-08-19','2012-01-17','https://www.ema.europa.eu/en/medicines/human/EPAR/victrelis','Hepatitis C, Chronic','RR not conducted'),(2210,'2018-12-13 16:28:16','http://www.ncpe.ie/drugs/bosentan-tracleer/','2014-06-27','2014-07-04','Full Pharmacoeconomic Evaluation Not Recommended','2014-06-27, 2014-07-04',0,'Bosentan (Tracleer®)','Tracleer','Bosentan (Tracleer®) is indicated for the treatment pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO Functional Class (FC) III and WHO FC II.  It is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.',2014,'2002-05-14','Janssen-Cilag',1,'2014-06-27','2014-07-04','https://www.ema.europa.eu/en/medicines/human/EPAR/tracleer','Scleroderma, Systemic; Hypertension, Pulmonary','No HTA'),(2211,'2018-12-13 16:28:18','http://www.ncpe.ie/drugs/bosutinib-bosulif/','2013-08-09','2013-09-18','At the current price a full HTA would be required.','2013-08-09, 2013-09-18',0,'Bosutinib (Bosulif®)','Bosulif','Bosutinib is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.',2013,'2013-03-26','Pfizer',0,'2013-08-09','2013-09-18','https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif','Leukemia, Myeloid','HTA recommended at submitted price'),(2212,'2018-12-13 16:28:19','http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris-for-cd30-cutaneous-t-cell-lymphoma-ctcl/','2018-02-07','2018-03-06','Full pharmacoeconomic assessment recommended','2018-02-07, 2018-03-06',0,'Brentuximab vedotin (Adcetris®) for CD30+ cutaneous T-cell lymphoma (CTCL)','Adcetris','Brentuximab vedotin (Adcetris®) for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy. This is a license extension.',2018,'2012-10-25','Takeda',1,'2018-02-07','2018-03-06','https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris','Lymphoma, Non-Hodgkin; Hodgkin Disease','HTA recommended at submitted price'),(2213,'2018-12-13 16:28:23','http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris/','2012-11-28','2012-12-21','Full Pharmacoeconomic Assessment Recommended','2012-11-28, 2012-12-21',0,'Brentuximab vedotin (Adcetris®)','Adcetris','Brentuximab vedotin (Adcetris®) indicated for the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant  or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and is also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.',2015,'2012-10-25','Takeda',1,'2012-11-28','2015-12-01','https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris','Lymphoma, Non-Hodgkin; Hodgkin Disease','HTA recommended at submitted price'),(2214,'2018-12-13 16:28:29','http://www.ncpe.ie/drugs/brigatinib-alunbrig/','2018-11-19','2018-12-11','A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brigatinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.\n ','2018-11-19, 2018-12-11',0,'Brigatinib (Alunbrig®)','Alunbrig','Brigatinib (Alunbrig ®) is indicated as monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.',2018,'2018-11-22','Takeda',0,'2018-11-19','2018-12-11','https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig','Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2215,'2018-12-13 16:28:30','http://www.ncpe.ie/drugs/brimonidine-3-3-mgg-gel-mirvaso/','2014-04-09','2014-04-09','Full Pharmacoeconomic Evaluation Not Recommended','2014-04-09',0,'Brimonidine 3.3 mg/g gel (Mirvaso®)','Mirvaso','Brimonidine 3.3 mg/g gel (Mirvaso®) is indicated for the treatment of facial erythema of rosacea in adult patients.',2014,'2014-02-20','Galderma',0,'2014-04-09','2014-04-09','https://www.ema.europa.eu/en/medicines/human/EPAR/mirvaso','Skin Diseases','No HTA'),(2216,'2018-12-13 16:28:36','http://www.ncpe.ie/drugs/brivaracetam-briviact/','2016-02-15','2016-03-22','Full Pharmacoeconomic Evaluation Recommended at the submitted price.','2016-02-15, 2016-03-22',0,'Brivaracetam (Briviact®)','Briviact','Brivaracetam (Briviact®) is indicated as adjunctive therapy in the treatment of partial-onset seizures (POS) with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.',2016,'1996-10-04','CIS',0,'2016-02-15','2016-03-22','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','HTA recommended at submitted price'),(2217,'2018-12-13 16:28:40','http://www.ncpe.ie/drugs/brodalumab-kyntheum/','2017-07-25','2017-08-29','Full pharmacoeconomic assessment recommended at submitted price','2017-07-25, 2017-08-29',0,'Brodalumab (Kyntheum®)','Kyntheum','Brodalumab (Kyntheum®) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.',2018,'2017-07-17','LEO',0,'2017-07-25','2018-01-01','https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum','Psoriasis','HTA recommended at submitted price'),(2218,'2018-12-13 16:28:44','http://www.ncpe.ie/drugs/bronchitol/','2012-09-11','2012-09-21','Full HTA recommended','2012-09-11, 2012-09-21',0,'Mannitol Dry Powder (Bronchitol®)','Bronchitol','Bronchitol® – Mannitol dry powder for inhalation for the treatment of cystic fibrosis (CF)',2014,'2012-04-13','Pharmaxis',1,'2012-09-11','2014-08-29','https://www.ema.europa.eu/en/medicines/human/EPAR/bronchitol','Cystic Fibrosis','HTA recommended at submitted price'),(2219,'2018-12-13 16:28:46','http://www.ncpe.ie/drugs/c-drugs/calcipotriol-and-betamethasone-dipropionate-cutaneous-foam-enstilar/','2016-05-17','2016-06-21','Full Pharmacoeconomic Evaluation Not Recommended','2016-05-17, 2016-06-21',0,'Calcipotriol and betamethasone dipropionate cutaneous foam (Enstilar ®)','Enstilar','Calcipotriol and betamethasone dipropionate cutaneous foam is indicated for the topical treatment of psoriasis vulgaris in adults.',2016,'2009-10-10','GlaxoSmithKline',0,'2016-05-17','2016-06-21','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','No HTA'),(2220,'2018-12-13 16:28:53','http://www.ncpe.ie/drugs/c1inhibitor-human-cinryze/','2012-10-22','2012-11-14','Full pharmacoeconomic assessment not recommended','2012-10-22, 2012-11-14',0,'C1inhibitor (human) (Cinryze®)','Cinryze','C1inhibitor (human) (Cinryze® 500 Units powder and solvent for solution for injection)',2012,'2011-06-15','Shire',0,'2012-10-22','2012-11-14','https://www.ema.europa.eu/en/medicines/human/EPAR/cinryze','Angioedemas, Hereditary','No HTA'),(2221,'2018-12-13 16:28:55','http://www.ncpe.ie/drugs/cabozantinib-cabometyx/','2017-03-20','2017-04-25','Full pharmacoeconomic assessment\nrecommended','2017-03-20, 2017-04-25',0,'Cabozantinib (Cabometyx®)','Cabometyx','Cabozantinib (Cabometyx®) is indicated for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.',2018,'2009-10-10','GlaxoSmithKline',0,'2017-03-20','2018-07-03','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','HTA recommended at submitted price'),(2222,'2018-12-13 16:28:58','http://www.ncpe.ie/drugs/cabozantinib-cometriq/','2014-07-10','2014-08-12','Full pharmacoeconomic evaluation recommended at the submitted price','2014-07-10, 2014-08-12',0,'Cabozantinib (Cometriq®)','Cometriq','Cabozantinib (COMETRIQ®) is indicated for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.',2014,'2014-03-21','Ipsen',1,'2014-07-10','2014-08-12','https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq','Thyroid Neoplasms','HTA recommended at submitted price'),(2223,'2018-12-13 16:29:01','http://www.ncpe.ie/drugs/camellia-sinensis-folium-green-tea-leaf-catephen-10/','2015-05-26','2015-07-10','Full Pharmacoeconomic Evaluation not recommended','2015-05-26, 2015-07-10',0,'Camellia sinensis, folium (green tea leaf) (Catephen 10%®)','Catephen 10%','Catephen 10%® is indicated for the cutaneous treatment of external genital and perianal warts (condylomataacuminata) in immunocompetent patients from the age of 18 years.',2015,'1996-10-04','CIS',0,'2015-05-26','2015-07-10','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','No HTA'),(2224,'2018-12-13 16:29:04','http://www.ncpe.ie/drugs/canagliflozin-invokana/','2013-11-25','2013-12-02','Full HTA Recommended','2013-11-25, 2013-12-02',0,'Canagliflozin (Invokana®)','Invokana','Canagliflozin (Invokana®) is indicated for the treatment of type 2 diabetes as monotherapy or add-on combination therapy to other glucose-lowering medicinal products including insulin',2014,'2013-11-15','Janssen-Cilag',0,'2013-11-25','2014-12-01','https://www.ema.europa.eu/en/medicines/human/EPAR/invokana','Diabetes Mellitus, Type 2','HTA recommended at submitted price'),(2225,'2018-12-13 16:29:09','http://www.ncpe.ie/drugs/capsaicin-8ww-patch-qutenza/','2012-06-15','2012-06-28','Full Pharmacoeconomic Evaluation Recommended','2012-06-15, 2012-06-28',0,'Capsaicin 8%w/w patch (Qutenza®)','Qutenza','Capsaicin 8% w/w patch (Qutenza®) for peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain.',2012,'2009-05-15','Grunenthal',0,'2012-06-15','2012-06-28','https://www.ema.europa.eu/en/medicines/human/EPAR/qutenza','Neuralgia','HTA recommended at submitted price'),(2226,'2018-12-13 16:29:11','http://www.ncpe.ie/drugs/carbazitaxel-jevtana-for-prostate-cancer/','2011-06-02','2011-06-09','Full Pharmacoeconomic Evaluation Recommended.','2011-06-02, 2011-06-09',0,'Cabazitaxel (Jevtana®)','Jevtana','Economic Evaluation of cabazitaxel (Jevtana®) for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with docetaxel-containing treatment regimen.',2014,'2011-03-17','sanofi-aventis',0,'2011-06-02','2014-03-01','https://www.ema.europa.eu/en/medicines/human/EPAR/jevtana','Prostatic Neoplasms','HTA recommended at submitted price'),(2227,'2018-12-13 16:29:16','http://www.ncpe.ie/drugs/carfilzomib-kyprolis/','2015-12-07','2016-01-06','Full Pharmacoeconomic Evaluation Recommended','2015-12-07, 2016-01-06',0,'Carfilzomib (Kyprolis®)','Kyprolis','Kyprolis® (in combination with lenalidomide and dexamethasone) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.',2018,'2015-11-19','Amgen',1,'2015-12-07','2018-09-01','https://www.ema.europa.eu/en/medicines/human/EPAR/kyprolis','Multiple Myeloma','HTA recommended at submitted price'),(2228,'2018-12-13 16:29:22','http://www.ncpe.ie/drugs/catumaxomab-removab/','2011-08-05','2011-09-06','Full Pharmacoeconomic Evaluation not Recommended.','2011-08-05, 2011-09-06',0,'Catumaxomab (Removab®)','Removab','Catumazomab (Removab®) for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.',2011,'2009-04-20','Neovii',0,'2011-08-05','2011-09-06','https://www.ema.europa.eu/en/medicines/human/EPAR/removab','Ascites; Cancer','No HTA'),(2229,'2018-12-13 16:29:25','http://www.ncpe.ie/drugs/ceftaroline-zinforo/','2012-10-08','2012-10-12','Full pharmacoeconomic evaluation not recommended','2012-10-08, 2012-10-12',0,'Ceftaroline (Zinforo®)','Zinforo','For the treatment of adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia (CAP).',2012,'2012-08-22','Pfizer',0,'2012-10-08','2012-10-12','https://www.ema.europa.eu/en/medicines/human/EPAR/zinforo','Community-Acquired Infections; Skin Diseases, Infectious; Pneumonia','No HTA'),(2230,'2018-12-13 16:29:29','http://www.ncpe.ie/drugs/ceftazidime-avibactam-cef-avizavicefta/','2017-05-17','2017-06-13','Full Pharmacoeconomic Evaluation Recommended at the Submitted Price ','2017-05-17, 2017-06-13',0,'Ceftazidime-avibactam (CEF-AVI)(Zavicefta®)','Zavicefta','Ceftazidime-avibactam (CEF-AVI)(Zavicefta®) is indicated for the treatment of CIAI, cUTI, HAP (including VAP) and gram negative infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.',2017,'2016-06-23','Pfizer',0,'2017-05-17','2017-11-01','https://www.ema.europa.eu/en/medicines/human/EPAR/zavicefta','Pneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections','HTA recommended at submitted price'),(2231,'2018-12-13 16:29:34','http://www.ncpe.ie/drugs/ceftolozanetazobactam-zerbaxa/','2016-03-03','2016-04-26','Full Pharmacoeconomic Evaluation recommended at the Submitted Price.','2016-03-03, 2016-04-26',0,'Ceftolozane/tazobactam (Zerbaxa®)','Zerbaxa','Zerbaxa® is indicated for the treatment of complicated urinary tract infections (cUTI), acute pyelonephritis and complicated intra-abdominal infections (cIAI) in adults.',2016,'2015-09-18','Merck',0,'2016-03-03','2016-09-01','https://www.ema.europa.eu/en/medicines/human/EPAR/zerbaxa','Bacterial Infections','HTA recommended at submitted price'),(2232,'2018-12-13 16:29:36','http://www.ncpe.ie/drugs/ceritinib-zykadia/','2015-05-29','2015-07-22','Full Pharmacoeconomic Evaluation Recommended at the submitted price.','2015-05-29, 2015-07-22',0,'Ceritinib (Zykadia®)','Zykadia','Zykadia® is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.',2015,'2015-05-06','Novartis',0,'2015-05-29','2015-07-22','https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia','Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2233,'2018-12-13 16:29:40','http://www.ncpe.ie/drugs/cerliponase-alfa-brineura/','2017-10-11','2017-11-27','A full pharmacoeconomic evaluation is recommended.','2017-10-11, 2017-11-27',0,'Cerliponase alfa (Brineura®)','Brineura','Cerliponase alfa (Brineura®) is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.',2018,'2017-05-30','BioMarin',1,'2017-10-11','2018-08-02','https://www.ema.europa.eu/en/medicines/human/EPAR/brineura','Neuronal Ceroid-Lipofuscinoses','HTA recommended at submitted price'),(2234,'2018-12-13 16:29:44','http://www.ncpe.ie/drugs/certolizumab-pegol-cimzia/',NULL,'2017-11-27','','',0,'Certolizumab pegol (Cimzia®)','Cimzia','Cost-effectiveness of certolizumab pegol (Cimzia®) for the treatment of moderate to severe rheumatoid arthritis.',2010,'2009-10-01','UCB',0,'2010-03-13','2010-09-02','https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia-0','Arthritis, Rheumatoid','RR not conducted'),(2235,'2018-12-13 16:29:49','http://www.ncpe.ie/drugs/ciclosporin-1mgml-eye-drops-ikervis/','2015-01-07','2016-01-18','Full Pharmacoeconomic Evaluation Not Recommended','2015-01-07, 2016-01-18',0,'Ciclosporin 1mg/ml eye drops (Ikervis®)','Ikervis','Ikervis® is indicated for the treatment of severe keratitis in adult patients with dry eye disease (DED), which has not improved despite treatment with tear substitutes.',2016,'2015-03-19','Santen',0,'2015-01-07','2016-01-18','https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis','Corneal Diseases','No HTA'),(2236,'2018-12-13 16:29:54','http://www.ncpe.ie/drugs/cladribine-mavenclad/','2017-08-22','2017-09-18','A Full pharmacoeconomic assessment is recommended','2017-08-22, 2017-09-18',0,'Cladribine (Mavenclad®)','Mavenclad','Cladribine (Mavenclad®) for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features',2018,'2017-08-22','Merck',0,'2017-08-22','2018-09-01','https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad','Multiple Sclerosis','HTA recommended at submitted price'),(2237,'2018-12-13 16:29:58','http://www.ncpe.ie/drugs/clindamycin-1-with-tretinoin-0-025-treclinac/','2014-04-08','2014-05-06','Full Pharmacoeconomic Evaluation Not Recommended','2014-04-08, 2014-05-06',0,'Clindamycin 1% with tretinoin 0.025% (Treclinac®)','Treclinac','Clindamycin 1% with tretinoin 0.025% (Treclinac®) is indicated for the topical treatment of acne vulgaris when comedones, papules and pustules are present in patients 12 years or older.',2014,'1996-10-04','CIS',0,'2014-04-08','2014-05-06','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','No HTA'),(2238,'2018-12-13 16:30:02','http://www.ncpe.ie/drugs/cobimetinib-cotellic/','2016-04-19','2016-04-26','Full Pharmacoeconomic Evaluation Recommended','2016-04-19, 2016-04-26',0,'Cobimetinib (Cotellic®)','Cotellic','Cotellic® is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.',2018,'2015-11-20','Roche',0,'2016-04-19','2018-03-01','https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic','Melanoma','HTA recommended at submitted price'),(2239,'2018-12-13 16:30:03','http://www.ncpe.ie/drugs/colesevelam-cholestagel/','2010-10-19','2010-10-22','Full Pharmacoeconomic Evaluation not Recommended.','2010-10-19, 2010-10-22',0,'Colesevelam (Cholestagel®)','Cholestagel','Cost-effectiveness of Colesevelam (Cholestagel®)',2010,'2004-03-09','Genzyme',0,'2010-10-19','2010-10-22','https://www.ema.europa.eu/en/medicines/human/EPAR/cholestagel','Hypercholesterolemia','No HTA'),(2240,'2018-12-13 16:30:06','http://www.ncpe.ie/drugs/colistimethate-sodium-colobreathe/','2013-06-07','2013-06-28','Full Pharmacoeconomic Evaluation Not Recommended','2013-06-07, 2013-06-28',0,'Colistimethate sodium (Colobreathe®)','Colobreathe','Colistimethate sodium (colobreathe®) is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.',2013,'2012-02-13','Teva',0,'2013-06-07','2013-06-28','https://www.ema.europa.eu/en/medicines/human/EPAR/colobreathe','Cystic Fibrosis','No HTA'),(2241,'2018-12-13 16:30:17','http://www.ncpe.ie/drugs/collagenase-clostridium-histolyticum-xiapex/','2011-05-20','2011-06-09','Full Pharmacoeconomic Evaluation not Recommended','2011-05-20, 2011-06-09',0,'Collagenase Clostridium Histolyticum (Xiapex®)','Xiapex',' Collagenase Clostridium Histolyticum (Xiapex®) is indicated for the treatment of Dupuytren’s contracture in adult patients with a palpable cord.',2011,'2011-02-28','Swedish',0,'2011-05-20','2011-06-09','https://www.ema.europa.eu/en/medicines/human/EPAR/xiapex','Dupuytren Contracture','No HTA'),(2242,'2018-12-13 16:30:20','http://www.ncpe.ie/drugs/corifollitropin-alfa-elonva/','2010-10-22','2010-09-01','Full Pharmacoeconomic Evaluation not Recommended.','2010-10-22, 2010-09-01',0,'Corifollitropin alfa (Elonva®)','Elonva','Cost-effectiveness of Corifollitropin alfa (Elonva®).',2010,'2010-01-25','Merck',0,'2010-09-01','2010-10-22','https://www.ema.europa.eu/en/medicines/human/EPAR/elonva','Reproductive Techniques, Assisted; Ovulation Induction','No HTA'),(2243,'2018-12-13 16:30:24','http://www.ncpe.ie/drugs/crizotinib-xalkori-for-first-line-alk-nsclc/','2017-02-06','2017-04-24','Full Pharmacoeconomic Evaluation Not Recommended.','2017-02-06, 2017-04-24',0,'Crizotinib (Xalkori®) for first line ALK+ NSCLC','Xalkori','Crizotinib is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).',2017,'2012-10-23','Pfizer',0,'2017-02-06','2017-04-24','https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori','Carcinoma, Non-Small-Cell Lung','No HTA'),(2244,'2018-12-13 16:30:29','http://www.ncpe.ie/drugs/crizotinib-xalkori-for-ros1-nsclc/','2017-02-06','2017-04-24','Full Pharmacoeconomic Evaluation Not Recommended.','2017-02-06, 2017-04-24',0,'Crizotinib (Xalkori®) for ROS1 NSCLC','Xalkori','Crizotinib is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).',2017,'2012-10-23','Pfizer',0,'2017-02-06','2017-04-24','https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori','Carcinoma, Non-Small-Cell Lung','No HTA'),(2245,'2018-12-13 16:30:34','http://www.ncpe.ie/drugs/crizotinib-xalkori/','2013-01-09','2013-01-31','Full Pharmacoeconomic Evaluation Recommended','2013-01-09, 2013-01-31',0,'Crizotinib (Xalkori®)','Xalkori','For the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (i.e. in the 2nd / 3rd–line treatment setting)',2015,'2012-10-23','Pfizer',0,'2013-01-09','2015-08-01','https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori','Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2246,'2018-12-13 16:30:37','http://www.ncpe.ie/drugs/cysteamine-bitartrate-procysbi/','2015-12-01','2015-12-15','Full pharmacoeconomic assessment recommended at the submitted price','2015-12-01, 2015-12-15',0,'Cysteamine bitartrate delayed-release (Procysbi®)','Procysbi','Procysbi® for the treatment of proven nephropathic cystinosis.',2017,'2013-09-05','Chiesi',1,'2015-12-01','2017-11-15','https://www.ema.europa.eu/en/medicines/human/EPAR/procysbi','Cystinosis','HTA recommended at submitted price'),(2247,'2018-12-13 16:30:43','http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-2/','2014-05-09','2014-06-13','Full Pharmacoeconomic Evaluation Not Recommended','2014-05-09, 2014-06-13',0,'Dabigatran Etexilate (Pradaxa®) for the treatment of DVT and PE','Pradaxa','Dabigatran etexilate (Pradaxa®) is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.',2014,'2008-03-17','Boehringer',0,'2014-05-09','2014-06-13','https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa','Arthroplasty, Replacement; Venous Thromboembolism','No HTA'),(2248,'2018-12-13 16:30:51','http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-for-the-prevention-of-stroke-and-systematic-embolisom-in-atrial-fibrillation/',NULL,'2014-06-13','','',0,'Dabigatran etexilate (Pradaxa®) – for the prevention of stroke and systematic embolisom in atrial fibrillation','Pradaxa','Dabigatran etexilate (Pradaxa®) for the Prevention of Stroke and Systemic Embolism in Adult Patients with Atrial Fibrillation',2012,'2008-03-17','Boehringer',0,'2010-11-02','2012-10-03','https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa','Arthroplasty, Replacement; Venous Thromboembolism','RR not conducted'),(2249,'2018-12-13 16:30:57','http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-vte-prevention/',NULL,'2014-06-13','','',0,'Dabigatran Etexilate (Pradaxa®) for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement','Pradaxa','Economic Evaluation of the Cost Effectiveness of Dabigatran Etexilate (Pradaxa®) for the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have undergone Total Hip Replacement or Total Knee Surgery.',2008,'2008-03-17','Boehringer',0,'2008-07-01','2008-09-01','https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa','Arthroplasty, Replacement; Venous Thromboembolism','RR not conducted'),(2250,'2018-12-13 16:30:59','http://www.ncpe.ie/drugs/dabrafenib-tafinlar/','2013-09-11','2013-10-02','Full Pharmacoeconomic Evaluation Recommended','2013-09-11, 2013-10-02',0,'Dabrafenib (Tafinlar®)','Tafinlar','Dabrafenib (Tafinlar® ) is indicated for the treatment of adult patients with unresectable or Metastic Melanoma with a BRAF V600 mutation.',2014,'2013-08-26','Novartis',0,'2013-09-11','2014-06-24','https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar','Melanoma','HTA recommended at submitted price'),(2251,'2018-12-13 16:31:02','http://www.ncpe.ie/drugs/daclatasvir-daklinza/','2014-08-05','2014-09-12','Full Pharmacoeconomic Evaluation Recommended.','2014-08-05, 2014-09-12',0,'Daclatasvir (Daklinza®)','Daklinza','Daclatasvir (Daklinza®) is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (genotype 1,3 and 4). ',2015,'2014-08-22','Bristol-Myers',0,'2014-08-05','2015-05-29','https://www.ema.europa.eu/en/medicines/human/EPAR/daklinza','Hepatitis C, Chronic','HTA recommended at submitted price'),(2252,'2018-12-13 16:31:08','http://www.ncpe.ie/drugs/daclizumab-zinbryta/','2016-09-26','2016-11-23','Full Pharmacoeconomic Evaluation Recommended at the Submitted Price','2016-09-26, 2016-11-23',0,'Daclizumab (Zinbryta®)','Zinbryta','Daclizumab is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.',2018,'2016-07-01','Biogen',0,'2016-09-26','2018-03-07','https://www.ema.europa.eu/en/medicines/human/EPAR/zinbryta','Multiple Sclerosis','HTA recommended at submitted price'),(2253,'2018-12-13 16:31:12','http://www.ncpe.ie/drugs/dalbavancin-xydalba/','2017-03-07','2017-04-28','Full pharmacoeconomic assessment recommended at the submitted price','2017-03-07, 2017-04-28',0,'Dalbavancin (Xydalba®)','Xydalba','Dalbavancin (Xydalba®) is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.',2017,'2015-02-19','Allergan',0,'2017-03-07','2017-11-01','https://www.ema.europa.eu/en/medicines/human/EPAR/xydalba','Soft Tissue Infections; Skin Diseases, Bacterial','HTA recommended at submitted price'),(2254,'2018-12-13 16:31:18','http://www.ncpe.ie/drugs/dapagliflozin-forxiga/','2012-10-10','2012-10-22','Full pharmacoeconomic Evaluation Recommended','2012-10-10, 2012-10-22',0,'Dapagliflozin (Forxiga®)','Forxiga','Dapagliflozin (Forxiga®) is indicated in adults aged 18 years and older with Type 2 Diabetes Mellitus to improve glycaemic control as:\nMonotherapy\nWhen diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.\nAdd-on combination therapy\nIn combination with other glucose lowering drugs including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.',2013,'2012-11-11','AstraZeneca',0,'2012-10-10','2013-12-31','https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga','Diabetes Mellitus, Type 2','HTA recommended at submitted price'),(2255,'2018-12-13 16:31:21','http://www.ncpe.ie/drugs/daratumumab-darzalex/','2016-05-31','2016-06-14','Full Pharmacoeconomic Evaluation Recommended','2016-05-31, 2016-06-14',0,'Daratumumab (Darzalex®)','Darzalex','Daratumumab monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.',2018,'2017-04-28','Janssen-Cilag',1,'2016-05-31','2018-03-01','https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex','Multiple Myeloma','HTA recommended at submitted price'),(2256,'2018-12-13 16:31:25','http://www.ncpe.ie/drugs/darunavir-cobicistat-emtricitabine-tenofovir-alafenamide-symtuza/','2017-09-27','2017-10-26','Full pharmacoeconomic assessment not recommended','2017-09-27, 2017-10-26',0,'Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza®)','Symtuza','Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza®) is indicated for the treatment of HIV-1 in adults and adolescents.',2017,'2017-09-20','Janssen-Cilag',0,'2017-09-27','2017-10-26','https://www.ema.europa.eu/en/medicines/human/EPAR/symtuza','HIV Infections','No HTA'),(2257,'2018-12-13 16:31:30','http://www.ncpe.ie/drugs/darunavir-cobicistat-rezolsta/','2014-12-02','2015-01-08','Full Pharmacoeconomic Evaluation not Recommended','2014-12-02, 2015-01-08',0,'Darunavir & cobicistat (Rezolsta®)','Rezolsta','Indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older.',2015,'2014-11-19','Janssen-Cilag',0,'2014-12-02','2015-01-08','https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta','HIV Infections','No HTA'),(2258,'2018-12-13 16:31:35','http://www.ncpe.ie/drugs/darvadstrocel-alofisel/','2018-06-14','2018-07-17','A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of darvadstrocel compared with the current standard of care.','2018-06-14, 2018-07-17',0,'Darvadstrocel (Alofisel®)','Alofisel','Darvadstrocel (Alofisel®) for the treatment of complex perianal fistulae in adult patients with non-active/ mildly active luminal Crohn’s Disease when fistulae have shown an inadequate response to at least one conventional or biologic therapy and should be used after conditioning of fistula.',2018,'2018-03-23','Takeda',1,'2018-06-14','2018-07-31','https://www.ema.europa.eu/en/medicines/human/EPAR/alofisel','Rectal Fistula','HTA recommended at submitted price'),(2259,'2018-12-13 16:31:40','http://www.ncpe.ie/drugs/decitabine-dacogen/','2012-11-08','2012-12-13','Full Pharmacoeconomic Assessment Recommended','2012-11-08, 2012-12-13',0,'Decitabine (Dacogen®)','Dacogen','Decitabine (Dacogen®) is indicated for AML in patients who are >65yrs who are not candidates for standard induction therapy',2013,'2012-09-20','Janssen-Cilag',1,'2012-11-08','2013-12-05','https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen','Leukemia, Myeloid','HTA recommended at submitted price'),(2260,'2018-12-13 16:31:44','http://www.ncpe.ie/drugs/defibrotide-defitelio/','2014-05-12','2014-07-10','Full Pharmacoeconomic Evaluation Recommended at the Submitted Price','2014-05-12, 2014-07-10',0,'Defibrotide (Defitelio®)','Defitelio','Defibrotide (Defitelio®) indicated in adults, children and infants (>1month) for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy.',2014,'2013-10-18','Gentium',1,'2014-05-12','2014-07-10','https://www.ema.europa.eu/en/medicines/human/EPAR/defitelio','Hepatic Veno-Occlusive Disease','HTA recommended at submitted price'),(2261,'2018-12-13 16:31:47','http://www.ncpe.ie/drugs/degarelix-firmagon/','2009-10-15','2009-10-15','Full Pharmacoeconomic Evaluation not Recommended','2009-10-15',0,'Degarelix (Firmagon®)','Firmagon','Cost-effectiveness of Degarelix (Firmagon®)',2009,'2009-02-17','Ferring',0,'2009-10-15','2009-10-15','https://www.ema.europa.eu/en/medicines/human/EPAR/firmagon','Prostatic Neoplasms','No HTA'),(2262,'2018-12-13 16:31:52','http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-cannabidiol-thc-cbd-sativex/','2018-02-12','2018-04-03','A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of Sativex® compared with the current standard of care.','2018-02-12, 2018-04-03',0,'Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex®)','Sativex','Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex®) which is indicated as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.',2018,'2009-10-10','GlaxoSmithKline',0,'2018-02-12','2018-04-20','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','HTA recommended at submitted price'),(2263,'2018-12-13 16:31:59','http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-thccannabidiol-cbd-sativex/','2012-12-05','2013-01-04',' Full Pharmacoeconomic Assessment Recommended','2012-12-05, 2013-01-04',0,'Delta-9-tetrahydrocannabinol (THC) /Cannabidiol (CBD) (Sativex®)','Sativex','For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy',2014,'2009-10-10','GlaxoSmithKline',0,'2012-12-05','2014-09-26','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','HTA recommended at submitted price'),(2264,'2018-12-13 16:32:04','http://www.ncpe.ie/drugs/denosumab-prolia/',NULL,'2013-01-04','','',0,'Denosumab (Prolia®)','Prolia','The Cost-effectiveness of Denosumab (Prolia®) for the Prevention of Osteoporotic Fractures in Postmenopausal Women.',2010,'2010-05-26','Amgen',0,'2010-05-27','2010-07-01','https://www.ema.europa.eu/en/medicines/human/EPAR/prolia','Bone Resorption; Osteoporosis, Postmenopausal','RR not conducted'),(2265,'2018-12-13 16:32:08','http://www.ncpe.ie/drugs/denosumab-xgeva-3/',NULL,'2013-01-04','','',0,'Denosumab (Xgeva®)','Xgeva','Cost-effectiveness of denosumab (Xgeva®) for the prevention of skeletal related events in adults with bone metastases from solid tumours in Ireland.',2011,'2011-07-13','Amgen',0,'2011-08-15','2011-12-08','https://www.ema.europa.eu/en/medicines/human/EPAR/xgeva','Fractures, Bone; Neoplasm Metastasis','RR not conducted'),(2266,'2018-12-13 16:32:12','http://www.ncpe.ie/drugs/dexamethasone-intravitreal-implant-ozurdex/','2010-11-12','2010-12-16','Full Pharmacoeconomic Evaluation Recommended','2010-11-12, 2010-12-16',0,'Dexamethasone Intravitreal Implant (Ozurdex®)','Ozurdex','Cost-effectiveness of Ozurdex® in the treatment of macular oedema following Retinal Vein Occlusion.',2012,'2010-07-26','Allergan',0,'2010-11-12','2012-03-16','https://www.ema.europa.eu/en/medicines/human/EPAR/ozurdex','Macular Edema; Uveitis','HTA recommended at submitted price'),(2267,'2018-12-13 16:32:15','http://www.ncpe.ie/drugs/dexmedetomidine-dexdor/','2011-07-08','2011-09-06','Full Pharmacoeconomic Evaluation not Recommended','2011-07-08, 2011-09-06',0,'Dexmedetomidine (Dexdor®)','Dexdor','Dexmedetomidine (Dexdor®) for the treatemnt of ICU adult patients requiring light to moderate sedation.',2011,'2011-09-15','Orion',0,'2011-07-08','2011-09-06','https://www.ema.europa.eu/en/medicines/human/EPAR/dexdor','Conscious Sedation','No HTA'),(2268,'2018-12-13 16:32:21','http://www.ncpe.ie/drugs/dienogest-visanne/','2010-09-17','2010-10-04','Full Pharmacoeconomic Evaluation Recommended','2010-09-17, 2010-10-04',0,'Dienogest (Visanne®)','Visanne','Dienogest (Visanne®) for the Treatment of Endometriosis',2010,'2009-10-10','GlaxoSmithKline',0,'2010-09-17','2010-10-04','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','HTA recommended at submitted price'),(2269,'2018-12-13 16:32:24','http://www.ncpe.ie/drugs/dimethyl-fumarate-skilarence/','2018-01-15','2018-02-06','Full pharmacoeconomic assessment recommended','2018-01-15, 2018-02-06',0,'Dimethyl fumarate (Skilarence®)','Skilarence','Dimethyl fumarate (Skilarence®) for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.',2018,'2017-06-23','Almirall',0,'2018-01-15','2018-02-06','https://www.ema.europa.eu/en/medicines/human/EPAR/skilarence','Psoriasis','HTA recommended at submitted price'),(2270,'2018-12-13 16:32:26','http://www.ncpe.ie/drugs/dimethyl-fumarate-tecfidera/','2014-02-04','2014-03-06','Full Pharmacoeconomic Evaluation Recommended','2014-02-04, 2014-03-06',0,'Dimethyl fumarate (Tecfidera®)','Tecfidera','Dimethyl fumarate (Tecfidera®) is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (MS).',2015,'2014-01-30','Biogen',0,'2014-02-04','2015-04-14','https://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera','Multiple Sclerosis','HTA recommended at submitted price'),(2271,'2018-12-13 16:32:29','http://www.ncpe.ie/drugs/dinutuximab-beta-dinutuximab-beta-eusa/','2017-10-19','2017-11-23','Following assessment of the applicant’s submission, the NCPE recommends that dinutuximab beta (Qarziba®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Goods) Act 2013.','2017-10-19, 2017-11-23',0,'Dinutuximab beta (Qarziba®)','Qarziba','Dinutuximab beta EUSA for the treatment of high-risk neuroblastoma in patients ≥ 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease.',2018,'2009-12-09','Pfizer',0,'2017-10-19','2018-10-18','https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13','Pneumococcal Infections; Immunization','No HTA at submitted price'),(2272,'2018-12-13 16:32:34','http://www.ncpe.ie/drugs/dolutegravir-rilpivirine-juluca/','2018-06-08','2018-07-12','A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Juluca® not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\n ','2018-06-08, 2018-07-12',0,'Dolutegravir/Rilpivirine (Juluca®)','Juluca','Dolutegravir/rilpivirine (Juluca®)is indicated for the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.',2018,'2018-05-16','ViiV',0,'2018-06-08','2018-10-01','https://www.ema.europa.eu/en/medicines/human/EPAR/juluca','HIV Infections','No HTA at submitted price'),(2273,'2018-12-13 16:32:36','http://www.ncpe.ie/drugs/dolutegravir-tivicay/','2014-02-10','2014-03-13','Full Pharmacoeconomic Evaluation not recommended','2014-02-10, 2014-03-13',0,'Dolutegravir (Tivicay®)','Tivicay','Dolutegravir (Tivicay®) is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age.',2014,'2014-01-16','ViiV',0,'2014-02-10','2014-03-13','https://www.ema.europa.eu/en/medicines/human/EPAR/tivicay','HIV Infections','No HTA'),(2274,'2018-12-13 16:32:39','http://www.ncpe.ie/drugs/dronedarone-multaq/','2010-01-12','2010-01-01','Full Pharmacoeconomic Evaluation not Recommended.','2010-01-12, 2010-01-01',0,'Dronedarone (Multaq®)','Multaq','Rapid Review',2010,'2009-11-25','Sanofi-aventis',0,'2010-01-01','2010-01-12','https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0','Atrial Fibrillation','No HTA'),(2275,'2018-12-13 16:32:42','http://www.ncpe.ie/drugs/dulaglutide-trulicity/','2015-03-04','2015-04-29','Full pharmacoeconomic assessment not recommended','2015-03-04, 2015-04-29',0,'Dulaglutide (Trulicity®)','Trulicity','Dulaglutide is indicated as monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.',2015,'2014-11-21','Eli',0,'2015-03-04','2015-04-29','https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity','Diabetes Mellitus, Type 2','No HTA'),(2276,'2018-12-13 16:32:46','http://www.ncpe.ie/drugs/dupilumab-dupixent/','2017-11-13','2017-11-24','Full pharmacoeconomic assessment recommended','2017-11-13, 2017-11-24',0,'Dupilumab (Dupixent®)','Dupixent','Dupilumab (Dupixent®) is indicated for treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.',2018,'2017-09-27','sanofi-aventis',0,'2017-11-13','2018-06-18','https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent','Dermatitis, Atopic','HTA recommended at submitted price'),(2277,'2018-12-13 16:32:53','http://www.ncpe.ie/drugs/eculizumab-soliris/',NULL,'2017-11-24','','',0,'Eculizumab (Soliris®)','Soliris','An Economic Evaluation of Eculizumab (Soliris®) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in the Irish healthcare setting.',2013,'2007-06-20','Alexion',1,'2010-01-01','2013-10-14','https://www.ema.europa.eu/en/medicines/human/EPAR/soliris','Hemoglobinuria, Paroxysmal','RR not conducted'),(2278,'2018-12-13 16:32:55','http://www.ncpe.ie/drugs/edoxaban-lixiana/','2015-06-26','2015-07-10','Full Pharmacoeconomic Evaluation Not Recommended','2015-06-26, 2015-07-10',0,'Edoxaban (Lixiana®)','Lixiana','Edoxaban is indicated for the prevention of stroke/SE in adults with NVAF and for the treatment/secondary prevention of DVT and PE in adults.',2015,'2015-06-19','Daiichi',0,'2015-06-26','2015-07-10','https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana','Stroke; Venous Thromboembolism','No HTA'),(2279,'2018-12-13 16:33:00','http://www.ncpe.ie/drugs/elbasvirgrazoprevir-zepatier-2/','2016-08-10','2016-10-13','Full Pharmacoeconomic Evaluation Not Recommended','2016-08-10, 2016-10-13',0,'Elbasvir/Grazoprevir (Zepatier®)','Zepatier','Elbasvir 50mg/100mg grazoprevir (EBR/GZR)(Zepatier®) is indicated for the treatment of genotypes 1 and 4 chronic HCV infection in patients with Child-Turcotte-Pugh score A (CTPA).',2016,'2016-07-22','Merck',0,'2016-08-10','2016-10-13','https://www.ema.europa.eu/en/medicines/human/EPAR/zepatier','Hepatitis C, Chronic','No HTA'),(2280,'2018-12-13 16:33:03','http://www.ncpe.ie/drugs/eliglustat-cerdelga/','2016-03-21','2016-05-17','A Full pharmacoeconomic assessment is recommended','2016-03-21, 2016-05-17',0,'Eliglustat (Cerdelga®)','Cerdelga','Eliglustat (Cerdelga®) is indicated for the long-term treatment of adult patients with Gaucher disease type 1.',2018,'2015-01-19','Genzyme',1,'2016-03-21','2018-09-01','https://www.ema.europa.eu/en/medicines/human/EPAR/cerdelga','Gaucher Disease','HTA recommended at submitted price'),(2281,'2018-12-13 16:33:05','http://www.ncpe.ie/drugs/elosulfase-alfa-vimizim/','2015-03-30','2015-05-08','Full Pharmacoeconomic Evaluation Recommended','2015-03-30, 2015-05-08',0,'Elosulfase alfa (Vimizim®)','Vimizim','Elosulfase alfa (Vimzim®) is indicated for the treatment of mucopolysaccharidosis, type IVA (Morquio A syndrome, MPS IVA) in patients of all ages.',2018,'2014-04-27','BioMarin',1,'2015-03-30','2018-04-01','https://www.ema.europa.eu/en/medicines/human/EPAR/vimizim','Mucopolysaccharidosis IV','HTA recommended at submitted price'),(2282,'2018-12-13 16:33:12','http://www.ncpe.ie/drugs/eltrombopag-revolade-2/','2014-01-10','2014-02-13','Full Pharmacoeconomic Evaluation not Recommended.','2014-01-10, 2014-02-13',0,'Eltrombopag (Revolade®) for Thrombocytopenia in HCV','Revolade','Eltrombopag (Revolade®) is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy',2014,'2010-03-11','Novartis',1,'2014-01-10','2014-02-13','https://www.ema.europa.eu/en/medicines/human/EPAR/revolade','Purpura, Thrombocytopenic, Idiopathic','No HTA'),(2283,'2018-12-13 16:33:17','http://www.ncpe.ie/drugs/eltrombopag-revolade-3/','2016-02-05','2016-03-01','Full Pharmacoeconomic Evaluation Not Recommended','2016-02-05, 2016-03-01',0,'Eltrombopag (Revolade®) for Severe Aplastic Anaemia (SAA)','Revolade','Revolade® for the treatment adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation.',2016,'2010-03-11','Novartis',1,'2016-02-05','2016-03-01','https://www.ema.europa.eu/en/medicines/human/EPAR/revolade','Purpura, Thrombocytopenic, Idiopathic','No HTA'),(2284,'2018-12-13 16:33:23','http://www.ncpe.ie/drugs/eltrombopag-revolade/','2017-12-04','2017-12-01','A full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with currently available therapies.','2017-12-04, 2018-04-16, 2017-12-01',1,'Eltrombopag (Revolade®) for ITP','Revolade','Cost-effectiveness of eltrombopag (Revolade®) for the treatment of chronic immune thrombocytopenic purpura (ITP).',2018,'2010-03-11','Novartis',1,'2010-07-30','2018-04-16','https://www.ema.europa.eu/en/medicines/human/EPAR/revolade','Purpura, Thrombocytopenic, Idiopathic','HTA recommended at submitted price'),(2285,'2018-12-13 16:33:26','http://www.ncpe.ie/drugs/elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-genvoya/','2015-11-24','2016-01-05','Full Pharmacoeconomic Evaluation Not Recommended','2015-11-24, 2016-01-05',0,'Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide (Genvoya®)','Genvoya','Genvoya® is indicated for the treatment of adults and adolescents infected with human immunodeficiency virus – 1 (HIV-1).',2016,'2015-11-19','Gilead',0,'2015-11-24','2016-01-05','https://www.ema.europa.eu/en/medicines/human/EPAR/genvoya','HIV Infections','No HTA'),(2286,'2018-12-13 16:33:32','http://www.ncpe.ie/drugs/empagliflozin-jardiance/','2014-05-22','2014-06-12','Full Pharmacoeconomic Evaluation Not Recommended','2014-05-22, 2014-06-12',0,'Empagliflozin (Jardiance®)','Jardiance','Add-on combination therapy ',2014,'2014-05-22','Boehringer',0,'2014-05-22','2014-06-12','https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance','Diabetes Mellitus, Type 2','No HTA'),(2287,'2018-12-13 16:33:37','http://www.ncpe.ie/drugs/emtricitabine-tenofovir-disoproxil-fumarate-truvada/','2017-06-12','2017-07-18','Full pharmacoeconomic assessment recommended','2017-06-12, 2017-07-18',0,'Emtricitabine / tenofovir disoproxil fumarate (Truvada®)','Truvada','Truvada® is indicated in combination with safer sex practices for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.',2017,'2005-02-20','Gilead',0,'2017-06-12','2017-07-19','https://www.ema.europa.eu/en/medicines/human/EPAR/truvada','HIV Infections','HTA recommended at submitted price'),(2288,'2018-12-13 16:33:43','http://www.ncpe.ie/drugs/emtricitabine-tenovir-disoproxil-teva/','2017-12-11','2017-12-21','Full pharmacoeconomic assessment recommended','2017-12-11, 2017-12-21',0,'Emtricitabine/tenofovir disoproxil (TEVA®)','TEVA','Emtricitabine/tenofovir disoproxil (TEVA®) for pre-exposure prophylaxis in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults in high risk.',2017,'1996-10-04','CIS',0,'2017-12-11','2017-12-21','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','HTA recommended at submitted price'),(2289,'2018-12-13 16:33:48','http://www.ncpe.ie/drugs/emtricitabinetenofovir-alafenamide-descovy/','2016-04-26','2016-04-26','Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.','2016-04-26, 2016-04-26',0,'Emtricitabine/tenofovir alafenamide (Descovy®)','Descovy','Descovy® (F/TAF) is licensed in combination with other antiretroviral agents (ARVs) for the treatment of adults and adolescents (≥12 years; body weight ≥35 kg) infected with human immunodeficiency virus (HIV) type 1.',2016,'2016-04-21','Gilead',0,'2016-04-26','2016-04-26','https://www.ema.europa.eu/en/medicines/human/EPAR/descovy','HIV Infections','HTA recommended at submitted price'),(2290,'2018-12-13 16:33:52','http://www.ncpe.ie/drugs/enzalutamide-xtandi/','2013-06-28','2013-07-10','Full Pharmacoeconomic Evaluation Recommended','2013-06-28, 2013-07-10',0,'Enzalutamide (Xtandi®) on or after chemotherapy','Xtandi','Enzalutamide (Xtandi®) is indicated for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed on or after docetaxel therapy.',2014,'2013-06-21','Astellas',0,'2013-06-28','2014-04-10','https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi','Prostatic Neoplasms','HTA recommended at submitted price'),(2291,'2018-12-13 16:33:59','http://www.ncpe.ie/drugs/epoprostenol-veletri/','2016-12-13','2017-02-06','Full Pharmacoeconomic Evaluation Not Recommended','2016-12-13, 2017-02-06',0,'Epoprostenol (Veletri®)','Veletri','Veletri® is indicated for the treatment of pulmonary arterial hypertension (PAH) (idiopathic or heritable PAH and PAH associated with connective tissue diseases) in patients with WHO FC III–IV symptoms to improve exercise capacity.',2017,'1996-10-04','CIS',0,'2016-12-13','2017-02-06','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','No HTA'),(2292,'2018-12-13 16:34:03','http://www.ncpe.ie/drugs/erenumab-aimovig/','2018-07-19','2018-08-15','A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of erenumab compared with the current standard of care.','2018-07-19, 2018-08-15',0,'Erenumab (Aimovig®)','Aimovig','Erenumab (Aimovig®)  is indicated for the treatment of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig®.',2018,'2018-07-26','Novartis',0,'2018-07-19','2018-08-15','https://www.ema.europa.eu/en/medicines/human/EPAR/aimovig','Migraine Disorders','HTA recommended at submitted price'),(2293,'2018-12-13 16:34:07','http://www.ncpe.ie/drugs/eribulin-halaven/','2011-03-11','2011-02-09','Full Pharmacoeconomic Evaluation Recommended','2011-03-11, 2011-02-09',0,'Eribulin (Halaven®)','Halaven','Eribulin (Halaven®) for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.',2014,'2011-03-17','Eisai',0,'2011-02-09','2014-12-01','https://www.ema.europa.eu/en/medicines/human/EPAR/halaven','Breast Neoplasms; Liposarcoma','HTA recommended at submitted price'),(2294,'2018-12-13 16:34:09','http://www.ncpe.ie/drugs/eslicarbazepine-zebinix/','2009-09-01','2009-08-01','Full Pharmacoeconomic Evaluation Recommended.','2009-09-01, 2009-08-01',0,'Eslicarbazepine (Zebinix®)','Zebinix','Eslicarbazepine (Zebinix®) for the treatment of Epilepsy',2009,'2009-04-21','BIAL',0,'2009-08-01','2009-09-01','https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix','Epilepsy','HTA recommended at submitted price'),(2295,'2018-12-13 16:34:12','http://www.ncpe.ie/drugs/etanercept-benepali/','2016-03-22','2016-05-10','Full Pharmacoeconomic Evaluation not Recommended','2016-03-22, 2016-05-10',0,'Etanercept (Benepali®)','Benepali','Benepali® is a biosimilar of the TNF-α inhibitor Etanercept (Enbrel®) for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, axial spondylitis and plaque psoriasis.',2016,'2016-01-13','Samsung',0,'2016-03-22','2016-05-10','https://www.ema.europa.eu/en/medicines/human/EPAR/benepali','Arthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis','No HTA'),(2296,'2018-12-13 16:34:15','http://www.ncpe.ie/drugs/etelcalcetide-parsabiv/','2017-06-14','2017-09-01','Full pharmacoeconomic assessment recommended at the submitted price','2017-06-14, 2017-09-01',0,'Etelcalcetide (Parsabiv®)','Parsabiv','Etelcalcitide (Parsabiv®) is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis.',2018,'2016-11-11','Amgen',0,'2017-06-14','2018-03-01','https://www.ema.europa.eu/en/medicines/human/EPAR/parsabiv','Hyperparathyroidism, Secondary','HTA recommended at submitted price'),(2297,'2018-12-13 16:34:21','http://www.ncpe.ie/drugs/eurartesim-piperaquine-tetraphosphatedihidroartemisinin/','2012-05-22','2012-05-28','Full Pharmacoeconomic Evaluation not Recommended.','2012-05-22, 2012-05-28',0,'Piperaquine tetraphosphate/dihidroartemisinin (Eurartesim®)','Eurartesim','Eurartesim® (Piperaquine tetraphosphate/dihidroartemisinin) for uncomplicated malaria caused by the Plasmodium falciparum parasite',2012,'2011-10-27','Alfasigma',0,'2012-05-22','2012-05-28','https://www.ema.europa.eu/en/medicines/human/EPAR/eurartesim','Malaria','No HTA'),(2298,'2018-12-13 16:34:24','http://www.ncpe.ie/drugs/everolimus-afinitor/','2012-09-21','2012-10-12','Full Pharmacoeconomic Evaluation Recommended','2012-09-21, 2012-10-12',0,'Everolimus (Afinitor®)','Afinitor','Treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor',2012,'2009-08-02','Novartis',0,'2012-09-21','2012-10-12','https://www.ema.europa.eu/en/medicines/human/EPAR/afinitor','Carcinoma, Renal Cell; Breast Neoplasms; Pancreatic Neoplasms','HTA recommended at submitted price'),(2299,'2018-12-13 16:34:26','http://www.ncpe.ie/drugs/everolimus-votubia-for-refractory-seizures-associated-with-tuberous-sclerosis-complex-tsc/','2017-04-19','2017-04-26','Full Pharmacoeconomic Evaluation Recommended','2017-04-19, 2017-04-26',0,'Everolimus (Votubia ®) for refractory seizures associated with tuberous sclerosis complex (TSC)','Votubia','Everolimus (Votubia®) is indicated for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with TSC.',2017,'2011-09-02','Novartis',1,'2017-04-19','2017-04-26','https://www.ema.europa.eu/en/medicines/human/EPAR/votubia','Tuberous Sclerosis','HTA recommended at submitted price'),(2300,'2018-12-13 16:34:29','http://www.ncpe.ie/drugs/everolimus-votubia/','2011-09-30','2011-10-14','Full Pharmacoeconomic Evaluation Recommended','2011-09-30, 2011-10-14',0,'Everolimus (Votubia®)','Votubia','Everolimus (Votubia®) for the treatment of patients aged 3 years and older with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery',2011,'2011-09-02','Novartis',1,'2011-09-30','2011-10-14','https://www.ema.europa.eu/en/medicines/human/EPAR/votubia','Tuberous Sclerosis','HTA recommended at submitted price'),(2301,'2018-12-13 16:34:36','http://www.ncpe.ie/drugs/evolocumab-repatha/',NULL,'2011-10-14','','',0,'Evolocumab (Repatha®)','Repatha','Evolocumab (Repatha®) is indicated for both primary hypercholesterolaemia and mixed dyslipidaemia and heterozygous familial hypercholesterolaemia.',2018,'2015-07-17','Amgen',0,'2016-01-01','2018-05-16','https://www.ema.europa.eu/en/medicines/human/EPAR/repatha','Dyslipidemias; Hypercholesterolemia','RR not conducted'),(2302,'2018-12-13 16:34:41','http://www.ncpe.ie/drugs/exenatide-bydureon/','2011-05-31','2011-06-09','Full Pharmacoeconomic Evaluation not Recommended','2011-05-31, 2011-06-09',0,'Exenatide (Bydureon®)','Bydureon','Exenatide (Bydureon®) for the treatment of type II diabetes mellitus combined with Metformin, Sulphonylurea, Thiazolidinedione, Metform and SU and Metformn and TZD in adults who have not acheived glycaemic control on maximally tolerated doses of these oral therapies.',2011,'2011-06-17','AstraZeneca',0,'2011-05-31','2011-06-09','https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon','Diabetes Mellitus, Type 2','No HTA'),(2303,'2018-12-13 16:34:44','http://www.ncpe.ie/drugs/fampridine-fampyra/','2011-09-11','2011-09-01','Full Pharmacoeconomic Evaluation Recommended','2011-09-11, 2011-09-01',0,'Fampridine (Fampyra®)','Fampyra','Fampridine (Fampyra®) for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7).',2012,'2011-07-20','Blogen',0,'2011-09-01','2012-08-17','https://www.ema.europa.eu/en/medicines/human/EPAR/fampyra','Multiple Sclerosis','HTA recommended at submitted price'),(2304,'2018-12-13 16:34:48','http://www.ncpe.ie/drugs/ferric-maltol-feraccru_/','2016-08-12','2016-09-06','Reimbursement not recommended','2016-08-12, 2016-09-06',0,'Ferric maltol (Feraccru®)','Feraccru','Ferric maltol indicated for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD) in adult patients.',2016,'2016-02-18','Shield',0,'2016-08-12','2016-09-06','https://www.ema.europa.eu/en/medicines/human/EPAR/feraccru','Anemia, Iron-Deficiency','Reimbursement not recommended'),(2305,'2018-12-13 16:34:51','http://www.ncpe.ie/drugs/fidaxomicin-dificlir/','2012-03-09','2012-03-23','Full Pharmacoeconomic Evaluation Recommended.','2012-03-09, 2012-03-23',0,'Fidaxomicin (Dificlir®)','Dificlir','Fidaxomicin is indicated for the treatment of CDI also known as CDAD in adult patients.',2013,'2011-12-05','Astellas',0,'2012-03-09','2013-02-05','https://www.ema.europa.eu/en/medicines/human/EPAR/dificlir','Clostridium Infections','HTA recommended at submitted price'),(2306,'2018-12-13 16:34:56','http://www.ncpe.ie/drugs/fingolimod-gilenya-4/','2011-01-10','2010-12-03','Full Pharmacoeconomic Evaluation recommended','2011-01-10, 2010-12-03',0,'Fingolimod (Gilenya®)','Gilenya','Cost effectiveness of Fingolimod (Gilenya®) for the treatment of highly active relapsing-remitting multiple sclerosis.',2011,'2011-03-17','Novartis',0,'2010-12-03','2011-09-22','https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya','Multiple Sclerosis','HTA recommended at submitted price'),(2307,'2018-12-13 16:35:01','http://www.ncpe.ie/drugs/fluocinolone-acetonide-iluvien/','2016-02-15','2016-03-01','Full Pharmacoeconomic Evaluation Not Recommended','2016-02-15, 2016-03-01',0,'Fluocinolone acetonide (Iluvien®)','Iluvien','Iluvien® is indicated for the treatment of vision impairment associated with chronic diabetic macular oedema (DMO) considered insufficiently responsive to available therapies.',2016,'2009-10-10','GlaxoSmithKline',0,'2016-02-15','2016-03-01','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','No HTA'),(2308,'2018-12-13 16:35:05','http://www.ncpe.ie/drugs/fluticasone-furoate-umeclidinium-vilantero-trelegy-ellipta/','2018-04-30','2018-06-18','A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Trelegy™ Ellipta™ be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\n ','2018-04-30, 2018-06-18',0,'Fluticasone furoate/ umeclidinium/ vilantero (Trelegy™ Ellipta™)','Trelegy Ellipta','Trelegy™ Ellipta™ which is indicated as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA.',2018,'2017-11-15','GlaxoSmithKline',0,'2018-04-30','2018-06-18','https://www.ema.europa.eu/en/medicines/human/EPAR/trelegy-ellipta','Pulmonary Disease, Chronic Obstructive','Reimbursement without HTA'),(2309,'2018-12-13 16:35:09','http://www.ncpe.ie/drugs/follitropin-delta-rekovelle/','2017-07-25','2017-08-15','Full pharmacoeconomic assessment recommended at submitted price\n','2017-07-25, 2017-08-15',0,'Follitropin delta (Rekovelle®)','Rekovelle','Follitropin delta (Rekovelle ®) is indicated for controlled ovarian stimulation (COS) for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle',2019,'2016-12-12','Ferring',0,'2017-07-25','2019-02-01','https://www.ema.europa.eu/en/medicines/human/EPAR/rekovelle','Anovulation','HTA recommended at submitted price'),(2310,'2018-12-13 16:35:12','http://www.ncpe.ie/drugs/gefitinib-iressa/',NULL,'2017-08-15','','',0,'Gefitinib (Iressa®)','Iressa','A review of the economic evaluation of oral gefitinib (Iressa®) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR.',2010,'2009-06-24','AstraZeneca',0,'2010-06-16','2010-11-05','https://www.ema.europa.eu/en/medicines/human/EPAR/iressa','Carcinoma, Non-Small-Cell Lung','RR not conducted'),(2311,'2018-12-13 16:35:15','http://www.ncpe.ie/drugs/gemtuzumab-ozogamicin-mylotarg/','2018-06-21','2018-07-17','A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of gemtuzumab ozogamicin compared with the current standard of care.','2018-06-21, 2018-07-17',0,'Gemtuzumab ozogamicin (Mylotarg®)','Mylotarg','Gemtuzumab ozogamicin (Mylotarg®) which is indicated for combination therapy with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive AML, except acute promyelocytic leukaemia.',2018,'2018-04-19','Pfizer',1,'2018-06-21','2018-07-31','https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0','Leukemia, Myeloid, Acute','HTA recommended at submitted price'),(2312,'2018-12-13 16:35:19','http://www.ncpe.ie/drugs/glecaprevirpibrentasvir-maviret/','2017-07-11','2017-08-17','Full pharmacoeconomic assessment not recommended','2017-07-11, 2017-08-17',0,'Glecaprevir/Pibrentasvir (Maviret®)','Maviret','Glecaprevir/pibrentasvir (Maviret®) is licensed for the treatment of chronic hepatitis C virus (HCV) infection in adults – pangenotypic GT1-6.',2017,'2017-07-26','AbbVie',0,'2017-07-11','2017-08-17','https://www.ema.europa.eu/en/medicines/human/EPAR/maviret','Hepatitis C, Chronic','No HTA'),(2313,'2018-12-13 16:35:25','http://www.ncpe.ie/drugs/glucosamine-sulfate-dona/',NULL,'2017-08-17','','',0,'Glucosamine sulfate (Dona®)','Dona','Economic evalution of glucosamine sulfate (Dona®) for the treatment of oestoarthritis in the Irish Healthcare setting.',2009,'1996-10-04','CIS',0,'2009-04-01','2009-06-01','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','RR not conducted'),(2314,'2018-12-13 16:35:32','http://www.ncpe.ie/drugs/glycerol-phenylbutyrate-ravicti/','2018-03-26','2018-06-20','A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Glycerol Phenylbutyrate (Ravicti®) be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.','2018-03-26, 2018-06-20',0,'Glycerol Phenylbutyrate (Ravicti®)','Ravicti','Glycerol phenylbutyrate (Ravicti®) which is indicated for use as adjunctive therapy for chronic management of adult and paediatric patients ≥2 months of age with urea cycle disorders (UCDs).',2018,'2015-11-26','Horizon',1,'2018-03-26','2018-06-20','https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti','Urea Cycle Disorders, Inborn','Reimbursement without HTA'),(2315,'2018-12-13 16:35:38','http://www.ncpe.ie/drugs/glycopyrronium-bromide-seebri-breezhaler/','2012-08-12','2012-08-17','Full pharmacoeconomic evaluation not recommended','2012-08-12, 2012-08-17',0,'Glycopyrronium bromide (Seebri Breezhaler®)','Seebri Breezhaler','Seebri Breezhaler® is indicated as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD).',2012,'2012-09-28','Novartis',0,'2012-08-12','2012-08-17','https://www.ema.europa.eu/en/medicines/human/EPAR/seebri-breezhaler','Pulmonary Disease, Chronic Obstructive','No HTA'),(2316,'2018-12-13 16:35:40','http://www.ncpe.ie/drugs/glypyrronium-bromide-sialanar/','2017-03-07','2017-03-13','Full pharmacoeconomic evaluation recommended at the submitted price','2017-03-07, 2017-03-13',0,'Glycopyrronium bromide (Sialanar®)','Sialanar','Glycopyrronium bromide (Sialanar®) is indicated for symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders',2017,'2016-09-15','Proveca',0,'2017-03-07','2017-03-13','https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar','Sialorrhea','HTA recommended at submitted price'),(2317,'2018-12-13 16:35:47','http://www.ncpe.ie/drugs/golimumab-simponi-2/','2013-10-11','2013-10-31','Full HTA not recommended','2013-10-11, 2013-10-31',0,'Golimumab (Simponi®) for UC','Simponi','Golimumab is indicated for the treatment of moderately-to-severely active UC in patients who have failed or are intolerant to conventional treatments.',2013,'2009-10-01','Janssen',0,'2013-10-11','2013-10-31','https://www.ema.europa.eu/en/medicines/human/EPAR/simponi','Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid','No HTA'),(2318,'2018-12-13 16:35:54','http://www.ncpe.ie/drugs/golimumab-simponi/',NULL,'2013-10-31','','',0,'Golimumab (Simponi®)','Simponi','Cost-effectiveness of golimumab (Simponi®) in the treatment of moderate to severe rheumatoid arthritis.',2010,'2009-10-01','Janssen',0,'2009-11-20','2010-06-01','https://www.ema.europa.eu/en/medicines/human/EPAR/simponi','Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid','RR not conducted'),(2319,'2018-12-13 16:35:56','http://www.ncpe.ie/drugs/grass-pollen-allergen-extract-oralair/','2011-10-11','2011-09-26','Full Pharmacoeconomic Evaluation not Recommended','2011-10-11, 2011-09-26',0,'Grass pollen allergen extract (Oralair®)','Oralair',' Grass pollen allegen extract (Oralair®) for the treatment of allergic grass pollen rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms confirmed by a positive cutaneous test and/or a positive titre of the specific IgE to the grass pollen.',2011,NULL,'Unknown',0,'2011-09-26','2011-10-01','','Unknown','No HTA'),(2320,'2018-12-13 16:36:00','http://www.ncpe.ie/drugs/guanfacine-hydrochloride-intuniv/','2015-12-01','2015-12-18','Full Pharmacoeconomic Evaluation Not Recommended','2015-12-01, 2015-12-18',0,'Guanfacine hydrochloride (Intuniv®)','Intuniv','Intuniv® is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.  It must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.',2015,'2015-09-17','Shire',0,'2015-12-01','2015-12-18','https://www.ema.europa.eu/en/medicines/human/EPAR/intuniv','Attention Deficit Disorder with Hyperactivity','No HTA'),(2321,'2018-12-13 16:36:02','http://www.ncpe.ie/drugs/guselkumab-tremfya/','2017-12-01','2018-02-06','Full pharmacoeconomic assessment recommended at the submitted price','2017-12-01, 2018-02-06',0,'Guselkumab (Tremfya®)','Tremfya','Guselkumab (Tremfya®) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.',2018,'2017-11-10','Janssen-Cilag',0,'2017-12-01','2018-03-01','https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya','Psoriasis','HTA recommended at submitted price'),(2322,'2018-12-13 16:36:07','http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-a1pi-prolastin/','2017-05-05','2017-06-08','Full Pharmacoeconomic Evaluation Recommended at the Submitted Price ','2017-05-05, 2017-06-08',0,'Human alpha1-proteinase inhibitor (A1PI) (Prolastin®)','Prolastin','Human A1PI (Prolastin ®)  is indicated for long-term augmentation therapy in subjects with alpha1-proteinase inhibitor deficiency (phenotypes PiZZ, PiZ(null), Pi (null,null) and PiSZ) within the limits of moderate airflow obstruction (FEV1 35-60%) and the evaluation of the clinical condition (disability).',2017,'2009-10-10','GlaxoSmithKline',0,'2017-05-05','2017-06-08','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','HTA recommended at submitted price'),(2323,'2018-12-13 16:36:14','http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-respreeza/','2016-01-20','2016-02-05','Full Pharmacoeconomic Evaluation Recommended','2016-01-20, 2016-02-05',0,'Human alpha1-proteinase inhibitor (Respreeza®)','Respreeza','Respreeza® is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null, null), PiSZ). Patients are to be under optimal pharmacologic and nonpharmacological treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (FEV1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.',2017,'2015-08-20','CSL',0,'2016-01-20','2017-01-01','https://www.ema.europa.eu/en/medicines/human/EPAR/respreeza','Genetic Diseases, Inborn; Lung Diseases','HTA recommended at submitted price'),(2324,'2018-12-13 16:36:17','http://www.ncpe.ie/drugs/hyaluronic-acid-and-co-enzyme-q10-visuxl/','2017-11-06','2017-11-30','Reimbursement not recommended at the submitted price','2017-11-06, 2017-11-30',0,'Hyaluronic acid and co enzyme Q10 (VisuXL®)','VisuXL','Cross linked hyaluronic acid and co enzyme Q10 (VisuXL®) for the treatment of dry eye disease and the treatment of post-surgical intervention following elective surgery and trauma.',2017,'1996-10-04','CIS',0,'2017-11-06','2017-11-30','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','Reimbursement not recommended'),(2325,'2018-12-13 16:36:22','http://www.ncpe.ie/drugs/hydrocortisone-plenadren/','2017-11-08','2017-11-01','Reimbursement not recommended at the submitted price','2017-11-08, 2018-01-11, 2017-11-01',1,'Modified Release Hydrocortisone  (Plenadren®)','Plenadren','Modified release hydrocortisone (Plenadren®) for the treatment of adrenal insufficiency in adults.',2018,'2011-11-03','Shire',1,'2013-08-09','2018-01-11','https://www.ema.europa.eu/en/medicines/human/EPAR/plenadren','Adrenal Insufficiency','Reimbursement not recommended'),(2326,'2018-12-13 16:36:27','http://www.ncpe.ie/drugs/hydroxcarbamide-siklos/','2011-08-22','2011-09-06','Full Pharmacoeconomic Evaluation not Recommended','2011-08-22, 2011-09-06',0,'Hydroxycarbamide (Siklos®)','Siklos',' Hydroxycarbamide (Siklos®) is indicated for use in the prevention of painful, recurrent vaso-occlusive crises, including acute chest syndrome, in adults, adolescents and children over 2 years of age suffering from symptomatic sickle-cell disease.',2011,'2007-06-29','Addmedica',1,'2011-08-22','2011-09-06','https://www.ema.europa.eu/en/medicines/human/EPAR/siklos','Anemia, Sickle Cell','No HTA'),(2327,'2018-12-13 16:36:32','http://www.ncpe.ie/drugs/ibrutinib-imbruivca-for-previously-untreated-cll/','2016-08-02','2016-08-24','Full pharmacoeconomic evaluation recommended','2016-08-02, 2016-08-24',0,'Ibrutinib (Imbruvica®) for previously untreated CLL','Imbruvica','Ibrutinib (Imbruvica®), as a single agent, is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). This indication is an extension to the original licence in the relapsed/refractory setting.',2016,'2014-10-21','Janssen-Cilag',1,'2016-08-02','2016-08-24','https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica','Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell','HTA recommended at submitted price'),(2328,'2018-12-13 16:36:36','http://www.ncpe.ie/drugs/ibrutinib-imbruvica-for-mcl/','2014-11-07','2014-12-18','Full Pharmacoeconomic Evaluation Recommended','2014-11-07, 2014-12-18',0,'Ibrutinib (Imbruvica®) for MCL','Imbruvica','Ibrutinib (Imbruvica®) is indicated in the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).',2015,'2014-10-21','Janssen-Cilag',1,'2014-11-07','2015-10-06','https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica','Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell','HTA recommended at submitted price'),(2329,'2018-12-13 16:36:40','http://www.ncpe.ie/drugs/icatibant-firazyr/','2013-07-01','2013-07-01','Full pharmacoeconomic evaluation not recommended','2013-07-01, 2013-07-01',0,'Icatibant (Firazyr®)','Firazyr','Icatibant (Firazyr®) indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (type I and II HAE).',2013,'2008-07-11','Shire',1,'2013-07-01','2013-07-01','https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr','Angioedemas, Hereditary','No HTA'),(2330,'2018-12-13 16:36:43','http://www.ncpe.ie/drugs/idarucizumab-praxbind/','2015-12-11','2015-12-18','Full Pharmacoeconomic Evaluation Not Recommended','2015-12-11, 2015-12-18',0,'Idarucizumab (Praxbind®)','Praxbind','Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required:',2015,'2015-11-20','Boehringer',0,'2015-12-11','2015-12-18','https://www.ema.europa.eu/en/medicines/human/EPAR/praxbind','Hemorrhage','No HTA'),(2331,'2018-12-13 16:36:50','http://www.ncpe.ie/drugs/idebenone-raxone/','2016-02-10','2016-04-14','A Full pharmacoeconomic assessment is recommended','2016-02-10, 2016-04-14',0,'Idebenone (Raxone®)','Raxone','Raxone® is indicated for the treatment of visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON).',2018,'2015-09-08','Santhera',1,'2016-02-10','2018-08-28','https://www.ema.europa.eu/en/medicines/human/EPAR/raxone','Optic Atrophy, Hereditary, Leber','HTA recommended at submitted price'),(2332,'2018-12-13 16:36:56','http://www.ncpe.ie/drugs/idelalisib-zydelig/','2014-12-08','2014-12-30','Full Pharmacoeconomic Evaluation Recommended','2014-12-08, 2014-12-30',0,'Idelalisib (Zydelig®)','Zydelig','Indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.',2016,'2014-09-18','Gilead',0,'2014-12-08','2016-12-01','https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig','Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell','HTA recommended at submitted price'),(2333,'2018-12-13 16:36:59','http://www.ncpe.ie/drugs/imiquimod-zyclara/','2013-09-10','2013-09-18','Full Pharmacoeconomic Evaluation not recommended','2013-09-10, 2013-09-18',0,'Imiquimod 3.75% (Zyclara®)','Zyclara','Imiquimod 3.75%(Zyclara®) indicated for topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis (AK) of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.',2013,'2012-08-23','Meda',0,'2013-09-10','2013-09-18','https://www.ema.europa.eu/en/medicines/human/EPAR/zyclara','Keratosis; Keratosis, Actinic','No HTA'),(2334,'2018-12-13 16:37:01','http://www.ncpe.ie/drugs/incobotulinum-toxin-type-a-xeomin/','2014-02-07','2014-03-05','Full Pharmacoeconomic Evaluation not recommended','2014-02-07, 2014-03-05',0,'Incobotulinum Toxin Type A (Xeomin®)','Xeomin','Incobotulinum Toxin Type A (Xeomin®) is indicated for the symptomatic treatment of blepharospasm, cervical dystonia of a predominantly rotational form (spasmodic torticollis) and of post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults.',2014,'1996-10-04','CIS',0,'2014-02-07','2014-03-05','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','No HTA'),(2335,'2018-12-13 16:37:04','http://www.ncpe.ie/drugs/indacaterol-onbrez/','2010-01-15','2010-01-15','Full Pharmacoeconomic Evaluation not Recommended.','2010-01-15',0,'Indacaterol (Onbrez®)','Onbrez','Review of Indacaterol (Onbrez®) for the treatment of COPD.',2010,NULL,'Unknown',0,'2010-01-15','2010-01-15','','Unknown','No HTA'),(2336,'2018-12-13 16:37:07','http://www.ncpe.ie/drugs/infliximab-inflectra/',NULL,'2010-01-15','','',0,'Infliximab (Inflectra®)','Inflectra','Inflectra® is a biosimilar product indicated for Rheumatoid Arthritis, Adult Crohn’s disease, Paediatric Crohn’s disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis.',2013,'2013-09-09','Pfizer',0,'2013-09-10','2013-09-20','https://www.ema.europa.eu/en/medicines/human/EPAR/inflectra','Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Psoriasis; Crohn Disease; Arthritis, Rheumatoid','RR not conducted'),(2337,'2018-12-13 16:37:09','http://www.ncpe.ie/drugs/inotuzumab-ozogamicin-besponsa/','2017-07-03','2017-09-08','Full pharmacoeconomic assessment recommended','2017-07-03, 2017-09-08',0,'Inotuzumab ozogamicin (Besponsa®)','Besponsa','Inotuzumab ozogamicin (Besponsa®) is indicated as monotherapy for the treatment of adults with relapsed or refractory (R/R) CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).',2018,'2017-06-28','Pfizer',1,'2017-07-03','2018-09-14','https://www.ema.europa.eu/en/medicines/human/EPAR/besponsa','Precursor Cell Lymphoblastic Leukemia-Lymphoma','HTA recommended at submitted price'),(2338,'2018-12-13 16:37:16','http://www.ncpe.ie/drugs/insulin-aspart-fiasp/','2017-05-17','2017-06-14','Full Pharmacoeconomic Evaluation Not Recommended','2017-05-17, 2017-06-14',0,'Insulin aspart (Fiasp®)','Fiasp','Insulin aspart (Fiasp®) is indicated for the treatment of diabetes mellitus in adults.',2017,'2017-01-09','Novo',0,'2017-05-17','2017-06-14','https://www.ema.europa.eu/en/medicines/human/EPAR/fiasp','Diabetes Mellitus','No HTA'),(2339,'2018-12-13 16:37:21','http://www.ncpe.ie/drugs/insulin-aspart-novorapid-flextouch/','2014-07-22','2014-08-28','Full pharmacoeconomic evaluation recommended at the submitted price.','2014-07-22, 2014-08-28',0,'Insulin aspart (NovoRapid® FlexTouch ®)','NovoRapid FlexTouch','Insulin aspart (NovoRapid® FlexTouch ®) is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.',2014,NULL,'Unknown',0,'2014-07-22','2014-08-28','','Unknown','HTA recommended at submitted price'),(2340,'2018-12-13 16:37:25','http://www.ncpe.ie/drugs/insulin-degludec-tresiba/','2012-12-17','2013-01-04',' Full Pharmacoeconomic Assessment Recommended','2012-12-17, 2013-01-04',0,'Insulin Degludec (Tresiba®)','Tresiba','Treatment of diabetes mellitus',2015,'2013-01-20','Novo',0,'2012-12-17','2015-12-01','https://www.ema.europa.eu/en/medicines/human/EPAR/tresiba','Diabetes Mellitus','HTA recommended at submitted price'),(2341,'2018-12-13 16:37:30','http://www.ncpe.ie/drugs/insulin-degludecliraglutide-ideglira-xultophy/','2016-09-19','2016-10-17','Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.  ','2016-09-19, 2016-10-17',0,'Insulin degludec/liraglutide (IDegLira) (Xultophy®)','Xultophy','IDegLira is indicated for the treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or in combination with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) or basal insulin does not provide adequate glycaemic control.',2016,'2014-09-18','Novo',0,'2016-09-19','2016-10-17','https://www.ema.europa.eu/en/medicines/human/EPAR/xultophy','Diabetes Mellitus, Type 2','HTA recommended at submitted price'),(2342,'2018-12-13 16:37:36','http://www.ncpe.ie/drugs/insulin-glargine-abasaglar/','2015-09-04','2015-10-12','Full Pharmacoeconomic Evaluation Not Recommended','2015-09-04, 2015-10-12',0,'Insulin Glargine (Abasaglar®)','Abasaglar','Abasaglar® is indicated in the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.',2015,'2009-10-10','GlaxoSmithKline',0,'2015-09-04','2015-10-12','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','No HTA'),(2343,'2018-12-13 16:37:40','http://www.ncpe.ie/drugs/insulin-glargine-u300-toujeo/','2015-05-14','2015-07-02','Full Pharmacoeconomic Evaluation Recommended at the Submitted Price','2015-05-14, 2015-07-02',0,'Insulin Glargine U300 (Toujeo®)','Toujeo','Toujeo® is indicated for the treatment of diabetes mellitus in adults.',2015,'2009-10-10','GlaxoSmithKline',0,'2015-05-14','2015-07-02','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','HTA recommended at submitted price'),(2344,'2018-12-13 16:37:43','http://www.ncpe.ie/drugs/ipilimumab-yervoy/','2011-05-31','2011-06-09','Full Pharmacoeconomic Evaluation Recommended','2011-05-31, 2011-06-09',0,'Ipilimumab (Yervoy®)','Yervoy','Pharmacoeconomic evaluation of Ipilimumab (Yervoy®) for the treatment of advanced (unresectable or metastatic) melanoma in adult patients who have received prior therapy.',2013,'2011-07-12','Bristol-Myers',0,'2011-05-31','2013-09-01','https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy','Melanoma','HTA recommended at submitted price'),(2345,'2018-12-13 16:37:49','http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-diafer/','2015-10-10','2015-11-18','Full Pharmacoeconomic Evaluation Not Recommended','2015-10-10, 2015-11-18',0,'Iron (III) isomaltoside 1000 (Diafer®)','Diafer','Diafer® is indicated in adults for the treatment of iron deficiency in patients with chronic kidney disease on dialysis, when oral iron preparations are ineffective or cannot be used.',2015,'2009-10-10','GlaxoSmithKline',0,'2015-10-10','2015-11-18','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','No HTA'),(2346,'2018-12-13 16:37:52','http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-monover/','2015-10-10','2015-11-18','Full Pharmacoeconomic Evaluation Not Recommended','2015-10-10, 2015-11-18',0,'Iron (III) isomaltoside 1000 (Monover®)','Monover','Monover® is indicated in the treatment of Iron deficiency anaemia when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly.',2015,'2009-10-10','GlaxoSmithKline',0,'2015-10-10','2015-11-18','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','No HTA'),(2347,'2018-12-13 16:38:02','http://www.ncpe.ie/drugs/iron-isomaltoside-1000-monover/','2011-01-10','2011-02-02','Full Pharmacoeconomic Evaluation not Recommended','2011-01-10, 2011-02-02',0,'Iron isomaltoside 1000 (MonoVer®)','MonoVer','MonoVer is indicated for the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly.',2011,'2009-10-10','GlaxoSmithKline',0,'2011-01-10','2011-02-02','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','No HTA'),(2348,'2018-12-13 16:38:07','http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-invasive-aspergillosis/','2016-04-11','2016-05-11','Full Pharmacoeconomic Evaluation Recommended at the submitted price.','2016-04-11, 2016-05-11',0,'Isavuconazole (Cresemba®) for the treatment of invasive aspergillosis.','Cresemba','Isavuconazole (Cresemba®) is indicated for the treatment of invasive aspergillosis',2018,'2015-10-15','Basilea',1,'2016-04-11','2018-03-01','https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba','Aspergillosis','HTA recommended at submitted price'),(2349,'2018-12-13 16:38:09','http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-mucormycosis/','2016-04-11','2016-05-11','Full Pharmacoeconomic Evaluation Not Recommended. ','2016-04-11, 2016-05-11',0,'Isavuconazole (Cresemba®) for the treatment of mucormycosis','Cresemba','Isavuconazole (Cresemba®) is indicated in adults for the treatment of mucormycosis in patients for whom amphotericin B is inappropriate.',2018,'2015-10-15','Basilea',1,'2016-04-11','2018-03-01','https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba','Aspergillosis','No HTA'),(2350,'2018-12-13 16:38:15','http://www.ncpe.ie/drugs/ivacaftor-kaldeco/','2012-08-13','2012-08-22','Full pharmacoeconomic assessment recommended','2012-08-13, 2012-08-22',0,'Ivacaftor (Kalydeco®)','Kalydeco','For the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation',2013,'2012-07-22','Vertex',1,'2012-08-13','2013-01-21','https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco','Cystic Fibrosis','HTA recommended at submitted price'),(2351,'2018-12-13 16:38:21','http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-patients-with-cf-2-years/','2015-11-19','2015-12-18','Full Pharmaoeconomic Evaluation Recommended','2015-11-19, 2015-12-18',0,'Ivacaftor (Kalydeco®) for patients with CF 2 years +','Kalydeco','Kalydeco® is indicated for the treatment of children with CF aged 2 years and older and weighing less than 25 kg who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.',2016,'2012-07-22','Vertex',1,'2015-11-19','2016-10-12','https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco','Cystic Fibrosis','HTA recommended at submitted price'),(2352,'2018-12-13 16:38:24','http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-the-treatment-of-cf-patients-with-the-r117h-mutation/','2016-01-14','2016-02-10','Full Pharmacoeconomic Evaluation Recommended','2016-01-14, 2016-02-10',0,'Ivacaftor (Kalydeco®) for the treatment of CF patients with the R117H mutation.','Kalydeco','Kalydeco® for the treatment of patients with cystic fibrosis aged 18 years and older who have the R117H mutation in the CFTR gene.',2017,'2012-07-22','Vertex',1,'2016-01-14','2017-01-05','https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco','Cystic Fibrosis','HTA recommended at submitted price'),(2353,'2018-12-13 16:38:29','http://www.ncpe.ie/drugs/ixazomib-ninlaro/','2016-11-23','2017-01-16','Full pharmacoeconomic assessment recommended','2016-11-23, 2017-01-16',0,'Ixazomib (Ninlaro®)','Ninlaro','Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.',2018,'2016-11-21','Takeda',1,'2016-11-23','2018-12-01','https://www.ema.europa.eu/en/medicines/human/EPAR/ninlaro','Multiple Myeloma','HTA recommended at submitted price'),(2354,'2018-12-13 16:38:34','http://www.ncpe.ie/drugs/ixekizumab-taltz-for-psoriatic-arthritis/','2018-10-16','2018-11-19','A Full pharmacoeconomic assessment is not recommended. The NCPE recommends that ixekizumab not be considered for reimbursement at the submitted price. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013','2018-10-16, 2018-11-19',0,'Ixekizumab (Taltz®) for psoriatic arthritis','Taltz','Ixekizumab (Taltz®) is indicated for the treatment of active PsA in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.',2018,'2016-04-25','Eli',0,'2018-10-16','2018-11-19','https://www.ema.europa.eu/en/medicines/human/EPAR/taltz','Psoriasis','No HTA at submitted price'),(2355,'2018-12-13 16:38:37','http://www.ncpe.ie/drugs/ixekizumab-taltz/','2016-06-28','2016-07-26','Full Pharmacoeconomic Evaluation Recommended at the Submitted Price','2016-06-28, 2016-07-26',0,'Ixekizumab (Taltz®)','Taltz','Taltz® is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.',2016,'2016-04-25','Eli',0,'2016-06-28','2016-09-01','https://www.ema.europa.eu/en/medicines/human/EPAR/taltz','Psoriasis','HTA recommended at submitted price'),(2356,'2018-12-13 16:38:39','http://www.ncpe.ie/drugs/l/lisdexamfetamine-dimesylate-tyvense/','2013-02-09','2013-02-28','Full Pharmacoeconomic Assessment Not Recommended','2013-02-09, 2013-02-28',0,'Lisdexamfetamine dimesylate (Tyvense®)','Tyvense','Lisdexamfetamine dimesylate (Tyvense®) for Attention Deficit Hyperactivity Disorder in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.',2013,'1996-10-04','CIS',0,'2013-02-09','2013-02-28','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','No HTA'),(2357,'2018-12-13 16:38:44','http://www.ncpe.ie/drugs/lacosamide-vimpat/','2017-09-11','2017-10-31','A full pharmacoeconomic evaluation is recommended at the submitted price.\n ','2017-09-11, 2017-10-31',0,'Lacosamide (Vimpat ®)','Vimpat','Vimpat ® is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.  The Applicant is seeking reimbursement for an extension to the product license to cover children (≥4 years of age) and adolescents (≤ 15 years of age).',2017,'2008-08-29','UCB',0,'2017-09-11','2017-10-31','https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat','Epilepsy','HTA recommended at submitted price'),(2358,'2018-12-13 16:38:50','http://www.ncpe.ie/drugs/lapatinib-tyverb/',NULL,'2017-10-31','','',0,'Lapatinib (Tyverb®)','Tyverb','Cost-effectiveness of Lapatinib (Tyverb®) for the treatment of women with previously treated advanced or metastatic HER2 positive breast cancer.',2008,'2008-06-10','Novartis',0,'2008-01-01','2008-01-01','https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb','Breast Neoplasms','RR not conducted'),(2359,'2018-12-13 16:38:56','http://www.ncpe.ie/drugs/ledipasvirsofosbuvir-harvoni/','2014-11-14','2014-12-18','Full Pharmacoeconomic Evaluation Recommended.','2014-11-14, 2014-12-18',0,'Ledipasvir/sofosbuvir (Harvoni®)','Harvoni','Ledipasvir/sofosbuvir (Harvoni®) is indicated for the treatment of Chronic Hepatitis C (CHC) infection (Genotye 1, 3 and 4)  in adults.',2015,'2014-11-17','Gilead',0,'2014-11-14','2015-11-20','https://www.ema.europa.eu/en/medicines/human/EPAR/harvoni','Hepatitis C, Chronic','HTA recommended at submitted price'),(2360,'2018-12-13 16:39:05','http://www.ncpe.ie/drugs/lenalidomide-revlimid/','2015-10-05','2015-11-20','Full Pharmacoeconomic Evaluation Recommended at submitted price.','2015-10-05, 2015-11-20',0,'Lenalidomide (Revlimid®)','Revlimid','Revlimid® for the treatment of adult patients with previously untreated multiple myelomas (MM) who are not eligible for transplant (licence extension).',2018,'2007-06-14','Celgene',1,'2015-10-05','2018-01-01','https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid','Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes','HTA recommended at submitted price'),(2361,'2018-12-13 16:39:07','http://www.ncpe.ie/drugs/lenvatinib-kisplyx/','2017-05-05','2017-05-18','Full Pharmacoeconomic Evaluation Recommended','2017-05-05, 2017-05-18',0,'Lenvatinib (Kisplyx®)','Kisplyx','Lenvatinib (Kisplyx®) is Indicated in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.',2017,'2016-08-25','Eisai',0,'2017-05-05','2017-05-18','https://www.ema.europa.eu/en/medicines/human/EPAR/kisplyx','Carcinoma, Renal Cell','HTA recommended at submitted price'),(2362,'2018-12-13 16:39:11','http://www.ncpe.ie/drugs/lenvatinib-lenvima-2/','2018-08-07','2018-08-16','A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of lenvatinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.','2018-08-07, 2018-08-16',0,'Lenvatinib (Lenvima®) for HCC','Lenvima','Lenvatinib (Lenvima®) which is indicated as monotherapy for the treatment of adult patients with advanced or unresectable HCC who have received no prior systemic therapy.',2018,'2015-05-28','Eisai',0,'2018-08-07','2018-08-16','https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima','Thyroid Neoplasms','HTA recommended at submitted price'),(2363,'2018-12-13 16:39:15','http://www.ncpe.ie/drugs/lenvatinib-lenvima/','2015-05-05','2015-07-09','Full pharmacoeconomic evaluation recommended at the submitted price.','2015-05-05, 2015-07-09',0,'Lenvatinib (Lenvima®)','Lenvima','Lenvatinib is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine.',2015,'2015-05-28','Eisai',0,'2015-05-05','2015-07-09','https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima','Thyroid Neoplasms','HTA recommended at submitted price'),(2364,'2018-12-13 16:39:20','http://www.ncpe.ie/drugs/lesinurad-zurampic/','2017-03-15','2017-03-20','Full pharmacoeconomic assessment recommended','2017-03-15, 2017-03-20',0,'Lesinurad (Zurampic®)','Zurampic','Lesinurad (Zurampic®) for the treatment of hyperuricaemia in adult patients with gout who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor.',2018,'2016-02-18','Grünenthal',0,'2017-03-15','2018-12-06','https://www.ema.europa.eu/en/medicines/human/EPAR/zurampic','Hyperuricemia','HTA recommended at submitted price'),(2365,'2018-12-13 16:39:25','http://www.ncpe.ie/drugs/letermovir-prevymis/','2018-03-12','2018-05-10','A Full pharmacoeconomic assessment is recommended','2018-03-12, 2018-05-10',0,'Letermovir (Prevymis®)','Prevymis','Letermovir for the prophylaxis of cytomegalovirus (CMV) reactivation or disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).',2018,'2018-01-08','Merck',1,'2018-03-12','2018-05-10','https://www.ema.europa.eu/en/medicines/human/EPAR/prevymis','Cytomegalovirus Infections','HTA recommended at submitted price'),(2366,'2018-12-13 16:39:28','http://www.ncpe.ie/drugs/levodopa-20mgml-carbidopa-monohydrate-5mg-intestinal-gel-duodopa/','2013-03-13','2013-04-16','Full Pharmacoeconomic Evaluation Recommended.','2013-03-13, 2013-04-16',0,'Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel (Duodopa®)','Duodopa','For the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. A positive test of the clinical response to Duodopa® administered via a temporary nasoduodenal tube is required before a permanent tube is inserted.',2018,NULL,'Unknown',0,'2013-03-13','2018-12-05','','Unknown','HTA recommended at submitted price'),(2367,'2018-12-13 16:39:34','http://www.ncpe.ie/drugs/levofloxacin-quinsair/','2016-02-10','2016-03-01','Full pharmacoeconomic evaluation recommended at the submitted price. ','2016-02-10, 2016-03-01',0,'Levofloxacin (Quinsair®)','Quinsair','Levofloxacin (Quinsair®) is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with Cystic Fibrosis.',2016,'2015-03-25','Horizon',0,'2016-02-10','2016-03-01','https://www.ema.europa.eu/en/medicines/human/EPAR/quinsair','Cystic Fibrosis; Respiratory Tract Infections','HTA recommended at submitted price'),(2368,'2018-12-13 16:39:39','http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-delivery-system-lng-ius-12-kyleena/','2017-02-08','2017-03-16','Full Pharmacoeconomic Evaluation Not Recommended','2017-02-08, 2017-03-16',0,'Levonorgestrel intrauterine delivery system LNG IUS 12 (Kyleena®)','Kyleena','Kyleena® (19.5mg levonorgestrel intrauterine delivery system; LNG IUS 12)  which is indicated for contraception for up to 5 years.',2017,'1996-10-04','CIS',0,'2017-02-08','2017-03-16','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','No HTA'),(2369,'2018-12-13 16:39:44','http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-system-lng-ius-jaydess/','2013-03-07','2013-03-25','Full Pharmacoeconomic Assessment Not Recommended','2013-03-07, 2013-03-25',0,'Levonorgestrel intrauterine system LNG-IUS (Jaydess®)','Jaydess','Levonorgestrel Intrauterine System LNG-IUS (Jaydess®) for contraception for up to three years.',2013,NULL,'Unknown',0,'2013-03-07','2013-03-25','','Unknown','No HTA'),(2370,'2018-12-13 16:39:46','http://www.ncpe.ie/drugs/lidocaine-5-plasters-versatis/','2010-09-09','2010-10-22','Full Pharmacoeconomic Evaluation Recommended.','2010-09-09, 2010-10-22',0,'Lidocaine 5% plasters (Versatis®)','Versatis','Symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN).',2015,NULL,'Unknown',0,'2010-09-09','2015-09-24','','Unknown','HTA recommended at submitted price'),(2371,'2018-12-13 16:39:51','http://www.ncpe.ie/drugs/linaclotide-clonstella/','2013-05-28','2013-06-28','Full Pharmacoeconomic Evaluation Not Recommended','2013-05-28, 2013-06-28',0,'Linaclotide (Constella®)','Constella','Linaclotide (Constella®) is indicated for the treatment of symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults.',2013,'2012-11-26','Allergan',0,'2013-05-28','2013-06-28','https://www.ema.europa.eu/en/medicines/human/EPAR/constella','Irritable Bowel Syndrome','No HTA'),(2372,'2018-12-13 16:39:54','http://www.ncpe.ie/drugs/linagliptin-trajenta/','2011-08-18','2011-09-06','Full Pharmacoeconomic Evaluation not Recommended','2011-08-18, 2011-09-06',0,'Linagliptin (Trajenta®)','Trajenta','Lingagliptin (Trajenta®) for treatment of type 2 diabetes mellitus to improve glycaemic control in adults, as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment, as combination therapy in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control, in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.',2011,'2011-08-23','Boehringer',0,'2011-08-18','2011-09-06','https://www.ema.europa.eu/en/medicines/human/EPAR/trajenta','Diabetes Mellitus, Type 2','No HTA'),(2373,'2018-12-13 16:39:57','http://www.ncpe.ie/drugs/lipegfilgrastim-lonquex/','2013-08-20','2013-09-20','Full Pharmacoeconomic Evaluation not recommended','2013-08-20, 2013-09-20',0,'Lipegfilgrastim (Lonquex®)','Lonquex','Lonquex® is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).',2013,'2013-07-25','Sicor',0,'2013-08-20','2013-09-20','https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex','Neutropenia','No HTA'),(2374,'2018-12-13 16:40:00','http://www.ncpe.ie/drugs/liposomal-daunorubicin-and-cytarabine-cpx-351vyxeos/','2018-09-28','2018-11-08','A Full Pharmacoeconomic Assessment is recommended','2018-09-28, 2018-11-08',0,'Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos®)','Vyxeos','Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos®) for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes.',2018,'2018-08-23','Jazz',1,'2018-09-28','2018-11-08','https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos','Leukemia, Myeloid, Acute','HTA recommended at submitted price'),(2375,'2018-12-13 16:40:06','http://www.ncpe.ie/drugs/liposomal-irinotecan-nal-iri-onivyde/','2017-06-13','2017-07-13','Full Pharmacoeconomic Evaluation Recommended','2017-06-13, 2017-07-13',0,'Liposomal irinotecan (Onivyde®)','Onivyde','Liposomal irinotecan (Onivyde®) is indicated for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and leucovorin in adult patients who have progressed following gemcitabine based therapy.',2017,'2016-10-14','Baxalta',1,'2017-06-13','2017-07-13','https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-0','Pancreatic Neoplasms','HTA recommended at submitted price'),(2376,'2018-12-13 16:40:09','http://www.ncpe.ie/drugs/liquid-paraffin-ointment-vita-pos-opthalmic/','2014-01-15','2014-01-27','Full Pharmacoeconomic Evaluation Not Recommended','2014-01-15, 2014-01-27',0,'Liquid Paraffin Ointment (VitA-POS Opthalmic®)','VitA-POS Opthalmic','Liquid Paraffin Ointment (VitA-POS Opthalmic®) is indicated for the treatment of mild to moderate form of dry eye.',2014,'2009-10-10','GlaxoSmithKline',0,'2014-01-15','2014-01-27','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','No HTA'),(2377,'2018-12-13 16:40:13','http://www.ncpe.ie/drugs/liraglutide-victoza/','2009-09-01','2009-10-07','Full pharmacoeconomic evaluation not recommended','2009-09-01, 2009-10-07',0,'Liraglutide (Victoza®)','Victoza','Victoza®  is indicated for treatment of adults with type 2 diabetes mellitus.',2018,'2009-06-30','Novo',0,'2009-09-01','2018-10-30','https://www.ema.europa.eu/en/medicines/human/EPAR/victoza','Diabetes Mellitus, Type 2','No HTA'),(2378,'2018-12-13 16:40:17','http://www.ncpe.ie/drugs/lixisenatide-lyxumia/','2013-03-21','2013-04-10','Full Pharmacoeconomic Evaluation Recommended','2013-03-21, 2013-04-10',0,'Lixisenatide (Lyxumia®)','Lyxumia','Lixisenatide (Lyxumia®) for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.',2014,'2009-12-09','Pfizer',0,'2013-03-21','2014-08-07','https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13','Pneumococcal Infections; Immunization','HTA recommended at submitted price'),(2379,'2018-12-13 16:40:19','http://www.ncpe.ie/drugs/lomitapide-lojuxta/','2014-09-09','2014-09-15','Full Pharmacoeconomic Evaluation Recommended.','2014-09-09, 2014-09-15',0,'Lomitapide (Lojuxta®)','Lojuxta','Lojuxta® is indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH).',2014,'2013-07-31','Amryt',0,'2014-09-09','2014-09-15','https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta','Hypercholesterolemia','HTA recommended at submitted price'),(2380,'2018-12-13 16:40:22','http://www.ncpe.ie/drugs/lornoxicam-xefo/','2011-06-23','2011-07-07','Full Pharmacoeconomic Evaluation not Recommended','2011-06-23, 2011-07-07',0,'Lornoxicam (Xefo®)','Xefo',' Lornoxicam (Xefo®) for the Short-term relief of acute mild to moderate pain and symptomatic relief of pain and inflammation in osteoarthritis and symptomatic relief of pain and inflammation in rheumatoid arthritis',2011,'2009-12-09','Pfizer',0,'2011-06-23','2011-07-07','https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13','Pneumococcal Infections; Immunization','No HTA'),(2381,'2018-12-13 16:40:24','http://www.ncpe.ie/drugs/lotemax-0-5-eye-drops-suspension-loteprednol/','2011-11-15','2011-12-05','Full Pharmacoeconomic Evaluation not Recommended','2011-11-15, 2011-12-05',0,'Lotemax 0.5% eye drops suspension (Loteprednol)','Loteprednol',' Indicated for treatment of post-operative inflammation following ocular surgery.',2011,NULL,'Unknown',0,'2011-11-15','2011-12-05','','Unknown','No HTA'),(2382,'2018-12-13 16:40:30','http://www.ncpe.ie/drugs/loxapine-inhalation-powder-adasuve/','2016-06-21','2016-07-28','Full Pharmacoeconomic Evaluation Recommended','2016-06-21, 2016-07-28',0,'Loxapine inhalation powder (Adasuve®)','Adasuve','Inhaled loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.',2016,'2013-02-20','Ferrer',0,'2016-06-21','2016-07-28','https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve','Schizophrenia; Bipolar Disorder','HTA recommended at submitted price'),(2383,'2018-12-13 16:40:34','http://www.ncpe.ie/drugs/lumacaftorivacaftor-orkambi/','2015-11-26','2015-12-15','Full Pharmacoeconomic Evaluation Recommended','2015-11-26, 2015-12-15',0,'Lumacaftor/ivacaftor (Orkambi®)','Orkambi','Orkambi® is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene.',2016,'2015-11-19','Vertex',0,'2015-11-26','2016-06-01','https://www.ema.europa.eu/en/medicines/human/EPAR/orkambi','Cystic Fibrosis','HTA recommended at submitted price'),(2384,'2018-12-13 16:40:36','http://www.ncpe.ie/drugs/lutetium-177lu-oxodotreotide-lutathera/','2018-10-23','2018-11-16','A full pharmacoeconomic assessment is recommended','2018-10-23, 2018-11-16',0,'Lutetium (177Lu) Oxodotreotide (Lutathera®)','Lutathera','Lutetium (177Lu) Oxodotreotide (Lutathera®) for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.',2018,'2017-09-26','Advanced',1,'2018-10-23','2018-11-16','https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera','Neuroendocrine Tumors','HTA recommended at submitted price'),(2385,'2018-12-13 16:40:41','http://www.ncpe.ie/drugs/macitentan-opsumit/','2014-01-10','2014-01-27','Full Pharmacoeconomic Evaluation Not Recommended','2014-01-10, 2014-01-27',0,'Macitentan (Opsumit®)','Opsumit','Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.',2014,'2013-12-20','Janssen-Cilag',1,'2014-01-10','2014-01-27','https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit','Hypertension, Pulmonary','No HTA'),(2386,'2018-12-13 16:40:43','http://www.ncpe.ie/drugs/melatonin-circadin/',NULL,'2014-01-27','','',0,'Melatonin (Circadin®)','Circadin','A Review of the Economic Evaluation of Prolonged Release Melatonin (Circadin®) For The Short-Term Treatment of Primary Insomnia.',2008,'2007-06-29','RAD',0,'2008-08-01','2008-10-01','https://www.ema.europa.eu/en/medicines/human/EPAR/circadin','Sleep Initiation and Maintenance Disorders','RR not conducted'),(2387,'2018-12-13 16:40:45','http://www.ncpe.ie/drugs/mepolizumab-nucala/','2016-03-16','2016-04-04','Full Pharmacoeconomic Evaluation Recommended.','2016-03-16, 2016-04-04',0,'Mepolizumab (Nucala®)','Nucala','Mepolizumab (Nucala®) is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients.',2018,'2015-12-01','GlaxoSmithKline',0,'2016-03-16','2018-04-01','https://www.ema.europa.eu/en/medicines/human/EPAR/nucala','Asthma','HTA recommended at submitted price'),(2388,'2018-12-13 16:40:51','http://www.ncpe.ie/drugs/methoxyflurane-penthrox/','2015-11-23','2015-12-18','Full Pharmacoeconomic Evaluation Not Recommended','2015-11-23, 2015-12-18',0,'Methoxyflurane (Penthrox®)','Penthrox','Penthrox® is indicated for the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.  It is an inhaled anesthetic with analgesic effects at sub-anesthetic doses.',2015,NULL,'Unknown',0,'2015-11-23','2015-12-18','','Unknown','No HTA'),(2389,'2018-12-13 16:40:56','http://www.ncpe.ie/drugs/midostaurin-rydapt-for-aml/','2018-08-13','2018-09-10','A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care.','2018-08-13, 2018-09-10',0,'Midostaurin (Rydapt®) for AML','Rydapt','Midostaurin (Rydapt®) is indicated in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive.',2018,'2017-09-18','Novartis',1,'2018-08-13','2018-09-10','https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt','Leukemia, Myeloid, Acute; Mastocytosis','HTA recommended at submitted price'),(2390,'2018-12-13 16:41:02','http://www.ncpe.ie/drugs/midostaurin-rydapt-for-asm/','2018-08-13','2018-09-10','A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care.','2018-08-13, 2018-09-10',0,'Midostaurin (Rydapt®) for ASM','Rydapt','Midostaurin (Rydapt®) is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL).',2018,'2017-09-18','Novartis',1,'2018-08-13','2018-09-10','https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt','Leukemia, Myeloid, Acute; Mastocytosis','HTA recommended at submitted price'),(2391,'2018-12-13 16:41:04','http://www.ncpe.ie/drugs/mifamurtide-mepact/','2010-06-22','2010-07-13','Full Pharmacoeconomic Evaluation Recommended','2010-06-22, 2010-07-13',0,'Mifamurtide (Mepact®)','Mepact','Mifamurtide (Meptact®) for the treatment of osteosarcoma.',2010,'2009-03-06','Takeda',1,'2010-06-22','2010-07-13','https://www.ema.europa.eu/en/medicines/human/EPAR/mepact','Osteosarcoma','HTA recommended at submitted price'),(2392,'2018-12-13 16:41:06','http://www.ncpe.ie/drugs/migalastat-galafold/','2016-07-14','2016-08-18','Full Pharmacoeconomic Evaluation Recommended','2016-07-14, 2016-08-18',0,'Migalastat (Galafold®)','Galafold','Migalastat is indicated for the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.',2017,'2016-05-25','Amicus',1,'2016-07-14','2017-06-01','https://www.ema.europa.eu/en/medicines/human/EPAR/galafold','Fabry Disease','HTA recommended at submitted price'),(2393,'2018-12-13 16:41:13','http://www.ncpe.ie/drugs/mirabegron-betmiga/','2012-12-19','2013-03-12','Full Pharmacoeconomic Assessment Not Recommended','2012-12-19, 2013-03-12',0,'Mirabegron (Betmiga®)','Betmiga','Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome',2013,'2012-12-20','Astellas',0,'2012-12-19','2013-03-12','https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga','Urinary Bladder, Overactive','No HTA'),(2394,'2018-12-13 16:41:15','http://www.ncpe.ie/drugs/nab-paclitaxel-abraxane/','2014-01-23','2014-03-02','Full Pharmacoeconomic Evaluation Recommended','2014-01-23, 2014-03-02',0,'Nab-paclitaxel (Abraxane®)','Abraxane','Nab-paclitaxel (Abraxane®) in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinomoa of the pancreas.',2015,'2008-01-10','Celgene',0,'2014-01-23','2015-12-01','https://www.ema.europa.eu/en/medicines/human/EPAR/abraxane','Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2395,'2018-12-13 16:41:18','http://www.ncpe.ie/drugs/nalmefene-selincro/','2013-06-07','2013-06-28','Full Pharmacoeconomic Evaluation Recommended','2013-06-07, 2013-06-28',0,'Nalmefene (Selincro®)','Selincro','Nalmefene (Selincro®) is indicated for the reduction of alcohol consumption in those aged ≥18 years with alcohol dependence, who do not require immediate detoxification.',2014,'2013-02-24','Lundbeck',0,'2013-06-07','2014-04-08','https://www.ema.europa.eu/en/medicines/human/EPAR/selincro','Alcohol-Related Disorders','HTA recommended at submitted price'),(2396,'2018-12-13 16:41:24','http://www.ncpe.ie/drugs/naloxegel-moventig/','2015-02-10','2015-04-13','Full Pharmacoeconomic Evaluation Not Recommended','2015-02-10, 2015-04-13',0,'Naloxegel (Moventig®)','Moventig','Naloxegel (Moventiq®) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).',2015,'2014-12-07','Kyowa',0,'2015-02-10','2015-04-13','https://www.ema.europa.eu/en/medicines/human/EPAR/moventig','Constipation; Opioid-Related Disorders','No HTA'),(2397,'2018-12-13 16:41:26','http://www.ncpe.ie/drugs/naltrexone-bupropion-mysimba/','2017-03-12','2017-03-28','A Full pharmacoeconomic assessment is recommended','2017-03-12, 2017-03-28',0,'Naltrexone / bupropion (Mysimba®)','Mysimba','Naltrexone / bupropion (Mysimba®) is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥ 18 years) with a BMI of ≥30 kg/m2 (obese) or ≥27 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities.',2018,'2015-03-26','Orexigen',0,'2017-03-12','2018-05-09','https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba','Obesity; Overweight','HTA recommended at submitted price'),(2398,'2018-12-13 16:41:30','http://www.ncpe.ie/drugs/natalizumab-tysabri/',NULL,'2017-03-28','','',0,'Natalizumab (Tysabri®)','Tysabri',' Economic Evaluation of Natalizumab (Tysabri®) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated.',2007,'2006-06-27','Biogen',0,'2007-01-01','2007-03-01','https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri','Multiple Sclerosis','RR not conducted'),(2399,'2018-12-13 16:41:35','http://www.ncpe.ie/drugs/ncpe-inhaled-insulin-exubera-assessment/',NULL,'2017-03-28','','',0,'Inhaled insulin (Exubera®)','Exubera','In April 2006, Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin (Exubera®) versus sub-cutaneous insulin in patients with diabetes mellitus in support of their application for reimbursement under the Community Drug Schemes. The following reports were prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.',2006,'2006-01-24','Pfizer',0,'2006-03-01','2006-03-01','https://www.ema.europa.eu/en/medicines/human/EPAR/exubera','Diabetes Mellitus','RR not conducted'),(2400,'2018-12-13 16:41:38','http://www.ncpe.ie/drugs/nepafenac-nevanac-2/','2011-06-14','2011-06-27','Full Pharmacoeconomic Evaluation not Recommended','2011-06-14, 2011-06-27',0,'Nepafenac (Nevanac®)','Nevanac','Nepafenac (Nevanac®) for the prevention and treatment of postoperative pain and inflammation associated with cataract surgery.',2011,'2007-12-11','Novartis',0,'2011-06-14','2011-06-27','https://www.ema.europa.eu/en/medicines/human/EPAR/nevanac','Pain, Postoperative; Ophthalmologic Surgical Procedures','No HTA'),(2401,'2018-12-13 16:41:41','http://www.ncpe.ie/drugs/netupitantpalonosetron-akynzeo/','2015-08-26','2015-10-13','Full Pharmacoeconomic Evaluation Not Recommended','2015-08-26, 2015-10-13',0,'Netupitant/palonosetron (Akynzeo®)','Akynzeo','Akynzeo® is indicated for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and for prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.',2015,'2015-05-27','Helsinn',0,'2015-08-26','2015-10-13','https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo','Vomiting; Cancer; Nausea','No HTA'),(2402,'2018-12-13 16:41:44','http://www.ncpe.ie/drugs/nilotinib-tasigna-newly-diagnosed-cml/','2010-10-06','2010-10-22','Full Pharmacoeconomic Evaluation Recommended.','2010-10-06, 2010-10-22',0,'Nilotinib (Tasigna®) newly diagnosed CML','Tasigna','Nilotinib (Tasigna®) for the newly diagnosed Chronic Phase Philadelpha Chromosone positive CML.',2010,'2007-11-19','Novartis',1,'2010-10-06','2010-10-22','https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna','Leukemia, Myelogenous, Chronic, BCR-ABL Positive','HTA recommended at submitted price'),(2403,'2018-12-13 16:41:51','http://www.ncpe.ie/drugs/nilotinib-tasigna/',NULL,'2010-10-22','','',0,'Nilotinib (Tasigna®) CML resistant/intolerant to imatinib','Tasigna','Cost-effectiveness of Nilotinib (Tasigna®) for the treatment of chronic phase CML.',2008,'2007-11-19','Novartis',1,'2008-01-01','2008-02-01','https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna','Leukemia, Myelogenous, Chronic, BCR-ABL Positive','RR not conducted'),(2404,'2018-12-13 16:41:53','http://www.ncpe.ie/drugs/nintedanib-ofev/','2015-01-30','2015-02-18','Full Pharmacoeconomic Evaluation Recommended','2015-01-30, 2015-02-18',0,'Nintedanib (Ofev®)','Ofev','Nintedanib (Ofev®) indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).',2017,'2015-01-14','Boehringer',1,'2015-01-30','2017-06-01','https://www.ema.europa.eu/en/medicines/human/EPAR/ofev','Idiopathic Pulmonary Fibrosis','HTA recommended at submitted price'),(2405,'2018-12-13 16:41:56','http://www.ncpe.ie/drugs/nintedanib-vargatef/','2015-01-02','2015-02-10','Full Pharmacoeconomic Evaluation Recommended','2015-01-02, 2015-02-10',0,'Nintedanib (Vargatef®)','Vargatef','Nintedanib (Vargatef®) indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy.',2017,'2014-11-21','Boehringer',0,'2015-01-02','2017-02-01','https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef','Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2406,'2018-12-13 16:42:00','http://www.ncpe.ie/drugs/niraparib-zejula/','2018-06-01','2018-06-21','A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of niraparib compared with the current standard of care','2018-06-01, 2018-06-21',0,'Niraparib (Zejula®)','Zejula','Niraparib (Zejula®) which is indicated as monotherapy for maintenance treatment of adult patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response [CR] or partial response [PR]) to platinum-based chemotherapy.',2018,'2017-11-16','Tesaro',1,'2018-06-01','2018-06-27','https://www.ema.europa.eu/en/medicines/human/EPAR/zejula','Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms','HTA recommended at submitted price'),(2407,'2018-12-13 16:42:06','http://www.ncpe.ie/drugs/nivolumab-opdivio-for-melanoma/','2015-05-28','2015-07-16','Full Pharmacoeconomic Evaluation Recommended','2015-05-28, 2015-07-16',0,'Nivolumab (Opdivo®) for Melanoma','Opdivo','Opdivo® is indicated as for monotherapy treatment for patients diagnosed with unresectable metastatic melanoma.',2017,'2015-06-19','Bristol-Myers',0,'2015-05-28','2017-10-01','https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo','Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2408,'2018-12-13 16:42:13','http://www.ncpe.ie/drugs/nivolumab-opdivio-for-non-squamous-nsclc/','2016-03-03','2016-04-04','Full Pharmacoeconomic Evaluation Recommended','2016-03-03, 2016-04-04',0,'Nivolumab (Opdivo®) for non-squamous NSCLC','Opdivo','Nivolumab (Opdivo®) is indicated for the treatment of adults with locally advanced or metastatic non-squamous NSCLC after prior chemotherapy.',2018,'2015-06-19','Bristol-Myers',0,'2016-03-03','2018-09-01','https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo','Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2409,'2018-12-13 16:42:20','http://www.ncpe.ie/drugs/nivolumab-opdivio-for-nsclc/','2015-07-02','2015-07-16','Full Pharmacoeconomic Evaluation Recommended','2015-07-02, 2015-07-16',0,'Nivolumab (Opdivo®) for NSCLC','Opdivo','Opdivo® is indicated for the treatment of locally advanced or metastatic squamous NSCLC after prior chemotherapy in adults.',2018,'2015-06-19','Bristol-Myers',0,'2015-07-02','2018-09-01','https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo','Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2410,'2018-12-13 16:42:26','http://www.ncpe.ie/drugs/nivolumab-opdivo-as-monotherapy-for-the-adjuvant-treatment-of-adults-with-melanoma/','2018-07-09','2018-07-27','A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care.','2018-07-09, 2018-07-27',0,'Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of adults with melanoma','Opdivo','Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of adults with melanoma  with involvement of lymph nodes or metastatic disease who have undergone complete resection.',2018,'2015-06-19','Bristol-Myers',0,'2018-07-09','2018-11-30','https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo','Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2411,'2018-12-13 16:42:31','http://www.ncpe.ie/drugs/nivolumab-opdivo-for-advanced-renal-cell-carcinoma/','2016-04-27','2016-05-16','Full Pharmacoeconomic Evaluation Recommended ','2016-04-27, 2016-05-16',0,'Nivolumab (Opdivo®) for advanced renal cell carcinoma','Opdivo','Nivolumab (Opdivo®) is licensed for the treatment of advanced renal cell carcinoma after prior therapy in adults.',2017,'2015-06-19','Bristol-Myers',0,'2016-04-27','2017-10-01','https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo','Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2412,'2018-12-13 16:42:33','http://www.ncpe.ie/drugs/nivolumab-opdivo-for-classical-hodgkin-lymphoma/','2016-11-22','2017-01-18','Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.','2016-11-22, 2017-01-18',0,'Nivolumab (Opdivo®) for classical Hodgkin Lymphoma','Opdivo','Nivolumab (Opdivo®) as monotherapy is indicated for the treatment of relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin.',2017,'2015-06-19','Bristol-Myers',0,'2016-11-22','2017-10-01','https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo','Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2413,'2018-12-13 16:42:36','http://www.ncpe.ie/drugs/nivolumab-opdivo-for-head-and-neck-cancer/','2017-05-03','2017-05-30','Full Pharmacoeconomic Evaluation Recommended at the Submitted Price ','2017-05-03, 2017-05-30',0,'Nivolumab (Opdivo®) for head and neck cancer','Opdivo','Nivolumab (Opdivo®) for the treatment of squamous cell carcinoma of the head and neck (SCCHN) in adults progressing on or after platinum-based therapy.',2018,'2015-06-19','Bristol-Myers',0,'2017-05-03','2018-04-01','https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo','Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2414,'2018-12-13 16:42:41','http://www.ncpe.ie/drugs/nivolumab-opdivo-for-urothelial-carcinoma/','2017-06-28','2017-08-10','Full pharmacoeconomic assessment recommended','2017-06-28, 2017-08-10',0,'Nivolumab (Opdivo®) for urothelial carcinoma','Opdivo','Nivolumab (Opdivo®) as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.',2018,'2015-06-19','Bristol-Myers',0,'2017-06-28','2018-09-12','https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo','Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2415,'2018-12-13 16:42:46','http://www.ncpe.ie/drugs/nivolumab-opdivo-in-combination-with-ipilimumab-yervoy/','2018-11-28','2018-12-11','Full pharmacoeconomic assessment is recommended','2018-11-28, 2018-12-11',0,'Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®)','Yervoy','Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).',2018,'2011-07-12','Bristol-Myers',0,'2018-11-28','2018-12-11','https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy','Melanoma','Unknown'),(2416,'2018-12-13 16:42:51','http://www.ncpe.ie/drugs/nivolumab-plus-ipilimumab-opdivio-plus-yervoy/',NULL,'2018-12-11','','',0,'Nivolumab plus ipilimumab (Opdivo® plus Yervoy®)','Opdivo plus Yervoy','Opdivo® plus Yervoy® Is indicated for the treatment of advanced melanoma.',2017,'2009-10-10','GlaxoSmithKline',0,'2016-06-27','2017-10-01','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','RR not conducted'),(2417,'2018-12-13 16:42:56','http://www.ncpe.ie/drugs/nomace2-zoely/','2011-12-08','2012-01-03','Full Pharmacoeconomic Evaluation not Recommended','2011-12-08, 2012-01-03',0,'Nomegestrol acetate/estradiol (Zoely®)','Zoely','Nomegestrol acetate/estradiol (Zoely®) oral contraception',2012,'2011-07-26','Teva',0,'2011-12-08','2012-01-03','https://www.ema.europa.eu/en/medicines/human/EPAR/zoely','Contraception','No HTA'),(2418,'2018-12-13 16:43:02','http://www.ncpe.ie/drugs/nusinersin-spinraza/','2017-07-11','2017-08-02','Full pharmacoeconomic evaluation recommended','2017-07-11, 2017-08-02',0,'Nusinersin (Spinraza®)','Spinraza','Nusinersen (Spinraza®) is indicated for the treatment of 5q spinal muscular atrophy (SMA)',2017,'2017-05-30','Biogen',1,'2017-07-11','2017-12-19','https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza','Muscular Atrophy, Spinal','HTA recommended at submitted price'),(2419,'2018-12-13 16:43:07','http://www.ncpe.ie/drugs/obeticholic-acid-ocaliva/','2016-11-18','2016-12-21','Full pharmacoeconomic assessment recommended','2016-11-18, 2016-12-21',0,'Obeticholic acid (Ocaliva®)','Ocaliva','Obeticholic acid is indicated for the treatment of primary biliary cirrhosis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.',2017,'2016-12-12','Intercept',1,'2016-11-18','2017-10-31','https://www.ema.europa.eu/en/medicines/human/EPAR/ocaliva','Liver Cirrhosis, Biliary','HTA recommended at submitted price'),(2420,'2018-12-13 16:43:10','http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-follicular-lymphoma/','2016-05-11','2016-05-31','Full Pharmacoeconomic Evaluation Recommended','2016-05-11, 2016-05-31',0,'Obinutuzumab (Gazyvaro®) for Follicular Lymphoma','Gazyvaro','Obinutuzumab (in combination with bendamustine) followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.',2017,'2014-07-22','Roche',1,'2016-05-11','2017-10-01','https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro','Leukemia, Lymphocytic, Chronic, B-Cell','HTA recommended at submitted price'),(2421,'2018-12-13 16:43:15','http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-previously-untreated-advanced-follicular-lymphoma/','2017-08-08','2017-09-13','Full pharmacoeconomic assessment recommended','2017-08-08, 2017-09-13',0,'Obinutuzumab (Gazyvaro®) for previously untreated advanced follicular lymphoma','Gazyvaro','Obinutuzumab (Gazyvaro®) in combination with chemotherapy, followed by obinutuzumab maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.',2018,'2014-07-22','Roche',1,'2017-08-08','2018-05-03','https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro','Leukemia, Lymphocytic, Chronic, B-Cell','HTA recommended at submitted price'),(2422,'2018-12-13 16:43:21','http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro/','2014-08-08','2014-09-11','Full Pharmacoeconomic Evaluation Recommended.','2014-08-08, 2014-09-11',0,'Obinutuzumab (Gazyvaro®) for Lymphocytic Leukaemia','Gazyvaro','Obinutuzumab (Gazyvaro®) in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia and with comorbidities making them unsuitable for full-dose fludarabine based therapy.',2015,'2014-07-22','Roche',1,'2014-08-08','2015-12-01','https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro','Leukemia, Lymphocytic, Chronic, B-Cell','HTA recommended at submitted price'),(2423,'2018-12-13 16:43:24','http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-ppms/','2017-11-29','2017-12-14','Full Pharmacoeconomic assessment recommended','2017-11-29, 2017-12-14',0,'Ocrelizumab (Ocrevus®) for PPMS','Ocrevus','Ocrelizumab (Ocrevus®) is indicated for the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.',2018,'2018-01-08','Roche',0,'2017-11-29','2018-10-04','https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus','Multiple Sclerosis','HTA recommended at submitted price'),(2424,'2018-12-13 16:43:30','http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-rms/','2017-11-29','2017-12-14','Full pharmacoeconomic assessment recommended','2017-11-29, 2017-12-14',0,'Ocrelizumab (Ocrevus®) for RMS','Ocrevus','Ocrelizumab (Ocrevus®) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.',2018,'2018-01-08','Roche',0,'2017-11-29','2018-08-29','https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus','Multiple Sclerosis','HTA recommended at submitted price'),(2425,'2018-12-13 16:43:34','http://www.ncpe.ie/drugs/ocriplasmin-jetrea/','2013-06-12','2013-07-09','Full Pharmacoeconomic Evaluation not Recommended','2013-06-12, 2013-07-09',0,'Ocriplasmin (Jetrea®)','Jetrea','Ocriplasmin (Jetrea®) is a hospital only product licensed in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.',2013,'2013-03-13','ThromboGenics',0,'2013-06-12','2013-07-09','https://www.ema.europa.eu/en/medicines/human/EPAR/jetrea','Retinal Diseases','No HTA'),(2426,'2018-12-13 16:43:39','http://www.ncpe.ie/drugs/ofatumumab-arzerra-previously-untreated-chronic-lymphocytic-leukaemia/','2014-10-13','2014-12-18','Full Pharmacoeconomic Evaluation Recommended at the submitted price.','2014-10-13, 2014-12-18',0,'Ofatumumab (Arzerra®) (Previously untreated Chronic Lymphocytic Leukaemia)','Arzerra','Ofatumumab (Arzerra®) in combination with chlorambucil or bendamustine for the treatment of patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy.',2014,'2010-04-19','Novartis',1,'2014-10-13','2014-12-18','https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra','Leukemia, Lymphocytic, Chronic, B-Cell','HTA recommended at submitted price'),(2427,'2018-12-13 16:43:46','http://www.ncpe.ie/drugs/ofatumumab-arzerra/','2010-06-22','2010-06-01','Full Pharmacoeconomic Evaluation Recommended','2010-06-22, 2010-06-01',0,'Ofatumumab (Arzerra®) (Refractory CLL)','Arzerra','Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.',2010,'2010-04-19','Novartis',1,'2010-06-01','2010-06-22','https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra','Leukemia, Lymphocytic, Chronic, B-Cell','HTA recommended at submitted price'),(2428,'2018-12-13 16:43:52','http://www.ncpe.ie/drugs/oladaterol-striverdi-respimat/','2014-04-07','2014-05-02','Full Pharmacoeconomic Evaluation Not Recommended','2014-04-07, 2014-05-02',0,'Oladaterol (Striverdi®, Respimat®)','Striverdi, Respimat','Striverdi Respimat is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD).',2014,'2009-10-10','GlaxoSmithKline',0,'2014-04-07','2014-05-02','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','No HTA'),(2429,'2018-12-13 16:43:57','http://www.ncpe.ie/drugs/olaparib-lynparza-2/','2015-01-05','2015-02-19','Full Pharmacoeconomic Evaluation Recommended','2015-01-05, 2015-02-19',0,'Olaparib (Lynparza®)','Lynparza','Lynparza® is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.',2017,'2014-12-16','AstraZeneca',0,'2015-01-05','2017-10-01','https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza','Ovarian Neoplasms','HTA recommended at submitted price'),(2430,'2018-12-13 16:44:03','http://www.ncpe.ie/drugs/olaparib-lynparza-for-platinum-sensitive-relapsed-ovarian-cancer/','2018-09-19','2018-10-01','The NCPE recommend  a full HTA to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.','2018-09-19, 2018-10-01',0,'Olaparib (Lynparza®) for platinum sensitive relapsed ovarian cancer','Lynparza','Olaparib (Lynparza®) monotherapy for the maintenance treatment of adult patients with PSR high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.',2018,'2014-12-16','AstraZeneca',0,'2018-09-19','2018-10-01','https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza','Ovarian Neoplasms','HTA recommended at submitted price'),(2431,'2018-12-13 16:44:08','http://www.ncpe.ie/drugs/omalizumab-xolair-for-the-treatment-of-severe-allergic-asthma/',NULL,'2018-10-01','','',0,'Omalizumab (Xolair®) for the treatment of severe allergic asthma','Xolair','Omalizumab is indicated as an add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1<80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.',2015,'2005-10-25','Novartis',0,'2014-08-22','2015-06-25','https://www.ema.europa.eu/en/medicines/human/EPAR/xolair','Asthma; Urticaria','RR not conducted'),(2432,'2018-12-13 16:44:14','http://www.ncpe.ie/drugs/omalizumab-xolair/','2014-03-25','2014-04-25','Full Pharmacoeconomic Evaluation Not Recommended for this indication.','2014-03-25, 2014-04-25',0,'Omalizumab (Xolair®)','Xolair','Omalizumab (Xolair®) is indicated as an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment. ',2014,'2005-10-25','Novartis',0,'2014-03-25','2014-04-25','https://www.ema.europa.eu/en/medicines/human/EPAR/xolair','Asthma; Urticaria','No HTA'),(2433,'2018-12-13 16:44:19','http://www.ncpe.ie/drugs/oral-oxycodonenaloxone-targin/',NULL,'2014-04-25','','',0,'Oxycodone/naloxone (Targin®)','Targin','Cost-effectiveness of oral oxycodone/naloxone prolonged release tablet (Targin®) for severe pain, which can be adequately managed only with opioid analgesics.',2010,'1996-10-04','CIS',0,'2010-05-05','2010-10-19','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','RR not conducted'),(2434,'2018-12-13 16:44:22','http://www.ncpe.ie/drugs/osimertinib-tagrisso-for-the-first-line-treatment-of-metastatic-nsclc/','2018-07-19','2018-08-07','A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations compared with the current standard of care.','2018-07-19, 2018-08-07',0,'Osimertinib (Tagrisso®) for the first-line treatment of metastatic NSCLC','Tagrisso','Osimertinib (Tagrisso®) as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.',2018,'2016-02-01','AstraZeneca',0,'2018-07-19','2018-08-07','https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso','Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2435,'2018-12-13 16:44:39','http://www.ncpe.ie/drugs/osimertinib-tagrisso/','2016-02-26','2017-01-10','Full pharmacoeconomic assessment recommended','2016-02-26, 2016-03-22, 2017-01-10',1,'Osimertinib (Tagrisso®)','Tagrisso','Osimertinib (Tagrisso®) for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor [EGFR] T790M mutation positive non-small cell lung cancer [NSCLC].',2018,'2016-02-01','AstraZeneca',0,'2016-02-26','2018-05-03','https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso','Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2436,'2018-12-13 16:44:40','http://www.ncpe.ie/drugs/ozenoxacin-dubine/','2018-11-12','2018-12-13','A full HTA is not recommended. The NCPE recommends that ozenoxacin cream not be considered for reimbursement at the submitted price.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.\n \n ','2018-11-12, 2018-12-13',0,'Ozenoxacin (Dubine®)','Dubine','Ozenoxacin (Dubine®) 10mg/g cream for the short term treatment of non-bullous impetigo in adults, adolescents, children, and infants aged 6 months and older.',2018,NULL,'Unknown',0,'2018-11-12','2018-12-13','','Unknown','Unknown'),(2437,'2018-12-13 16:44:43','http://www.ncpe.ie/drugs/p-drugs/pegylated-interferon-b-1a-plegridy/','2014-11-25','2014-12-22','Full Pharmacoeconomic Evaluation not Recommended.','2014-11-25, 2014-12-22',0,'Pegylated Interferon beta-1a (Plegridy ®)','Plegridy','Treatment of adult patients with relapsing remitting multiple sclerosis',2014,'2014-07-17','Biogen',0,'2014-11-25','2014-12-22','https://www.ema.europa.eu/en/medicines/human/EPAR/plegridy','Multiple Sclerosis','No HTA'),(2438,'2018-12-13 16:44:47','http://www.ncpe.ie/drugs/palbociclib-ibrance/','2016-09-10','2016-09-28','Full pharmacoeconomic assessment recommended','2016-09-10, 2016-09-28',0,'Palbociclib (Ibrance®)','Ibrance','Palbociclib is indicated for the treatment of women with metastatic hormone receptor-positive, HER2-negative breast cancer.',2017,'2016-11-09','Pfizer',0,'2016-09-10','2017-07-28','https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance','Breast Neoplasms','HTA recommended at submitted price'),(2439,'2018-12-13 16:44:53','http://www.ncpe.ie/drugs/paliperidone-palmitate-xeplion/','2011-03-11','2011-03-23','Full Pharmacoeconomic Evaluation not Recommended.','2011-03-11, 2011-03-23',0,'Paliperidone palmitate (Xeplion®)','Xeplion','Paliperidone palmitate (Xeplion®) is indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone. In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate, and a long acting injectable treatment is needed.',2011,'2011-03-04','Janssen-Cilag',0,'2011-03-01','2011-03-23','https://www.ema.europa.eu/en/medicines/human/EPAR/xeplion','Schizophrenia','No HTA'),(2440,'2018-12-13 16:44:57','http://www.ncpe.ie/drugs/panobinostat-farydak/','2016-01-26','2016-02-09','Full Pharmacoeconomic Evaluation Recommended','2016-01-26, 2016-02-09',0,'Panobinostat (Farydak®)','Farydak','Panobinostat in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.',2016,'2015-08-28','Novartis',1,'2016-01-26','2016-02-09','https://www.ema.europa.eu/en/medicines/human/EPAR/farydak','Multiple Myeloma','HTA recommended at submitted price'),(2441,'2018-12-13 16:45:01','http://www.ncpe.ie/drugs/paritaprevir-boosted-with-ritonavir-and-ombitasvir-vierkirax-with-or-without-dasabuvir-exviera/','2014-12-21','2015-01-13','Full Pharmacoeconomic Evaluation Recommended','2014-12-21, 2015-01-13',0,'Paritaprevir boosted with ritonavir and ombitasvir (Vierkirax®) with or without dasabuvir (Exviera®)','Exviera','Exviera® is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (CHC) in adults. Exviera® must not be administered as monotherapy. Depending on the patient population The recommended co-administered medicinal products for exviera® combination therapy are viekirax® or viekirax®   and ribavirin.',2016,'2015-01-14','AbbVie',0,'2014-12-21','2016-02-10','https://www.ema.europa.eu/en/medicines/human/EPAR/exviera','Hepatitis C, Chronic','HTA recommended at submitted price'),(2442,'2018-12-13 16:45:07','http://www.ncpe.ie/drugs/patiromer-veltassa/','2017-10-11','2017-11-17','Full pharmacoeconomic assessment\nrecommended','2017-10-11, 2017-11-17',0,'Patiromer (Veltassa®)','Veltassa','Patiromer (Veltassa®) is indicated for the treatment of hyperkalaemia in adults.',2018,'2017-07-19','Vifor',0,'2017-10-11','2018-11-13','https://www.ema.europa.eu/en/medicines/human/EPAR/veltassa','Hyperkalemia','HTA recommended at submitted price'),(2443,'2018-12-13 16:45:10','http://www.ncpe.ie/drugs/pembrolizumab-keytruda-1l-nsclc-with-chemotherapy/','2018-08-14','2018-08-29','A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.','2018-08-14, 2018-08-29',0,'Pembrolizumab (Keytruda®) 1L NSCLC with chemotherapy','Keytruda','Pembrolizumab (Keytruda®) is indicated in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.',2018,'2015-07-16','Merck',0,'2018-08-14','2018-08-29','https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda','Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2444,'2018-12-13 16:45:15','http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-adjuvant-melanoma/','2018-11-19','2018-12-07','A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.','2018-11-19, 2018-12-07',0,'Pembrolizumab (Keytruda®) for Adjuvant melanoma','Keytruda','Pembrolizuma (Keytruda®) as monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.',2018,'2015-07-16','Merck',0,'2018-11-19','2018-12-07','https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda','Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2445,'2018-12-13 16:45:18','http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-classical-hodgkin-lymphoma/','2017-12-06','2017-12-21','Full pharmacoeconomic assessment recommended at the submitted price','2017-12-06, 2017-12-21',0,'Pembrolizumab (Keytruda ®) for Classical Hodgkin Lymphoma','Keytruda','Pembrolizumab (Keytruda®) is indicated as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV.',2018,'2015-07-16','Merck',0,'2017-12-06','2018-11-01','https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda','Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2446,'2018-12-13 16:45:23','http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-first-line-nsclc/','2016-12-19','2017-01-10','Full pharmacoeconomic assessment recommended','2016-12-19, 2017-01-10',0,'Pembrolizumab (Keytruda®) for NSCLC (first line)','Keytruda','Keytruda® for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 (tumour proportion score [TPS] ≥ 50%) with no EGFR or ALK positive tumour mutations and no prior systemic therapy for advanced disease.',2018,'2015-07-16','Merck',0,'2016-12-19','2018-03-01','https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda','Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2447,'2018-12-13 16:45:28','http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-nsclc/','2016-08-03','2016-08-24','Full pharmacoeconomic assessment recommended','2016-08-03, 2016-08-24',0,'Pembrolizumab (Keytruda®) for NSCLC (second line)','Keytruda','Pembrolizumab (Keytruda®) is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received approved therapy for these mutations prior to receiving pembrolizumab.',2018,'2015-07-16','Merck',0,'2016-08-03','2018-11-01','https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda','Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2448,'2018-12-13 16:45:31','http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-the-treatment-of-unresectable-or-advanced-metastatic-melanoma-in-adults-refractory-to-ipilimumab/','2015-08-06','2015-08-13','Full Pharmacoeconomic Evaluation Recommended','2015-08-06, 2015-08-13',0,'Pembrolizumab (Keytruda®) for the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.','Keytruda','Keytruda® for the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.',2016,'2015-07-16','Merck',0,'2015-08-06','2016-06-01','https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda','Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2449,'2018-12-13 16:45:36','http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-uc-1l/','2017-12-06','2018-07-27','A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies','2017-12-06, 2017-12-21, 2018-06-21, 2018-07-10, 2018-07-27',1,'Pembrolizumab (Keytruda ®) for Urothelial  Carcinoma 1L','Keytruda','Pembrolizumab (Keytruda®) is indicated for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.',2018,'2015-07-16','Merck',0,'2017-12-06','2018-07-27','https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda','Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2450,'2018-12-13 16:45:38','http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-urothelial-carcinoma-2l/','2017-12-06','2017-12-21','Full pharmacoeconomic assessment recommended','2017-12-06, 2017-12-21',0,'Pembrolizumab (Keytruda ®) for Urothelial Carcinoma 2L','Keytruda','Pembrolizumab (Keytruda ®) is indicated as monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy.',2018,'2015-07-16','Merck',0,'2017-12-06','2018-12-05','https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda','Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2451,'2018-12-13 16:45:45','http://www.ncpe.ie/drugs/pembrolizumab-keytruda/','2015-08-06','2015-08-13','Full Pharmacoeconomic Evaluation Recommended','2015-08-06, 2015-08-13',0,'Pembrolizumab (Keytruda®) for the first line treatment of unresectable or advanced metastatic melanoma in adults.','Keytruda','Keytruda® is indicated for the first line treatment of unresectable or advanced metastatic melanoma in adults.',2016,'2015-07-16','Merck',0,'2015-08-06','2016-02-08','https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda','Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung','HTA recommended at submitted price'),(2452,'2018-12-13 16:45:50','http://www.ncpe.ie/drugs/perampanel-fycompa/','2013-07-01','2013-07-01','Full pharmacoeconomic evaluation not recommended','2013-07-01, 2013-07-01',0,'Perampanel (Fycompa®)','Fycompa','Perampanel (Fycompa®) indicated for treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older. ',2013,'2012-07-23','Eisai',0,'2013-07-01','2013-07-01','https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa','Epilepsies, Partial','No HTA'),(2453,'2018-12-13 16:45:56','http://www.ncpe.ie/drugs/pertuzumab-perjeta-for-her2-positive-breast-cancer/','2018-06-01','2018-06-22','A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of pertuzumab compared with the current standard of care.','2018-06-01, 2018-06-22',0,'Pertuzumab  (Perjeta®) for Adjuvant HER2 positive breast cancer','Perjeta','Pertuzumab is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.',2018,'2013-03-04','Roche',0,'2018-06-01','2018-12-03','https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta','Breast Neoplasms','HTA recommended at submitted price'),(2454,'2018-12-13 16:46:02','http://www.ncpe.ie/drugs/pertuzumab-perjeta-in-neoadjuvant-her2-positive-breast-cancer/','2015-08-10','2015-09-01','Full Pharmacoeconomic Evaluation Recommended','2015-08-10, 2015-09-01',0,'Pertuzumab (Perjeta®) in neoadjuvant HER2 positive breast cancer','Perjeta','Perjeta (pertuzumab) is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.',2016,'2013-03-04','Roche',0,'2015-08-10','2016-05-10','https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta','Breast Neoplasms','HTA recommended at submitted price'),(2455,'2018-12-13 16:46:04','http://www.ncpe.ie/drugs/pertuzumab-perjeta/','2013-01-14','2013-01-31','Pharmacoeconomic Evaluation Recommended','2013-01-14, 2013-01-31',0,'Pertuzumab (Perjeta®)','Perjeta','The proposed licensed indication is for use (in combination with trastuzumab and docetaxel) in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. ',2013,'2013-03-04','Roche',0,'2013-01-14','2013-08-28','https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta','Breast Neoplasms','HTA recommended at submitted price'),(2456,'2018-12-13 16:46:09','http://www.ncpe.ie/drugs/phenylephrine-hydrochloride-tropicamide-lidocaine-hydrochloride-fydrane/','2016-11-18','2016-12-19','Reimbursement not recommended at the submitted price','2016-11-18, 2016-12-19',0,'Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride (Fydrane®)','Fydrane','Fydrane® is indicated for cataract surgery to obtain mydriasis and intraocular anaesthesia, during the surgical procedure.',2016,NULL,'Unknown',0,'2016-11-18','2016-12-19','','Unknown','Reimbursement not recommended'),(2457,'2018-12-13 16:46:11','http://www.ncpe.ie/drugs/pirfenidone-esbriet/','2011-12-15','2012-01-05','Full Pharmacoeconomic Evaluation Recommended','2011-12-15, 2012-01-05',0,'Pirfenidone (Esbriet®)','Esbriet','Pirfenidone has been licensed by the European Medicines Agency (EMA) for the treatment of mild to moderate idiopathic pulmonary fibrosis.',2015,'2011-02-27','Roche',1,'2011-12-15','2015-03-01','https://www.ema.europa.eu/en/medicines/human/EPAR/esbriet','Idiopathic Pulmonary Fibrosis','HTA recommended at submitted price'),(2458,'2018-12-13 16:46:14','http://www.ncpe.ie/drugs/pitavastatin-livazo/','2010-12-22','2010-12-24','Full Pharmacoeconomic Evaluation not Recommended.','2010-12-22, 2010-12-24',0,'Pitavastatin (Livazo®)','Livazo','Pitavastatin is indicated for the reduction of elevated TC and LDL-C, in adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and combined (mixed) dyslipidaemia, when response to diet and other non-pharmacological measures are inadequate.',2010,'1996-10-04','CIS',0,'2010-12-22','2010-12-24','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','No HTA'),(2459,'2018-12-13 16:46:20','http://www.ncpe.ie/drugs/pitolisant-wakix/','2017-06-12','2017-06-15','Full Pharmacoeconomic Evaluation Not Recommended','2017-06-12, 2017-06-15',0,'Pitolisant hydrochloride (Wakix®)','Wakix','Pitolisant hydrochloride (Wakix®) is indicated for the treatment of narcolepsy with or without cataplexy and should be initiated by a physician experienced in the treatment of sleep disorders.',2017,'2016-03-31','Bioprojet',1,'2017-06-12','2017-06-15','https://www.ema.europa.eu/en/medicines/human/EPAR/wakix','Narcolepsy','No HTA'),(2460,'2018-12-13 16:46:24','http://www.ncpe.ie/drugs/pixantrone-pixuvri/','2015-02-10','2015-03-20','Full Pharmacoeconomic Evaluation Not Recommended','2015-02-10, 2015-03-20',0,'Pixantrone (Pixuvri®)','Pixuvri','Pixurvi® is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lynmphomas (NHL).',2015,'2012-05-10','CTI',0,'2015-02-10','2015-03-20','https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri','Lymphoma, Non-Hodgkin','No HTA'),(2461,'2018-12-13 16:46:27','http://www.ncpe.ie/drugs/polynuclear-ironiii-oxyhydroxide-pn-feooh-velphoro/','2014-09-12','2014-10-08','Full Pharmacoeconomic Evaluation Not Recommended.','2014-09-12, 2014-10-08',0,'Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro®)','Velphoro','Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro™) is indicated for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD).',2014,'2014-08-26','Vifor',0,'2014-09-12','2014-10-08','https://www.ema.europa.eu/en/medicines/human/EPAR/velphoro','Hyperphosphatemia; Renal Dialysis','No HTA'),(2462,'2018-12-13 16:46:30','http://www.ncpe.ie/drugs/pomalidomide-imnovid/','2013-09-20','2013-10-02','Full Pharmacoeconomic Evaluation Recommended','2013-09-20, 2013-10-02',0,'Pomalidomide (Imnovid®)','Imnovid','Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.',2015,'1996-10-04','CIS',0,'2013-09-20','2015-12-01','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','HTA recommended at submitted price'),(2463,'2018-12-13 16:46:32','http://www.ncpe.ie/drugs/ponatinib-iclusig/','2013-10-02','2013-12-01','Full HTA Recommended','2013-10-02, 2013-12-01',0,'Ponatinib (Iclusig®)','Iclusig','Ponatinib (Iclusig®) Is indicated for patients in chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation and for Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) patients who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.',2016,'2013-07-01','Incyte',1,'2013-10-02','2016-01-05','https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig','Leukemia, Myeloid; Leukemia, Lymphoid','HTA recommended at submitted price'),(2464,'2018-12-13 16:46:38','http://www.ncpe.ie/drugs/prasugrel-efient/',NULL,'2013-12-01','','',0,'Prasugrel (Efient®)','Efient','Economic Evaluation of Prasugrel (Efient®) for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention.',2010,'2009-02-24','Daiichi',0,'2009-07-01','2010-02-01','https://www.ema.europa.eu/en/medicines/human/EPAR/efient','Acute Coronary Syndrome; Angina, Unstable; Myocardial Infarction','RR not conducted'),(2465,'2018-12-13 16:46:46','http://www.ncpe.ie/drugs/pregabalin-lyrica-2/',NULL,'2013-12-01','','',0,'Pregabalin (Lyrica®) for the treatment of neuropathic pain','Lyrica','Lyrica® is indicated for the treatment of peripheral and central neuropathic pain, generalised anxiety disorder and as adjunctive therapy for epilepsy.',2015,'2004-07-05','Pfizer',0,'2013-09-30','2015-06-12','https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica','Epilepsy; Anxiety Disorders; Neuralgia','RR not conducted'),(2466,'2018-12-13 16:46:52','http://www.ncpe.ie/drugs/pregabalin-lyrica-for-the-treatment-of-generalised-anxiety-disorder/',NULL,'2013-12-01','','',0,'Pregabalin (Lyrica®) for the treatment of Generalised Anxiety Disorder','Lyrica','Pregabalin (Lyrica®) for the treatment of Generalised Anxiety Disorder.',2014,'2004-07-05','Pfizer',0,'2014-09-12','2014-12-15','https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica','Epilepsy; Anxiety Disorders; Neuralgia','RR not conducted'),(2467,'2018-12-13 16:46:58','http://www.ncpe.ie/drugs/prucalopride-resolor/','2011-03-11','2011-01-17','Full Pharmacoeconomic Evaluation not Recommended.','2011-03-11, 2011-01-17',0,'Prucalopride (Resolor®)','Resolor','Prucalopride (Resolor®) for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief.',2011,'2009-10-14','Shire',0,'2011-01-17','2011-03-01','https://www.ema.europa.eu/en/medicines/human/EPAR/resolor','Constipation','No HTA'),(2468,'2018-12-13 16:47:00','http://www.ncpe.ie/drugs/radium-223-xofigo/','2013-11-28','2013-12-23','Full Pharmacoeconomic Evaluation Recommended.','2013-11-28, 2013-12-23',0,'Radium-223 (Xofigo®)','Xofigo','Radium-223 (Xofigo®) is indicated for the treatment of adults with castration resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.  It is for use in the hospital setting.',2015,'2013-11-13','Bayer',0,'2013-11-28','2015-12-01','https://www.ema.europa.eu/en/medicines/human/EPAR/xofigo','Prostatic Neoplasms','HTA recommended at submitted price'),(2469,'2018-12-13 16:47:03','http://www.ncpe.ie/drugs/ramucirumab-cyramza/','2014-12-20','2014-12-23','Full Pharmacoeconomic Evaluation Recommended','2014-12-20, 2014-12-23',0,'Ramucirumab (Cyramza®)','Cyramza','Indicated in combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction (GEJ) adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.',2016,'2014-12-19','Eli',0,'2014-12-20','2016-07-26','https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza','Stomach Neoplasms','HTA recommended at submitted price'),(2470,'2018-12-13 16:47:06','http://www.ncpe.ie/drugs/ranolazine-ranexa/','2009-11-19','2009-11-19','Full Pharmacoeconomic Evaluation not Recommended','2009-11-19',0,'Ranolazine (Ranexa®)','Ranexa','Cost-effectiveness of Ranolazine (Ranexa®)',2009,'2009-10-10','GlaxoSmithKline',0,'2009-11-19','2009-11-19','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','No HTA'),(2471,'2018-12-13 16:47:13','http://www.ncpe.ie/drugs/regadenoson-rapiscan/','2011-09-19','2011-11-02','Full Pharmacoeconomic Evaluation not Recommended.','2011-09-19, 2011-11-02',0,'Regadenoson (Rapiscan®)','Rapiscan','Cost-effectiveness of Regadenoson (Rapiscan®)',2011,'2010-09-06','GE',0,'2011-09-19','2011-11-02','https://www.ema.europa.eu/en/medicines/human/EPAR/rapiscan','Myocardial Perfusion Imaging','No HTA'),(2472,'2018-12-13 16:47:17','http://www.ncpe.ie/drugs/regorafenib-stivarga-for-gist/','2014-09-18','2014-10-06','Full Pharmacoeconomic Evaluation Recommended.','2014-09-18, 2014-10-06',0,'Regorafenib (Stivarga®) for GIST','Stivarga','Regorafenib (Stivarga®) indicated for the treatment of patients with gastrointestinal stromal tumours (GIST) who have been previously treated with two tyrosine kinase inhibitors and have progressed or are intolerant to prior treatment with two TKI’s.',2014,'2013-08-26','Bayer',0,'2014-09-18','2014-10-06','https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga','Colorectal Neoplasms','HTA recommended at submitted price'),(2473,'2018-12-13 16:47:23','http://www.ncpe.ie/drugs/reslizumab-cinqaero/','2017-01-23','2017-03-01','Full Pharmacoeconomic Evaluation Recommended at the submitted price.','2017-01-23, 2017-03-01',0,'Reslizumab (Cinqaero®)','Cinqaero','Cinqaero® is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.',2017,'2016-08-15','Teva',0,'2017-01-23','2017-03-01','https://www.ema.europa.eu/en/medicines/human/EPAR/cinqaero','Asthma','HTA recommended at submitted price'),(2474,'2018-12-13 16:47:27','http://www.ncpe.ie/drugs/retigabine-trobalt/','2011-04-06','2011-03-01','Full Pharmacoeconomic Evaluation not Recommended.','2011-04-06, 2011-03-01',0,'Retigabine (Trobalt®)','Trobalt','Cost-effectiveness of Retigabine (Trobalt®)',2011,'2011-03-27','Glaxo',0,'2011-03-01','2011-04-06','https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt','Epilepsy','No HTA'),(2475,'2018-12-13 16:47:29','http://www.ncpe.ie/drugs/ribociclib-kisqali/','2017-09-04','2017-09-19','Following NCPE assessment of the company submission, the NCPE recommends that ribociclib (in combination with an aromatase inhibitor) for the treatment of postmenopausal women with HR+/HER2- locally advanced or metastatic BC as initial endocrine-based therapy, not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.','2017-09-04, 2017-09-19',0,'Ribociclib (Kisqali®)','Kisqali','Ribociclib (Kisqali®) in combination with an aromatase inhibitor (AI) is indicated for the treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine based therapy.',2018,'2017-08-22','Novartis',0,'2017-09-04','2018-08-13','https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali','Breast Neoplasms','No HTA at submitted price'),(2476,'2018-12-13 16:47:35','http://www.ncpe.ie/drugs/rifaximin-targaxan-2/','2013-07-09','2013-08-06','Full Pharmacoeconomic Evaluation Not Recommended','2013-07-09, 2013-08-06',0,'Rifaximin (Targaxan®)','Targaxan','Rifaximin (Targaxan®) is indicated for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients ≥ 18 years of age. ',2013,'1996-10-04','CIS',0,'2013-07-09','2013-08-06','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','No HTA'),(2477,'2018-12-13 16:47:38','http://www.ncpe.ie/drugs/rigorafenib-stivarga/','2013-09-12','2013-10-02','Full Pharmacoeconomic Evaluation Recommended','2013-09-12, 2013-10-02',0,'Regorafenib (Stivarga®) for mCRC','Stivarga','Regorafenib (Stivarga®) is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.',2014,'2013-08-26','Bayer',0,'2013-09-12','2014-06-30','https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga','Colorectal Neoplasms','HTA recommended at submitted price'),(2478,'2018-12-13 16:47:42','http://www.ncpe.ie/drugs/rilpivirine-edurant/','2011-12-14','2012-01-06','Full Pharmacoeconomic Evaluation not Recommended','2011-12-14, 2012-01-06',0,'Rilpivirine (Edurant®)','Edurant','Rilpivirine in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml.',2012,'2011-11-28','Janssen-Cilag',0,'2011-12-14','2012-01-06','https://www.ema.europa.eu/en/medicines/human/EPAR/edurant','HIV Infections','No HTA'),(2479,'2018-12-13 16:47:45','http://www.ncpe.ie/drugs/rilpivirine-r-emtricitabine-f-tenofovir-alafenamide-taf-odefsey/','2016-06-28','2016-07-11','Reimbursement Not Recommeded','2016-06-28, 2016-07-11',0,'Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF) (Odefsey®)','Odefsey','Odefsey® (R/F/TAF) is indicated for the treatment of adults and adolescents (≥ 12 years, body weight ≥35 kg) infected with HIV 1 without known mutations associated with resistance to the NNRTI class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV 1 RNA copies/ml.',2016,'2016-06-21','Gilead',0,'2016-06-28','2016-10-04','https://www.ema.europa.eu/en/medicines/human/EPAR/odefsey','HIV Infections','Reimbursement not recommended'),(2480,'2018-12-13 16:47:48','http://www.ncpe.ie/drugs/rimonabant-acomplia-2/',NULL,'2016-07-11','','',0,'Rimonabant (Acomplia®)','Acomplia','In June 2006, Sanofi-Aventis submitted an evaluation of the cost-effectiveness of rimonabant (in addition to diet and exercise) in the management of multiple cardiovascular risks in overweight or obese patients in Ireland, to support its application for reimbursement of rimonabant under the Community Drugs Schemes. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.',2006,'2006-06-19','sanofi-aventis',0,'2006-06-01','2006-06-01','https://www.ema.europa.eu/en/medicines/human/EPAR/acomplia','Obesity','RR not conducted'),(2481,'2018-12-13 16:47:53','http://www.ncpe.ie/drugs/riociguat-adempas/','2014-04-11','2014-05-16','Full HTA recommended at the current price.','2014-04-11, 2014-05-16',0,'Riociguat (Adempas®)','Adempas','Riociguat (Adempas®) is indicated for the treatment of Pulmonary arterial hypertension (PAH) and Chronic thromboembolic pulmonary hypertension (CTEPH).',2014,'2014-03-27','Bayer',1,'2014-04-11','2014-05-16','https://www.ema.europa.eu/en/medicines/human/EPAR/adempas','Hypertension, Pulmonary','HTA recommended at submitted price'),(2482,'2018-12-13 16:47:59','http://www.ncpe.ie/drugs/rituximab-mabthera/','2014-05-26','2014-09-22','Full Pharmacoeconomic Evaluation Not Recommended','2014-05-26, 2014-09-22',0,'Rituximab (MabThera®)','MabThera','Rituximab (MabThera®) subcutaneous formulation is indicated in adults for Non-Hodgkin’s lymphoma (NHL):',2014,'1998-06-02','Roche',0,'2014-05-26','2014-09-22','https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera','Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell','No HTA'),(2483,'2018-12-13 16:48:05','http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-atrial-fibrillation-patients-undergoing-pci/','2017-11-20','2017-11-21','Full pharmacoeconomic assessment recommended','2017-11-20, 2017-11-21',0,'Rivaroxaban (Xarelto®) for Atrial Fibrillation patients undergoing PCI','Xarelto','Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.',2017,'2008-09-30','Bayer',0,'2017-11-20','2017-11-21','https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto','Arthroplasty, Replacement; Venous Thromboembolism','HTA recommended at submitted price'),(2484,'2018-12-13 16:48:10','http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-dvt/','2011-08-17','2011-08-31','Full Pharmacoeconomic Evaluation Recommended','2011-08-17, 2011-08-31',0,'Rivaroxaban (Xarelto®) for the Treatment of Deep Vein Thrombosis','Xarelto','Economic evaluation of Rivaroxaban (Xarelto®) for the Treatment of Deep Vein Thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults.',2012,'2008-09-30','Bayer',0,'2011-08-17','2012-02-24','https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto','Arthroplasty, Replacement; Venous Thromboembolism','HTA recommended at submitted price'),(2485,'2018-12-13 16:48:15','http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-spaf-2/','2011-08-17','2011-08-31','Full Pharmacoeconomic Evaluation Recommended','2011-08-17, 2011-08-31',0,'Rivaroxaban (Xarelto®) for the Prevention of Stroke in Atrial Fibrillation','Xarelto','Cost Effectiveness of Rivaroxaban (Xarelto®) for the prevention of stroke in atrial fibrillation.',2012,'2008-09-30','Bayer',0,'2011-08-17','2012-06-19','https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto','Arthroplasty, Replacement; Venous Thromboembolism','HTA recommended at submitted price'),(2486,'2018-12-13 16:48:18','http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-the-prevention-of-atherothrombotic-events/','2018-09-26','2018-10-11','A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Rivaroxaban compared with the current standard of care.','2018-09-26, 2018-10-11',0,'Rivaroxaban (Xarelto®) for the prevention of atherothrombotic events','Xarelto','Rivaroxaban (Xarelto®) for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.',2018,'2008-09-30','Bayer',0,'2018-09-26','2018-10-11','https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto','Arthroplasty, Replacement; Venous Thromboembolism','HTA recommended at submitted price'),(2487,'2018-12-13 16:48:25','http://www.ncpe.ie/drugs/rivaroxaban-xarelto-low-dose-for-prevention-of-recurrent-venous-thromboembolism/','2017-11-20','2017-11-21','Full pharmacoeconomic assessment recommended','2017-11-20, 2017-11-21',0,'Rivaroxaban (Xarelto®) low dose for prevention of recurrent venous thromboembolism','Xarelto','Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.',2017,'2008-09-30','Bayer',0,'2017-11-20','2017-11-21','https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto','Arthroplasty, Replacement; Venous Thromboembolism','HTA recommended at submitted price'),(2488,'2018-12-13 16:48:30','http://www.ncpe.ie/drugs/rivaroxaban-xarelto/',NULL,'2017-11-21','','',0,'Rivaroxaban (Xarelto®) for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement','Xarelto','Cost Effectiveness of Rivaroxaban (Xarelto®) for the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Total Hip Replacement or Total Knee Replacement.',2008,'2008-09-30','Bayer',0,'2008-04-01','2008-09-01','https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto','Arthroplasty, Replacement; Venous Thromboembolism','RR not conducted'),(2489,'2018-12-13 16:48:33','http://www.ncpe.ie/drugs/roflumilast-daxas/',NULL,'2017-11-21','','',0,'Roflumilast (Daxas®)','Daxas','Cost Effectiveness of Roflumilast (Daxas®) for the maintenance treatment of severe Chronic Obstructive Pulmonary Disease associated with chronic bronchitis in patients with a history of frequent exacerbations.',2010,'2010-07-05','AstraZeneca',0,'2010-06-11','2010-11-03','https://www.ema.europa.eu/en/medicines/human/EPAR/daxas','Pulmonary Disease, Chronic Obstructive','RR not conducted'),(2490,'2018-12-13 16:48:40','http://www.ncpe.ie/drugs/rolapitant-varuby/','2017-05-15','2017-06-12','Full Pharmacoeconomic Evaluation Not Recommended','2017-05-15, 2017-06-12',0,'Rolapitant (Varuby®)','Varuby','Rolapitant (Varuby®)is indicated for the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.',2017,'2017-04-19','Tesaro',0,'2017-05-15','2017-06-12','https://www.ema.europa.eu/en/medicines/human/EPAR/varuby','Vomiting; Nausea; Cancer','No HTA'),(2491,'2018-12-13 16:48:43','http://www.ncpe.ie/drugs/romiplostim-nplate/',NULL,'2017-06-12','','',0,'Romiplostim (Nplate®)','Nplate','Romiplostim (Nplate®) is indicated for the treatment of adult chronic ITP splenectomised patients who have had either an inadequate response or who are intolerant of corticosteroids and immunoglobulins and also as second line treatment for adult ITP non-splenectomised patients where surgery is contraindicated.',2015,'2009-02-04','Amgen',1,'2015-04-02','2015-05-27','https://www.ema.europa.eu/en/medicines/human/EPAR/nplate','Purpura, Thrombocytopenic, Idiopathic','RR not conducted'),(2492,'2018-12-13 16:48:47','http://www.ncpe.ie/drugs/ropivacaine-readyfusor/','2018-11-09','2018-12-13','A full HTA is not recommended. The NCPE recommends that Ropivicaine Readyfusor not be considered for reimbursement at the submitted price.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.','2018-11-09, 2018-12-13',0,'Ropivacaine Readyfusor®','Ropivacaine Readyfusor','Ropivacaine Readyfusor for acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block (CPNB) via a continuous infusion.',2018,NULL,'Unknown',0,'2018-11-09','2018-12-13','','Unknown','Unknown'),(2493,'2018-12-13 16:48:50','http://www.ncpe.ie/drugs/ruxolitinib-jakavi-for-polycythaemia-vera/','2015-04-15','2015-05-28','Full Pharmacoeconomic Evaluation Recommended','2015-04-15, 2015-05-28',0,'Ruxolitinib (Jakavi®) for Polycythaemia Vera','Jakavi','Jakavi® is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.',2016,'2012-08-23','Novartis',1,'2015-04-15','2016-08-16','https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi','Myeloproliferative Disorders','HTA recommended at submitted price'),(2494,'2018-12-13 16:48:55','http://www.ncpe.ie/drugs/ruxolitinib-jakavi/','2012-08-01','2012-08-10','Full pharmacoeconomic evaluation recommended','2012-08-01, 2012-08-10',0,'Ruxolitinib (Jakavi®)','Jakavi','Ruxolitinib (Jakavi®) for the treatment of splenomegaly or disease-related symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.',2013,'2012-08-23','Novartis',1,'2012-08-01','2013-07-09','https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi','Myeloproliferative Disorders','HTA recommended at submitted price'),(2495,'2018-12-13 16:48:58','http://www.ncpe.ie/drugs/sacubitrilvalsartan-entresto/','2015-11-06','2015-11-30','Full Pharmacoeconomic Evaluation Recommended','2015-11-06, 2015-11-30',0,'Sacubitril/valsartan (Entresto®)','Entresto','Entresto® for the treatment of symptomatic chronic heart failure with reduced ejection fraction if adult patients.',2017,'2015-11-19','Novartis',0,'2015-11-06','2017-10-01','https://www.ema.europa.eu/en/medicines/human/EPAR/entresto','Heart Failure','HTA recommended at submitted price'),(2496,'2018-12-13 16:49:04','http://www.ncpe.ie/drugs/safinamide-methansulfonate-xadago/','2016-06-14','2016-07-06','Reimbursement not recommended.','2016-06-14, 2016-07-06',0,'Safinamide methansulfonate (Xadago®)','Xadago','Xadago® for the treatment of adult patients with idiopathic Parkinson’s disease.',2016,'2015-02-23','Zambon',0,'2016-06-14','2016-07-06','https://www.ema.europa.eu/en/medicines/human/EPAR/xadago','Parkinson Disease','Reimbursement not recommended'),(2497,'2018-12-13 16:49:07','http://www.ncpe.ie/drugs/sapropterin-kuvan/','2015-07-14','2015-07-01','Full pharmacoeconomic assessment recommended','2015-07-14, 2015-08-14, 2015-07-01',1,'Sapropterin (Kuvan®)','Kuvan','Sapropterin (Kuvan®) for the treatment of phenylketonuria (PKU).',2017,'2008-12-02','BioMarin',1,'2009-01-01','2017-09-15','https://www.ema.europa.eu/en/medicines/human/EPAR/kuvan','Phenylketonurias','HTA recommended at submitted price'),(2498,'2018-12-13 16:49:11','http://www.ncpe.ie/drugs/sarilumab-kevzara/','2017-08-18','2017-10-04','Full pharmacoeconomic assessment recommended at the submitted price.','2017-08-18, 2017-10-04',0,'Sarilumab (Kevzara®)','Kevzara','Sarilumab (Kevzara®) in combination with methotrexate (MTX) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARD). Sarilumab can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.',2017,'2017-06-23','sanofi-aventis',0,'2017-08-18','2017-10-04','https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara','Arthritis, Rheumatoid','HTA recommended at submitted price'),(2499,'2018-12-13 16:49:16','http://www.ncpe.ie/drugs/sebelipase-alfa-kanuma/','2017-02-08','2017-03-13','A Full pharmacoeconomic assessment is recommended','2017-02-08, 2017-03-13',0,'Sebelipase alfa (Kanuma®)','Kanuma','Sebelipase alfa is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.',2018,'2015-08-28','Alexion',1,'2017-02-08','2018-06-08','https://www.ema.europa.eu/en/medicines/human/EPAR/kanuma','Lipid Metabolism, Inborn Errors','HTA recommended at submitted price'),(2500,'2018-12-13 16:49:20','http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-ankylosing-spondylitis/','2015-12-02','2015-12-14','Full Pharmacoeconomic Evaluation Not Recommended','2015-12-02, 2015-12-14',0,'Secukinumab (Cosentyx®) for Ankylosing Spondylitis','Cosentyx','Cosentyx® is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy',2015,'2015-01-14','Novartis',0,'2015-12-02','2015-12-14','https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx','Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing','No HTA'),(2501,'2018-12-13 16:49:25','http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-psoriatic-arthritis/','2015-12-02','2015-12-15','Full Pharmacoeconomic Evaluation Not Recommended','2015-12-02, 2015-12-15',0,'Secukinumab (Cosentyx®) for Psoriatic Arthritis','Cosentyx','Cosentyx® alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.',2015,'2015-01-14','Novartis',0,'2015-12-02','2015-12-15','https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx','Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing','No HTA'),(2502,'2018-12-13 16:49:31','http://www.ncpe.ie/drugs/secukinumab-cosentyx/','2014-12-19','2015-02-05','Full Pharmacoeconomic Evaluation Recommended','2014-12-19, 2015-02-05',0,'Secukinumab (Cosentyx®)','Cosentyx','Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.',2015,'2015-01-14','Novartis',0,'2014-12-19','2015-12-01','https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx','Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing','HTA recommended at submitted price'),(2503,'2018-12-13 16:49:34','http://www.ncpe.ie/drugs/selexipag-uptravi/','2016-11-01','2016-12-05','Full pharmacoeconomic assessment recommended','2016-11-01, 2016-12-05',0,'Selexipag (Uptravi®)','Uptravi','Selexipag (Uptravi®) is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.',2018,'2016-05-12','Janssen',0,'2016-11-01','2018-05-21','https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi','Hypertension, Pulmonary','HTA recommended at submitted price'),(2504,'2018-12-13 16:49:39','http://www.ncpe.ie/drugs/semaglutide-ozempic/','2018-03-12','2018-04-10','A full pharmacoeconomic assessment is recommended on the basis of the proposed price, relative to currently available therapies.','2018-03-12, 2018-04-10',0,'Semaglutide (Ozempic®)','Ozempic','Semaglutide (Ozempic®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:',2018,'2018-02-08','Novo',0,'2018-03-12','2018-04-10','https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic','Diabetes Mellitus','HTA recommended at submitted price'),(2505,'2018-12-13 16:49:44','http://www.ncpe.ie/drugs/sildenafil-revatio/','2014-04-16','2014-05-23','Full Pharmacoeconomic Evaluation Not Recommended.','2014-04-16, 2014-05-23',0,'Sildenafil (Revatio®)','Revatio','Sildenafil (Revatio®) is indicated for:',2014,'2005-10-28','Pfizer',1,'2014-04-16','2014-05-23','https://www.ema.europa.eu/en/medicines/human/EPAR/revatio','Hypertension, Pulmonary','No HTA'),(2506,'2018-12-13 16:49:49','http://www.ncpe.ie/drugs/simeprevir-olysio-in-combination-with-sofosbuvir/','2014-05-27','2014-07-11','Full Pharmacoeconomic Assessment Recommended.','2014-05-27, 2014-07-11',0,'Simeprevir (Olysio®) in combination with Sofosbuvir','Olysio','Simeprevir (Olysio®) in combination with Sofosbuvir for the treatment of chronic hepatitis C (CHC) in adult patients who are intolerant to or ineligible for interferon therapy, and are in urgent need of treatment.',2015,'2014-05-14','Janssen-Cilag',0,'2014-05-27','2015-03-13','https://www.ema.europa.eu/en/medicines/human/EPAR/olysio','Hepatitis C, Chronic','HTA recommended at submitted price'),(2507,'2018-12-13 16:49:53','http://www.ncpe.ie/drugs/simeprevir-olysio/','2014-05-27','2014-07-11','Full pharmacoeconomic assessment not recommended when used in triple therapy with peg-interferon and ribavirin.','2014-05-27, 2014-07-11',0,'Simeprevir (Olysio®)','Olysio','Simeprevir (Olysio®) is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients as part of a triple therapy regimen (co-administered with PegInterferon + Ribavirin) to treat hepatitis C virus (HCV) Genotypes 1 and 4 who are treatment naïve or have previously been treated.',2014,'2014-05-14','Janssen-Cilag',0,'2014-05-27','2014-07-11','https://www.ema.europa.eu/en/medicines/human/EPAR/olysio','Hepatitis C, Chronic','No HTA'),(2508,'2018-12-13 16:50:00','http://www.ncpe.ie/drugs/sodium-chloride-70mgml-sodium-hyaluronate-1mgml-hyaneb/','2014-02-10','2014-03-19','Full Pharmacoeconomic Evaluation not recommended','2014-02-10, 2014-03-19',0,'Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml (Hyaneb®)','Hyaneb','Hyaneb® is particularly indicated in patients with cystic fibrosis and in patients with bronchiectasis.  Hyaneb® is classified as a medical device and carries a CE mark.',2014,'2009-10-10','GlaxoSmithKline',0,'2014-02-10','2014-03-19','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','No HTA'),(2509,'2018-12-13 16:50:06','http://www.ncpe.ie/drugs/sodium-hyaluronate-hyloforte-0-2/','2014-01-15','2014-01-27','Full Pharmacoeconomic Evaluation Not Recommended','2014-01-15, 2014-01-27',0,'Sodium Hyaluronate (Hyloforte® 0.2%)','Hyloforte 0.2%','Sodium Hyaluronate (Hyloforte® 0.2%) is indicated for the treatment of mild to moderate form of dry eye.',2014,'2009-10-10','GlaxoSmithKline',0,'2014-01-15','2014-01-27','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','No HTA'),(2510,'2018-12-13 16:50:09','http://www.ncpe.ie/drugs/sodium-hyaluronate-hylotear-0-1/','2014-01-15','2014-01-27','Full Pharmacoeconomic Evaluation Not Recommended','2014-01-15, 2014-01-27',0,'Sodium Hyaluronate (Hylotear® 0.1%)','Hylotear 0.1%','Sodium Hyaluronate (Hylotear® 0.1%) is indicated for the treatment of mild to moderate form of dry eye.',2014,'2009-10-10','GlaxoSmithKline',0,'2014-01-15','2014-01-27','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','No HTA'),(2511,'2018-12-13 16:50:15','http://www.ncpe.ie/drugs/sodium-phenylbutyrate-pheburane/','2013-07-17','2013-08-06','Full Pharmacoeconomic Evaluation Not Recommended','2013-07-17, 2013-08-06',0,'Sodium phenylbutyrate (Pheburane®)','Pheburane','Sodium phenylbutyrate (Pheburane®) is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.',2013,'2013-07-30','Lucane',0,'2013-07-17','2013-08-06','https://www.ema.europa.eu/en/medicines/human/EPAR/pheburane','Carbamoyl-Phosphate Synthase I Deficiency Disease','No HTA'),(2512,'2018-12-13 16:50:18','http://www.ncpe.ie/drugs/sofosbuvir-solvaldi/','2014-02-12','2014-03-10','Full Pharmacoeconomic Evaluation Recommended','2014-02-12, 2014-03-10',0,'Sofosbuvir (Solvaldi®)','Solvaldi','Sofosbuvir (Solvaldi®) is indicated in combination with other medicinal products for the treatment of Chronic Hepatitis C in adults.',2014,'2009-12-09','Pfizer',0,'2014-02-12','2014-10-24','https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13','Pneumococcal Infections; Immunization','HTA recommended at submitted price'),(2513,'2018-12-13 16:50:22','http://www.ncpe.ie/drugs/sofosbuvirvelpatasvir-epclusa-chronic-hepatitis-c-virus-hcv-pangenotypic/','2017-09-05','2017-10-19',' Full pharmacoeconomic assessment not recommended','2017-09-05, 2017-10-19',0,'Sofosbuvir/Velpatasvir (Epclusa®) chronic hepatitis C virus (HCV) – pangenotypic','Epclusa','Sofosbuvir/velpatasvir (Epclusa®) for the treatment of chronic hepatitis C virus (HCV) infection in adults. This indication covers all genotypes (GT1, 2, 3, 4, 5 and 6) i.e. pangenotypic.',2017,'2016-07-06','Gilead',0,'2017-09-05','2017-10-19','https://www.ema.europa.eu/en/medicines/human/EPAR/epclusa','Hepatitis C, Chronic','No HTA at submitted price'),(2514,'2018-12-13 16:50:26','http://www.ncpe.ie/drugs/sofosbuvirvelpatasvirvoxilaprevir-vosevi/','2017-09-19','2017-11-15','Full pharmacoeconomic assessment not recommended','2017-09-19, 2017-11-15',0,'Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®)','Vosevi','Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®) is indicated the treatment of chronic hepatitis C virus (HCV) infection in adults – pangenotypic i.e. all genotypes (GT1, 2, 3, 4, 5 and 6).',2017,'2017-07-26','Gilead',0,'2017-09-19','2017-11-15','https://www.ema.europa.eu/en/medicines/human/EPAR/vosevi','Hepatitis C, Chronic','No HTA'),(2515,'2018-12-13 16:50:32','http://www.ncpe.ie/drugs/st-johns-wort-pafica/','2015-04-14','2015-05-29','Full Pharmacoeconomic Evaluation Recommended','2015-04-14, 2015-05-29',0,'St Johns Wort (Pacifa®)','Pacifa','Pacifa® is indicated for the short term treatment of mild depressive symptoms.',2015,'1996-10-04','CIS',0,'2015-04-14','2015-05-29','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','HTA recommended at submitted price'),(2516,'2018-12-13 16:50:38','http://www.ncpe.ie/drugs/stiripentol-diacomit/','2017-07-06','2017-08-10','Full pharmacoeconomic assessment recommended','2017-07-06, 2017-08-10',0,'Stiripentol (Diacomit®)','Diacomit','Stiripentol (Diacomit®) for use in conjunction with clobazam and valproate as adjunctive therapy of\nrefractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy\n(SMEI, Dravet’s syndrome) whose seizures are not adequately controlled with clobazam and\nvalproate',2018,'2007-01-03','Biocodex',1,'2017-07-06','2018-10-19','https://www.ema.europa.eu/en/medicines/human/EPAR/diacomit','Myoclonic Epilepsy, Juvenile','HTA recommended at submitted price'),(2517,'2018-12-13 16:50:43','http://www.ncpe.ie/drugs/stribild-elvitegravircobicistatemtricitabinetenofovir-disoproxil-as-fumarate/','2013-04-28','2013-05-17','Full Pharmacoeconomic Evaluation Recommended','2013-04-28, 2013-05-17',0,'Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumarate)(Stribild®)','Stribild','Indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to the three antiretroviral agents in Stribild®.',2013,'2013-05-24','Gilead',0,'2013-04-28','2013-12-06','https://www.ema.europa.eu/en/medicines/human/EPAR/stribild','HIV Infections','HTA recommended at submitted price'),(2518,'2018-12-13 16:50:49','http://www.ncpe.ie/drugs/sublingual-immunotherapy-grazax/',NULL,'2013-05-17','','',0,'Sublingual Immunotherapy (Grazax®)','Grazax','A Review of the Cost-Effectiveness of Sublingual Immunotherapy (Grazax®) for the Prevention of Seasonal Grass Pollen-Induced Rhinoconjunctivitis.',2007,'1996-10-04','CIS',0,'2007-09-01','2007-09-01','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','RR not conducted'),(2519,'2018-12-13 16:50:50','http://www.ncpe.ie/drugs/suboxone-buprenorphinenaloxone/',NULL,'2013-05-17','','',0,'Buprenorphine/naloxone (Suboxone®)','Suboxone','An economic evaluation of suboxone for the management of opiate addiction.',2014,'2006-09-26','Indivior',0,'2007-11-01','2014-05-22','https://www.ema.europa.eu/en/medicines/human/EPAR/suboxone','Opioid-Related Disorders','RR not conducted'),(2520,'2018-12-13 16:50:54','http://www.ncpe.ie/drugs/sufentanil-zalviso/','2016-03-14','2016-03-22','Full Pharmacoeconomic Evaluation Recommended.','2016-03-14, 2016-03-22',0,'Sufentanil (Zalviso®)','Zalviso','Sufentanil (Zalviso®) is indicated for the management of acute moderate to severe post-operative pain in adult patients.',2018,'2015-09-18','Grünenthal',0,'2016-03-14','2018-06-27','https://www.ema.europa.eu/en/medicines/human/EPAR/zalviso','Pain, Postoperative','HTA recommended at submitted price'),(2521,'2018-12-13 16:50:59','http://www.ncpe.ie/drugs/sunitinib-sutent/',NULL,'2016-03-22','','',0,'Sunitinib (Sutent®)','Sutent','In September 2006, Pfizer Healthcare Ireland submitted an evaluation of the cost-effectiveness and budget impact of sunitinib as second-line treatment of patients with gastro-intestinal stromal tumours (GIST). Data on the cost-effectiveness and budget impact of sutinitinib as second line treatment for patients with metastatic renal cell carcinoma (mRCC) was also presented. The purpose of the submission was to support an application for reimbursement under the High Tech Drug Scheme. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.',2006,'2006-07-19','Pfizer',0,'2006-09-01','2006-09-01','https://www.ema.europa.eu/en/medicines/human/EPAR/sutent','Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Neuroendocrine Tumors','RR not conducted'),(2522,'2018-12-13 16:51:04','http://www.ncpe.ie/drugs/tadalafil-adcirca-2/','2011-07-13','2014-05-23','Full Pharmacoeconomic Evaluation Not Recommended','2011-07-13, 2011-09-21, 2014-05-09, 2014-05-23',1,'Tadalafil (Adcirca®)','Adcirca','Tadalafil (Adcirca®) is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as World Health Organisation (WHO) Functional Class (FC) II and III, to improve exercise capacity.',2014,'2009-10-10','GlaxoSmithKline',0,'2011-07-13','2014-05-23','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','No HTA'),(2523,'2018-12-13 16:51:09','http://www.ncpe.ie/drugs/tafamadis-meglumine-vyndaqel/','2018-03-12','2018-05-10','A full pharmacoeconomic assessment is not recommended until additional efficacy and/or safety data is submitted. On the basis of current evidence, the NCPE recommends that tafamidis not be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.','2018-03-12, 2018-05-10',0,'Tafamadis meglumine (Vyndaqel®)','Vyndaqel','Tafamadis meglumine (Vyndaqel®) for the treatment of transthyretin amyloidosis in adult patients with stage I symptomatic polyneuropathy to delay peripheral neurologic impairment.',2018,'2011-11-16','Pfizer',1,'2018-03-12','2018-05-10','https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel','Amyloidosis','No HTA until more evidence'),(2524,'2018-12-13 16:51:15','http://www.ncpe.ie/drugs/tafluprost-saflutan/','2011-03-11','2011-03-25','Full Pharmacoeconomic Evaluation not Recommended.','2011-03-11, 2011-03-25',0,'Tafluprost (Saflutan®)','Saflutan','Tafluoprost (Salflutan®) for the reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension.',2011,'2009-10-10','GlaxoSmithKline',0,'2011-03-01','2011-03-25','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','No HTA'),(2525,'2018-12-13 16:51:24','http://www.ncpe.ie/drugs/talimogene-laherparepvec-imlygic/','2016-02-16','2016-03-14','Full Pharmacoeconomic Evaluation Recommended.','2016-02-16, 2016-03-14',0,'Talimogene Laherparepvec (Imlygic®)','Imlygic','Talimogene laherparepvec (Imlygic®) is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.',2016,'2015-12-16','Amgen',0,'2016-02-16','2016-03-14','https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic','Melanoma','HTA recommended at submitted price'),(2526,'2018-12-13 16:51:28','http://www.ncpe.ie/drugs/tapentadol-palexia/','2010-10-19','2010-10-22','Full Pharmacoeconomic Evaluation Recommended','2010-10-19, 2010-10-22',0,'Tapentadol (Palexia®)','Palexia','Economic evaluation of oral tapentadol (Palexia®) for the management of adult patients with severe chronic/acute pain.',2011,'2009-10-10','GlaxoSmithKline',0,'2010-10-19','2011-04-08','https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted','Influenza, Human; Immunization; Disease Outbreaks','HTA recommended at submitted price'),(2527,'2018-12-13 16:51:34','http://www.ncpe.ie/drugs/tedizolid-phosphate-sivextro/','2015-05-07','2015-07-07','Full pharmacoeconomic evaluation not recommended','2015-05-07, 2015-07-07',0,'Tedizolid phosphate (Sivextro®)','Sivextro','Tedizolid phosphate (Sivextro®) is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults',2015,'2015-03-23','Merck',0,'2015-05-07','2015-07-07','https://www.ema.europa.eu/en/medicines/human/EPAR/sivextro','Soft Tissue Infections; Skin Diseases, Bacterial','No HTA'),(2528,'2018-12-13 16:51:38','http://www.ncpe.ie/drugs/teduglutide-revestive/','2017-03-13','2017-04-12','Full pharmacoeconomic assessment recommended','2017-03-13, 2017-04-12',0,'Teduglutide (Revestive®)','Revestive','Teduglutide (Revestive®) is indicated for the treatment of patients aged 1 year and above with short bowel syndrome. Patients should be stable following a period of intestinal adaptation.',2018,'2012-08-30','Shire',1,'2017-03-13','2018-03-16','https://www.ema.europa.eu/en/medicines/human/EPAR/revestive','Malabsorption Syndromes','HTA recommended at submitted price'),(2529,'2018-12-13 16:51:44','http://www.ncpe.ie/drugs/tegafurgimeraciloteracil-teysuno/','2012-02-27','2012-03-23','Full Pharmacoeconomic Evaluation not Recommended.','2012-02-27, 2012-03-23',0,'Tegafur/Gimeracil/Oteracil (Teysuno®)','Teysuno','Teysuno is indicated in adults for the treatment of advanced gastric cancer.',2012,'2011-03-14','Nordic',0,'2012-02-27','2012-03-23','https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno','Stomach Neoplasms','No HTA'),(2530,'2018-12-13 16:51:48','http://www.ncpe.ie/drugs/telapravir/','2011-10-28','2011-11-02','Full Pharmacoeconomic Evaluation Recommended','2011-10-28, 2011-11-02',0,'Telaprevir (Incivo®)','Incivo','Economic evaluation of Telaprevir (Incivo®) as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.',2012,'2011-09-19','Janssen-Cilag',0,'2011-10-28','2012-01-19','https://www.ema.europa.eu/en/medicines/human/EPAR/incivo','Hepatitis C, Chronic','HTA recommended at submitted price'),(2531,'2018-12-13 16:51:52','http://www.ncpe.ie/drugs/telavancin-vibativ/','2014-12-08','2015-01-13','Full Pharmacoeconomic Evaluation Not Recommended','2014-12-08, 2015-01-13',0,'Telavancin (Vibativ®)','Vibativ','Indicated for the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumomia, known or suspended to be caused by methicillin-resistant Staphylococcus aureas (MRSA).  Vabitiv® should be used only in situations where it is known or suspected that other alternatives are not suitable.',2015,'2011-09-02','Theravance',0,'2014-12-08','2015-01-13','https://www.ema.europa.eu/en/medicines/human/EPAR/vibativ-0','Pneumonia, Bacterial; Cross Infection','No HTA'),(2532,'2018-12-13 16:51:56','http://www.ncpe.ie/drugs/teriflunomide-aubagio/','2013-08-27','2013-09-20','Full Pharmacoeconomic Evaluation recommended','2013-08-27, 2013-09-20',0,'Teriflunomide (Aubagio®)','Aubagio','Aubagio® is indicated for the first line treatment of adult patients with relapsing remitting multiple sclerosis (MS).',2014,'2013-08-26','Sanofi-aventis',0,'2013-08-27','2014-09-05','https://www.ema.europa.eu/en/medicines/human/EPAR/aubagio','Multiple Sclerosis','HTA recommended at submitted price'),(2533,'2018-12-13 16:51:58','http://www.ncpe.ie/drugs/ticagrelor-brilique-2/','2016-02-29','2016-05-04','Full Pharmacoeconomic Evaluation Recommended','2016-02-29, 2016-05-04',0,'Ticagrelor (Brilique®)','Brilique','Ticagrelor (Brilique®) 60mg, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event.',2016,'2010-12-03','AstraZeneca',0,'2016-02-29','2016-05-04','https://www.ema.europa.eu/en/medicines/human/EPAR/brilique','Peripheral Vascular Diseases; Acute Coronary Syndrome','HTA recommended at submitted price'),(2534,'2018-12-13 16:52:01','http://www.ncpe.ie/drugs/ticagrelor-brilique/','2010-11-25','2011-01-20','Full Pharmacoeconomic Evaluation Recommended','2010-11-25, 2011-01-20',0,'Ticagrelor (Brilique®)','Brilique','Economic Evaluation of Ticagrelor (Brilique®) for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndrome (ACS) including patients managed medically, and those who are managed with PCI (Percutaneous Coronary Intervention) or CABG (Coronary Artery Bypass Graft).',2011,'2010-12-03','AstraZeneca',0,'2010-11-25','2011-10-10','https://www.ema.europa.eu/en/medicines/human/EPAR/brilique','Peripheral Vascular Diseases; Acute Coronary Syndrome','HTA recommended at submitted price'),(2535,'2018-12-13 16:52:07','http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-all/','2018-09-19','2018-10-19','A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care.','2018-09-19, 2018-10-19',0,'Tisagenlecleucel (Kymriah®) for ALL','Kymriah','Tisagenlecleucel (Kymriah®) for the treatment of paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.',2018,'2018-08-22','Novartis',1,'2018-09-19','2018-10-19','https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah','Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse','HTA recommended at submitted price'),(2536,'2018-12-13 16:52:13','http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-dlbcl/','2018-09-19','2018-10-18','A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care.','2018-09-19, 2018-10-18',0,'Tisagenlecleucel (Kymriah®) for DLBCL','Kymriah','Tisagenlecleucel (Kymriah®) which is licensed for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.',2018,'2018-08-22','Novartis',1,'2018-09-19','2018-10-18','https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah','Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse','HTA recommended at submitted price'),(2537,'2018-12-13 16:52:19','http://www.ncpe.ie/drugs/tobramycin-tobi-podhaler/','2010-11-10','2010-11-03','Full Pharmacoeconomic Evaluation not Recommended','2010-11-10, 2010-11-03',0,'Tobramycin (TOBI Podhaler®)','TOBI Podhaler','Tobramycin (TOBI Podhaler®) for the suppressive therapy of chronic pulmonary infection due to Ps aeruginosa in adults and children aged 6 years and older with CF.',2010,'1996-10-04','CIS',0,'2010-11-01','2010-11-03','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','No HTA'),(2538,'2018-12-13 16:52:24','http://www.ncpe.ie/drugs/tocilizumab-sc-roactemra/','2014-04-28','2014-07-16','Full Pharmacoeconomic Evaluation Recommended at theSubmitted Price.','2014-04-28, 2014-07-16',0,'Tocilizumab SC (RoActemra®)','RoActemra','It is licensed for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.  It is licensed in monotherapy in patients who are intolerant of methotrexate or in cases where methotrexate is inappropriate.',2014,'2009-01-15','Roche',0,'2014-04-28','2014-07-16','https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra','Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid','HTA recommended at submitted price'),(2539,'2018-12-13 16:52:30','http://www.ncpe.ie/drugs/tofacitinib-xeljanz-for-ulcerative-colitis/','2018-07-16','2018-09-18','A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tofacitinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.','2018-07-16, 2018-09-18',0,'Tofacitinib (Xeljanz®) for Ulcerative Colitis','Xeljanz','Tofacitinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy (i.e. corticosteroids, azathioprine, 6-mercaptopurine) or a biologic agent (i.e. TNF inhibitor).',2018,'2017-03-21','Pfizer',0,'2018-07-16','2018-09-18','https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz','Arthritis, Rheumatoid','HTA recommended at submitted price'),(2540,'2018-12-13 16:52:35','http://www.ncpe.ie/drugs/tofacitinib-xeljanz/','2017-03-08','2017-04-28','Full Pharmacoeconomic Evaluation Recommended at the Submitted Price','2017-03-08, 2017-04-28',0,'Tofacitinib (Xeljanz®)','Xeljanz','Tofacitinib (Xeljanz®) in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drug. Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.',2017,'2017-03-21','Pfizer',0,'2017-03-08','2017-10-01','https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz','Arthritis, Rheumatoid','HTA recommended at submitted price'),(2541,'2018-12-13 16:52:40','http://www.ncpe.ie/drugs/tolvaptan-jinarc/','2016-01-04','2016-01-12','Full pharmacoeconomic assessment recommended','2016-01-04, 2016-01-12',0,'Tolvaptan (Jinarc®)','Jinarc','Jinarc®) to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1-3 at initiation of treatment with evidence of rapidly progressing disease.',2018,'2015-05-27','Otsuka',0,'2016-01-04','2018-09-13','https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc','Polycystic Kidney, Autosomal Dominant','HTA recommended at submitted price'),(2542,'2018-12-13 16:52:45','http://www.ncpe.ie/drugs/tramadol-hydrochloridedexketoprofen-skudexa/','2017-10-17','2017-12-01','Reimursement not recommended at the submitted price','2017-10-17, 2017-12-01',0,'Tramadol hydrochloride/dexketoprofen (Skudexa®)','Skudexa','Tramadol hydrochloride/dexketoprofen (Skudexa ®) for the symptomatic short-term treatment of moderate to severe acute pain in adult patients whose pain is considered to require a combination of tramadol and dexketoprofen.',2017,'1996-10-04','CIS',0,'2017-10-17','2017-12-01','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','Reimbursement not recommended'),(2543,'2018-12-13 16:52:51','http://www.ncpe.ie/drugs/trametinib-mekinist/','2015-11-27','2015-12-22','Full Pharmacoeconomic Evaluation Recommended','2015-11-27, 2015-12-22',0,'Trametinib (Mekinist®)','Mekinist','Mekinist® for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.',2018,'2014-06-30','Novartis',0,'2015-11-27','2018-03-01','https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist','Melanoma','HTA recommended at submitted price'),(2544,'2018-12-13 16:52:56','http://www.ncpe.ie/drugs/trastuzumab-emtansine-kadcyla/','2013-09-25','2013-10-24','Full Pharmacoeconomic Evaluation recommended','2013-09-25, 2013-10-24',0,'Trastuzumab emtansine (Kadcyla®)','Kadcyla','Trastuzumab emtansine (Kadcyla®) is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and taxane, separately or in combination.',2015,'2013-11-15','Roche',0,'2013-09-25','2015-12-01','https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla','Breast Neoplasms','HTA recommended at submitted price'),(2545,'2018-12-13 16:53:00','http://www.ncpe.ie/drugs/trifluridinetipiracil-lonsurf/','2016-06-10','2016-07-11','Full Pharmacoeconomic Evaluation Recommended at the Submitted Price','2016-06-10, 2016-07-11',0,'Trifluridine/tipiracil (Lonsurf®)','Lonsurf','Trifluridine/tipiracil (Lonsurf®) is indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.',2016,'2016-04-25','Les',0,'2016-06-10','2016-07-11','https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf','Colorectal Neoplasms','HTA recommended at submitted price'),(2546,'2018-12-13 16:53:04','http://www.ncpe.ie/drugs/ulipristal-acetate-esmya-2/','2016-05-17','2016-05-31','Full Pharmacoeconomic Evaluation Not Recommended ','2016-05-17, 2016-05-31',0,'Ulipristal acetate (Esmya ®) intermittent treatment','Esmya','Ulipristal acetate is indicated for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.',2016,'2012-02-22','Gedeon',0,'2016-05-17','2016-05-31','https://www.ema.europa.eu/en/medicines/human/EPAR/esmya','Leiomyoma','No HTA'),(2547,'2018-12-13 16:53:08','http://www.ncpe.ie/drugs/ulipristal-acetate-esmya/','2013-09-03','2013-10-18','Full Pharmacoeconomic Evaluation Not Recommended','2013-09-03, 2013-10-18',0,'Ulipristal acetate (Esmya®) single course treatment','Esmya','Ulipristal acetate (Esmya®) is indicated for the pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.',2013,'2012-02-22','Gedeon',0,'2013-09-03','2013-10-18','https://www.ema.europa.eu/en/medicines/human/EPAR/esmya','Leiomyoma','No HTA'),(2548,'2018-12-13 16:53:10','http://www.ncpe.ie/drugs/umeclidiniumvilanterol-anoro/','2014-06-11','2014-07-10','Full Pharmacoeconomic Evaluation not Recommended','2014-06-11, 2014-07-10',0,'Umeclidinium/vilanterol (Anoro®)','Anoro','Umeclidinium/vilanterol (Anoro®) is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.',2014,'1996-10-04','CIS',0,'2014-06-11','2014-07-10','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','No HTA'),(2549,'2018-12-13 16:53:12','http://www.ncpe.ie/drugs/urea-glucorx-allpresan/','2018-07-09','2018-07-24','Full pharmacoeconomic assessment is not recommended. The NCPE recommends that GlucoRx Allpresan Diabetic Foam Cream not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.','2018-07-09, 2018-07-24',0,'Urea (GlucoRx Allpresan®)','GlucoRx Allpresan','GlucoRx Allpresan® Diabetic Foam Cream for the treatment of dry and sensitive foot skin (Basic) and very dry to chapped foot skin (Intensive) in patients with Diabetes Mellitus.',2018,NULL,'Unknown',0,'2018-07-09','2018-07-24','','Unknown','No HTA at submitted price'),(2550,'2018-12-13 16:53:17','http://www.ncpe.ie/drugs/ustekinumab-stelara-2/','2016-11-28','2017-01-11','Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.','2016-11-28, 2017-01-11',0,'Ustekinumab (Stelara®) for Crohn’s Disease','Stelara','Ustekinumab is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-α antagonist or have medical contraindications to such therapies',2017,'2009-01-15','Janssen-Cilag',0,'2016-11-28','2017-11-01','https://www.ema.europa.eu/en/medicines/human/EPAR/stelara','Psoriasis; Arthritis, Psoriatic; Crohn Disease','HTA recommended at submitted price'),(2551,'2018-12-13 16:53:23','http://www.ncpe.ie/drugs/ustekinumab-stelara/',NULL,'2017-01-11','','',0,'Ustekinumab (Stelara®)','Stelara','Cost-effectiveness of Ustekinumab (Stelara®) in the treament of moderate to severe psoriasis.',2009,'2009-01-15','Janssen-Cilag',0,'2009-07-01','2009-11-01','https://www.ema.europa.eu/en/medicines/human/EPAR/stelara','Psoriasis; Arthritis, Psoriatic; Crohn Disease','RR not conducted'),(2552,'2018-12-13 16:53:29','http://www.ncpe.ie/drugs/vandetanib-caprelsa/','2013-06-06','2013-07-03','Full Pharmacoeconomic Evaluation Recommended','2013-06-06, 2013-07-03',0,'Vandetanib (Caprelsa®)','Caprelsa','Vandetanib (Caprelsa®) for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.',2013,'2012-02-16','Genzyme',0,'2013-06-06','2013-07-03','https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa','Thyroid Neoplasms','HTA recommended at submitted price'),(2553,'2018-12-13 16:53:32','http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-crohns-disease/','2014-09-12','2014-10-01','Full Pharmacoeconomic Evaluation Recommended','2014-09-12, 2014-10-01',0,'Vedolizumab (Entyvio®) in Crohn’s Disease','Entyvio','Vedolizumab (Entyvio®) indicated for the treatment of adult patients with moderately toseverely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.',2017,'2014-05-22','Takeda',0,'2014-09-12','2017-10-01','https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio','Colitis, Ulcerative; Crohn Disease','HTA recommended at submitted price'),(2554,'2018-12-13 16:53:39','http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-ulcerative-colitis/','2014-09-12','2014-10-01','Full Pharmacoeconomic Evaluation Recommended','2014-09-12, 2014-10-01',0,'Vedolizumab (Entyvio®) in Ulcerative Colitis','Entyvio','Vedolizumab (Entyvio®) is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.',2017,'2014-05-22','Takeda',0,'2014-09-12','2017-10-01','https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio','Colitis, Ulcerative; Crohn Disease','HTA recommended at submitted price'),(2555,'2018-12-13 16:53:45','http://www.ncpe.ie/drugs/velaglucerase-alfa-vpriv-2/','2011-04-26','2011-06-20','Full Pharmacoeconomic Evaluation Recommended.','2011-04-26, 2011-06-20',0,'Velaglucerase Alfa (VPRIV®)','VPRIV','VPRIV is indicated for long-term enzyme replacement therapy (ERT) in patients with type1 Gaucher disease.',2011,'1996-10-04','CIS',0,'2011-04-26','2011-06-20','https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125','Radionuclide Imaging; Ovarian Neoplasms','HTA recommended at submitted price'),(2556,'2018-12-13 16:53:49','http://www.ncpe.ie/drugs/venetoclax-venclyxto-in-combination-with-rituximab/','2018-09-26','2018-10-18','A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of venetoclax compared with the current standard of care.','2018-09-26, 2018-10-18',0,'Venetoclax (Venclyxto®) in combination with rituximab','Venclyxto','Venetoclax (Venclyxto®) in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.',2018,'2016-12-04','AbbVie',1,'2018-09-26','2018-10-18','https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto','Leukemia, Lymphocytic, Chronic, B-Cell','HTA recommended at submitted price'),(2557,'2018-12-13 16:53:52','http://www.ncpe.ie/drugs/venetoclax-venclyxto/','2018-05-08','2018-06-21','Following a resubmission of the rapid review a full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with current available therapies.','2018-05-08, 2018-06-21',0,'Venetoclax (Venclyxto®)','Venclyxto','Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL)',2018,'2016-12-04','AbbVie',1,'2017-01-03','2018-12-01','https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto','Leukemia, Lymphocytic, Chronic, B-Cell','HTA recommended at submitted price'),(2558,'2018-12-13 16:53:58','http://www.ncpe.ie/drugs/vermurafenib-zelboraf/','2011-12-23','2012-01-04','Full Pharmacoeconomic Evaluation Recommended','2011-12-23, 2012-01-04',0,'Vemurafenib (Zelboraf®)','Zelboraf','Vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.',2014,'2012-02-17','Roche',0,'2011-12-23','2014-09-01','https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf','Melanoma','HTA recommended at submitted price'),(2559,'2018-12-13 16:54:00','http://www.ncpe.ie/drugs/vernakalant-brinavess/','2010-10-26','2010-11-04','Full Pharmacoeconomic Evaluation Recommended','2010-10-26, 2010-11-04',0,'Vernakalant (Brinavess®)','Brinavess','Economic evaluation of Vernakalant (Brinavess®) for haemodynamically stable, symptomatic patients with atrial fibrillation of less than 48 hours duration.',2011,'2010-09-01','Cardiome',0,'2010-10-26','2011-05-04','https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess','Atrial Fibrillation','HTA recommended at submitted price'),(2560,'2018-12-13 16:54:04','http://www.ncpe.ie/drugs/vismodegib-erivedge/','2013-05-02','2013-05-20','Full Pharmacoeconomic Evaluation Recommended','2013-05-02, 2013-05-20',0,'Vismodegib (Erivedge®)','Erivedge','Vismodegib (Erivedge®) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy or metastatic basal cell carcinoma.',2017,'2013-07-12','Roche',0,'2013-05-02','2017-10-01','https://www.ema.europa.eu/en/medicines/human/EPAR/erivedge','Carcinoma, Basal Cell','HTA recommended at submitted price'),(2561,'2018-12-13 16:54:11','http://www.ncpe.ie/drugs/vortioxetine-brintellix/','2014-10-01','2014-11-14','Full Pharmacoeconomic Evaluation Recommended','2014-10-01, 2014-11-14',0,'Vortioxetine (Brintellix®)','Brintellix','Vortioxetine (Brintellix®) is indicated for the treatment of major depressive episodes in adults.',2017,'2013-12-18','Lundbeck',0,'2014-10-01','2017-10-01','https://www.ema.europa.eu/en/medicines/human/EPAR/brintellix','Depressive Disorder, Major','HTA recommended at submitted price');
/*!40000 ALTER TABLE `scraped` ENABLE KEYS */;
UNLOCK TABLES;
/*!40103 SET TIME_ZONE=@OLD_TIME_ZONE */;

/*!40101 SET SQL_MODE=@OLD_SQL_MODE */;
/*!40014 SET FOREIGN_KEY_CHECKS=@OLD_FOREIGN_KEY_CHECKS */;
/*!40014 SET UNIQUE_CHECKS=@OLD_UNIQUE_CHECKS */;
/*!40101 SET CHARACTER_SET_CLIENT=@OLD_CHARACTER_SET_CLIENT */;
/*!40101 SET CHARACTER_SET_RESULTS=@OLD_CHARACTER_SET_RESULTS */;
/*!40101 SET COLLATION_CONNECTION=@OLD_COLLATION_CONNECTION */;
/*!40111 SET SQL_NOTES=@OLD_SQL_NOTES */;

-- Dump completed on 2019-09-28 13:47:48
